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1 
Preface 
Undoubtedly, the most important discovery in the field of medicine is the discovery of penicillin by 
Sir Alexander Fleming (1928). Prior to that time, bacteria were responsible for many of the world’s 
lethal diseases such as pneumonia, plague and tuberculosis, together responsible for killing more 
people than any other disease. With the advent of antibiotics –many others rapidly followed after 
penicillin– few people in the Western world nowadays consider bacterial infections as life–
threatening as for instance viral infections, heart diseases or cancer.  
However, the ever-increasing resistance of bacteria against commonly used antibiotics –
along with a growing number of infectious diseases– becomes a situation of most concern (Figure 
1). Also in Europe, most of the microbes responsible for causing invasive infections have already 
reached alarmingly high resistance percentages, e.g. 26% for methicillin resistant S. aureus 
(MRSA), 12% for erythromycin non-susceptible S. pneumoniae (ENSP) and 9% for vancomycin 
resistant enterococci (VRE). The most worrying trend in Europe is noted for E. coli (Table 1), the 
most common cause of infections due to Gram-negative bacilli and the principal pathogen in 
urinary tract infections. At the same time, there is a continuous decline of interest of the 
pharmaceutical industry in the development of novel antibiotics.
1
 As a result, no truly new 
antibiotics have emerged since the discovery of the fluoroquinolones in the early 1970s, with the 
single exception of Zyvox
TM
 (linezolid), the first of the class of oxazolidinones, approved for 
treatment of Gram-positive infections by the FDA in 2000.
2,3
  
 
antibiotic % resistance 
 
% increase 
(from 2001)
aminopenicillins  51      19 
aminoglycosides  6    36   
fluoroquinolones  16    82   
3rd gen. cephalosporins  3    113 
 
 
 
 
 
Figure 1.   Historic development of resistance 
against methicillin and vancomycin in U.S. 
hospitals.
4
 
Table 1.   Resistance of E. coli in Europe (2005) 
against commonly applied antibiotics and comparison 
with 2001.5 
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Another class of antibiotics with a broad antibacterial spectrum and proven efficacy particularly 
against aerobic Gram-negative bacteria is formed by the aminoglycosides. Although resistance of 
some bacteria has reached dramatic levels, e.g. an average of 66% for E. faecalis in Europe, with 
several enterococci phenotypes approaching 100% in some countries (Italy, Romania, Germania). 
The prime resistance mechanisms involve structural modification by bacterial enzymes; 
aminoglycoside phosphotransferases (APH), adenyltransferases (AAD or ANT) and 
acetyltransferases (AAC).
6,7
 Apart from that, extensive clinical use of the aminoglycosides is 
limited due to the associated nephro- and ototoxicities.
8
 These circumstances validate research into 
novel aminoglycoside analogues which do not display the undesirable features but maintain a strong 
bactericidal effect by evading resistance mechanisms. This notion has already awakened the 
chemical community and the number of papers along this line is rapidly expanding. Omnipresence 
in the aminoglycoside family is a cyclohexitol moiety termed 2-deoxystreptamine (2-DOS). An 
efficient route to obtain 2-DOS may therefore serve as a practical starting point for the assembly of 
aminoglycoside-type libraries. An overview of the synthetic routes leading toward 2-DOS that 
appeared in literature earlier is given in chapter 1. 
 Unfortunately, all synthetic routes toward 2-DOS that have been developed thus far require 
expensive starting material or numerous synthetic steps and offer minimal flexibility in protective 
groups. As a result, to date the most practical method to synthesize 2-DOS (derivatives) is via 
degradation of natural neomycin. However, the initially obtained “naked” meso-compound still 
demands desymmetrization as well as extensive protective group manipulations before 
incorporation in aminoglycoside entities can be ensured. The aim of the research described in this 
thesis is to first develop a fast route toward 2-DOS precursors (chapter 2-5) and secondly to 
synthesize from such a core structure a variety of aminoglycoside analogues (chapter 5 and 6). In 
the ideal scenario, a 2-DOS precursor was projected suitable to serve as scaffold for both 4,5- and 
4,6-linked aminoglycoside antibiotics. Consequently, our research initially focused on the synthesis 
of orthogonally protected derivatives of 2-DOS, starting from enantiomerically pure D-allylglycine 
(chapter 2). The following chapter 3 describes an alternative synthetic approach toward 2-DOS 
commencing with a Diels–Alder condensation of cyclopentadiene and p-benzoquinone. The most 
straightforward strategy leading to meso 5-O-benzylprotected diazidocyclitol precursors of 2-DOS 
employs commercially available kanamycin B sulfate as starting material (chapter 4). In the same 
chapter, several methodologies are explored to obtain enantiopure 1,3-diazidocyclohexitols 
(1,3-DACHs) via resolution of chiral intermediates or the final meso 5-O-protected precursor, for 
example by asymmetric alkylation, asymmetric allylic alkylation or enzymatic hydrolysis.  
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The synthesis of a carbohydrate mimic of 2-DOS starting from D-ribose is described in chapter 5. 
Moreover, glycosylation of the carbohydrate 2-DOS derivative with phenyl thioglycoside in the 
presence of TTBP and AgOTf followed by ring-closing metathesis yielded a conformationally 
restricted aminoglycoside analogue. In the final chapter 6 the synthesis of 4,6-linked carbohydrate 
and peptidyl 2-DOS derivatives from meso 2-DOS precursors is described as a potential new class 
of RNA ligands. 
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2-Deoxystreptamine, central scaffold of  
aminoglycoside antibiotics
1
 
 
 
 
 
Abstract 
2-Deoxystreptamine (2-DOS) is a common structure in nearly all of the aminoglycosides, a class of 
clinically important antibiotics, but with limited practical value due to high associated toxicities as 
well as microbial resistance. A possible strategy to develop new aminoglycoside antibiotics that do 
not display these undesirable features but maintain a strong bacterial effect starts from individually 
prepared components, such as 2-DOS. Therefore, an overview of synthetic routes leading toward 
this aminocyclitol moiety will be described in this chapter. 
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1.1 Introduction 
Since the discovery of the aminoglycoside antibiotic streptomycin in 1944,
1
 the family of 
aminoglycosides has steadily grown into a powerful class of antibiotics. Aminoglycosides form a 
large class of clinically important antibiotics with a broad antibacterial spectrum and proven 
efficacy, particularly against aerobic Gram-negative bacteria. (Table 1).
2
 Most of the 
aminoglycosides are naturally occurring substances and are readily obtained from actinomycetes of 
either genus Streptomyces (labeled “-mycin”) or Micromonospora (labeled “-micin”).3 The most 
relevant members of the family are streptomycin, tobramycin and gentamicin, the latter of which is 
used in the clinic most frequently due to its low cost and reliable activity. In general, 
aminoglycosides show a strong synergistic effect upon co-administration with penicillin, a 
particularly useful combination for treatment of patients with infections of unknown origin, 
although recent scientific reports appear to contradict the added value of co-administration.
4
 Some 
semi-synthetic derivatives, i.e. amikacin, netilmicin, arbekacin, isepamicin, and dibekacin, are also 
on the market and display particular activity against bacterial strains that have developed resistance 
against the early aminoglycosides.
5
 However, in recent years it has become apparent, after a long 
era of marginal interest in the search and development of antibacterials, that the battle against 
pathogenic bacteria is not over. In contrast, resistant strains of bacteria are reported with increasing 
frequency, with the associated dramatic consequences like untreatable patients or the temporary 
closure of hospital intensive cares.
6
  
 Apart from being versatile antibiotics, recent years have seen a shift of scientific interest in 
aminoglycosides to a related field of interest that has the potential of much broader application: the 
regulation of protein production at the RNA-level. Due to the fact that aminoglycosides are rather 
promiscuous ligands for all sorts of RNA, often in low micromolar concentration, they have earned 
themselves a strong position in the emerging research field ‘RNA as a drug target’: the perception 
that RNA plays a central (and active) role in the biochemical pathway required to produce proteins 
from DNA provides nearly untapped opportunities for biological and pharmacological 
development. For example, RNA is the genetic material of pathogenic viruses such as HIV or 
hepatitis C. Apart from that, the complex functions of RNA molecules in the control of gene 
expression in humans provide numerous opportunities to target specific RNA structures for treating 
a variety of chronic and degenerative conditions.
7,8 
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Table 1. Aminoglycosides in clinical use 
aminoglycoside year of 
intro- 
duction 
effective against 
bacterial strain
a
 
disease(s) associated with bacteria 
streptomycin  1944 M. tuberculosis  
E. histolytica 
C. parvum 
F. tularensis 
Y. pestis 
tuberculosis 
diarrhea 
diarrhea 
tularemia 
plague 
neomycin 1949 Enterobacteriaceae 
spp.c 
(including E. coli, 
Klebsiella sppc. etc) 
Salmonella spp.c 
S. aureus 
several infections, sepsis 
 
 
 
diarrhea 
wound infections, sepsis, toxic shock syndrome 
kanamycin 1957 Enterobacteriaceae spp.
c
 
P. aeruginosab 
several infections, sepsis 
outer ear infection, sepsis, long infections 
paromomycin 1959 E. histolytica  
C. parvum 
diarrhea 
diarrhea 
spectinomycin 1962 N. gonorrhoeae 
P. aeruginosab 
gonorrhea 
outer ear infection, sepsis, long infections 
gentamicin 1963 P. aeruginosab 
Enterobacteriaceae spp.
c
 
outer ear infection, sepsis, long infections 
several infections, sepsis 
tobramycin 
(nebramycin 
factor 6) 
1967 Enterobacteriaceae spp.
c
 
P. aeruginosab 
several infections, sepsis 
outer ear infection, sepsis, long infections 
sisomicin
d
 1970 Enterobacteriaceae spp.
c 
P. aeruginosab 
S. aureus 
several infections, sepsis 
outer ear infection, sepsis, long infections 
wound infections, sepsis, toxic shock syndrome 
dibekacin 1971   
amikacin
d
 1972 Enterobacteriaceae spp.
c
 
P. aeruginosab 
M. tuberculosis 
MOTT 
N. asteroides  
several infections, sepsis 
outer ear infection, sepsis, long infections 
tuberculosis 
opportunistic infections 
opportunistic infections 
netilmicin
d
 1975 Enterobacteriaceae spp.
c
 
P. aeruginosab 
intestinal infections 
outer ear infection, sepsis, long infections 
isepamicin
d
 1978  nosocomial pneumonia 
arbekacin
d
 1990   
aM. tuberculosis=Mycobacterium tuberculosis, E. histolytica=Entamoeba histolytica, C. 
parvum=Cryptosporidium parvum, F. tularensis=Francisella tularensis, Y. pestis=Yersinia pestis, E. 
coli=Escherichia coli, S. aureus=Staphylococcus aureus, P. aeruginosa=Pseudomonas aeruginosa, N. 
gonorrhoeae=Neisseria gonorrhoeae, MOTT=mycobacterium other than tuberculosis, N. 
asteroids=Nocardia asteroids. bTobramycin and sisomicin show a better activity against Pseudomonas 
aeruginosa cspp.= species dsemi-synthetic adducts. 
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Mechanism of action 
Aminoglycoside antibiotics bind to the A-site decoding region of the bacterial 16S ribosomal 
RNA.
9,10
 Since the natural role of the ribosome is to provide an environment for protein production, 
the effect of binding is expressed in mistranslation of mRNA or premature termination of protein 
synthesis, leading to cell death. In a more general sense, the aminoglycosides are found to have a 
broad, rather promiscuous preference for binding to A-form nucleic acids.
11
 An interesting 
observation of this phenomenon is the binding of neomycin with HIV RRE, as a competitive 
inhibitor of the natural protein ligand Rev, resulting in attenuated HIV replication in tissue culture 
cells.
12,13,14 
 
Toxicity 
Despite the apparent advantages, extensive clinical use of the aminoglycoside antibiotics is limited 
due to the associated toxicities, most notably nephrotoxicity and ototoxicity and to a lesser extent 
neuromuscular blockade.
3
 The exact mechanism of toxicity is unknown although aminoglycosides 
are known to accumulate in renal cortical cells and are able to damage proximal tubules. 
Nephrotoxicity is dose-dependent and generally reversible in the majority of patients when the drug 
is discontinued. Of higher impact is the associated ototoxicity that may lead, depending on the 
phenotype of a particular patient, to irreversible vestibular and/or cochlear damage.  
 
Resistance 
Another and arguably more alarming drawback of the aminoglycosides (and antibiotics in general), 
is the global development of microbial resistance. In case of the aminoglycosides, which are used 
predominantly against aerobic Gram-negative bacteria, the most common resistance mechanism is 
structural modification by bacterial enzymes; aminoglycoside phosphotransferases (APH), 
adenylyltransferases (AAD or ANT) and acetyltransferases (AAC). Typical sites of bacterial 
modification are exemplified (Figure 1) for kanamycin B, the aminoglycoside most susceptible to 
resistance.
5,15,16
 A second mechanism of resistance is decreased uptake and/or accumulation of the 
drug in bacteria. Finally, streptomycin is susceptible to resistance by alteration of the ribosomal 
binding sites.
5
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Figure 1. Major aminoglycoside-modifying enzymes acting on kanamycin B.
5
 
 
Structural features 
As the name aminoglycoside suggests, members of the aminoglycoside family are predominantly 
built up from a wide variety of aminosugars (Figure 2). These aminosugars, often of the 6-amino or 
the 2,6-diamino type, may be further decorated or functionalized, e.g. by deoxygenation, N- or 
C-methylation, or may contain additional stereocenters, and are always 1,2-cis glycosidically 
linked. Some additional rings or rare carbohydrates can also be identified in some aminoglycosides, 
but of utmost significance is a cyclohexitol present in each of the structures of Figure 2.  
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Figure 2.  
 
This ring, termed streptamine or 2-deoxystreptamine (2-deoxy-myo-inosa-1,3-diamine or 
all-trans-1,3-diamino-4,5,6-trihydroxycyclohexane, 2-DOS for short), as highlighted in Figure 2, 
provides the central scaffold of any known aminoglycoside. It is an all-trans cyclohexitol, 
1,3-substituted by two amino groups. Due to the presence of the plethora of amino functionalities, 
aminoglycosides are heavily protonated under physiological conditions, thus providing a rational 
for the strong affinity for (negatively charged) nucleotides.
17
 Apart from the conserved 1,3-diamino 
functionality, the cyclohexitol contains three (2-DOS) or four (streptamine) hydroxyls, that provide 
the anchoring points for the aminosugars. Based on the substitution pattern of the streptamine ring, 
the aminoglycosides may be categorized in 4,5- or 4,6-linked. Although the streptamine numbering 
seems rather odd at first it is directly derived from its biogenic precursor myo-inositol (Figure 3) 
and is therefore numbered according to the method proposed by Fletcher et al. for inositols.18 The 
same numbering is adapted in the case of 2-DOS (or 2-deoxy-myo-inosa-1,3-diamine), despite the 
fact that it is not biosynthetically derived from myo-inositol but from D-glucose-6-phosphate.  
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myo-inositol
OH
OH
OH
HO OH
HO
1
2
3
46
5
NH2
OH
HO OH
H2N
1
2
3
4 6
5
X
: streptamine
: 2-deoxystreptamine
X = OH
X = H (1)  
Figure 3.  
 
Central scaffold of aminoglycosides: 2-DOS 
The omnipresence and central location of 2-DOS in aminoglycoside structures suggests a pivotal 
role for biological activity, an intuitive assumption that is underlined by recently published X-ray 
crystal structures of several aminoglycosides complexed to the 30S ribosomal particle
19-22
 or an 
A-site oligonucleotide sequence
23-25
 which reveal without exception a similar binding pattern to 
2-DOS, regardless of its 4,5- or 4,6-substitution. Recently X-ray crystal structures of 
paromomycin,
19,20,21
 and hygromycin
22
 complexed to the 30 S ribosomal subunit and of 
paromomycin,
23
 tobraycin
24
 and geneticin
25
 complexed to oligonucleotides containing the minimal 
bacterial ribosomal A site are elucidated.
26
 Apart from that, synthetic approaches toward novel 
aminoglycoside type RNA-ligands have also revealed a crucial role of 2-DOS for biological 
activity,
27
 although some exceptions have been reported as well.
28,29
 Convincing evidence of the 
strong affinity of 2-DOS for RNA was most recently provided by the observation that the bivalent 
structure of 2-DOS alone, that is without aminosugar substitution, already shows low micromolar 
binding to RNA hairpin loops.
30
 An important reason therefore to synthesize 2-DOS is that by 
having the core structure in hand it should be possible to develop new and innovative antibiotics or, 
in a broader sense, RNA-binding molecules. From a chemical perspective, 2-DOS poses an 
interesting synthetic challenge due to the five contiguous stereogenic centers. In this respect, it is 
not surprising that numerous attempts have been made to obtain this aminocyclitol moiety 
synthetically and in this chapter a comprehensive overview of the synthetic routes that have 
appeared in literature will be provided.
31
  
A summary of the synthetic efforts aimed at (derivatives of) 2-DOS (1) in terms of 
retrosynthetic analysis to starting materials, is provided in (Figure 1, first page of this chapter). It is 
interesting to note that the starting materials vary from simple cycloalkenes to highly oxygenated 
structures such as inositols and carbohydrates and in most cases already contain stereocenters. 
Keeping in mind that 2-DOS is a meso compound, the choice of a starting material from the chiral 
pool seems rather awkward at first sight, but in this manner a range of useful enantiomerically pure 
(protected) derivatives could be obtained (marked with an asterisk in Figure 1). A comprehensive 
Chapter 1 
 12 
overview of the most important synthetic efforts will be provided in this chapter. Starting with the 
organic chemistry efforts, in three segments: (a) collection of meso 2-DOS and hyosamine (methyl-
2-DOS) by degradation of neomycin (§1.2) or via synthetic routes (§1.3), (b) enantiomerically pure 
protected derivatives of meso 2-DOS, either by enzymatic resolution (§1.4) or from starting 
materials from the chiral pool (§1.5). Synthetic routes leading to regioisomers, dideoxyderivatives 
or syntheses of streptamine have also been reported, but are scarcer and are not included in this 
chapter.
31
 
To date, the most practical method to obtain 2-DOS is by an acidic degradation of 
neomycin. One may wonder therefore: “What is the value of fully synthetic procedures that are 
inevitably more expensive and time-consuming?” The answer to this question lies in the fact that 
the “naked” compound obtained by hydrolysis of neomycin is as such useless for synthetic 
purposes. It demands extensive protective group manipulation but apart from that, since it is a meso 
compound, it also needs to undergo desymmetrization before incorporation in (enantiopure) 
aminoglycoside entities can be undertaken. For these reasons only, de novo synthesis from 
individually prepared components can already effectively compete with synthesis from neomycin. 
Apart from that, total synthesis has the obvious advantage that it not only allows full flexibility in 
design and preparation of novel aminoglycoside-type structures, but also opens up avenues leading 
to unnatural analogues. 
 
1.2 Degradation of neomycin 
Despite all efforts described later in this chapter, the simplest method to obtain 2-DOS still is by 
hydrolytic degradation of a natural aminoglycoside. In a strict sense, to obtain 2-DOS in this 
manner is not a synthesis, but since it is such a straightforward way to access 2-DOS it is by far the 
most popular route applied to date. The usual aminoglycoside of choice for this purpose is 
neomycin trisulfate (2), since it is readily obtained from Streptomyces fermentation,32 and 
commercially available for a reasonable price (±0.6 €/mmol). Treatment of neomycin with sulfuric 
acid gives compound 3 by selective cleavage of a single glycosidic linkage (Scheme 1). This 
product, originally termed neomycin A as it was identified as a constituent of a mixture of three 
neomycins (A-C)
33
 obtained from the bacterial broth, is now better known as neamine.
34
 
From neomycin B, two direct procedures to obtain (ammonium salts of) 2-DOS 1 have been 
described (Scheme 1), either by reaction of 2 with HBr (50% yield),
35
 or by heating 2 in 6 N 
hydrochloric acid (yield not reported).
36
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Scheme 1.  
aq. HBr
(50%)
1O
H2N
HO
OH
NH2
O
NH2H2N
OH
OH
2 (79-81%)
.2H2SO4
H2SO4
neomycin
or
6N HCl
3  
 
In an alternative to these two-step procedures, 2-DOS (1) can also be directly obtained by complete 
hydrolysis of neomycin as first described by Georgiadis.
37
 In order to separate 1 from the other 
carbohydrate constituents of neomycin, this route involves the isolation of 1 in a protected form. 
For example, selective N-protection of 1 with an acyl or urethane protective group is possible, but 
for spectroscopic and solubility reasons, it is most conveniently converted to a bisazide by 
diazotransfer. The latter transformation, first reported for neomycin by Alper et al.38converts both 
amines of 2-DOS directly to azides by a Cu
2+
 or Zn
2+
-catalyzed diazotransfer (Scheme 2). As 
reported by Swayze et al., 39,40,41 the resulting triol can be selectively blocked at O-4 and O-5 with 
an isopropylidene group to give 4 in racemic form. Finally, protection of the 6-position with a 
3-nitrobenzyl group, followed by removal of the isopropylidene group leads to compound 5 in an 
overall yield of 11% for the five steps.  
 
Scheme 2.  
(48%)(61%)
aq. HBr
N3 N3
Om-NO2BnHO
1. TfN3, CuSO4
2. DMP, TsOH
N3 N3
OHO
O
1. o-NO2BnBr
    NaH
4 5
(37%)
2 1
OH
2. aq. AcOH
 
 
1.3 De novo synthesis of 2-DOS 
It is obvious that a large variety of starting materials has been applied for the synthesis of 2-DOS, 
but only the most important synthetic routes leading toward 2-DOS will be discussed here. A 
comprehensive overview of syntheses of 2-DOS is given in a recent review.
31
 
Prinzbach and coworkers
42,43,44
 reported a synthesis of 2-DOS starting by epoxidation of 
1,4-cyclohexadiene (6, Scheme 3) with monoperphthalic acid (6→7).
45
 Subsequent allylic 
bromination with N-bromosuccinimide in CCl4 gives a 9:1 mixture of (the rather explosive) 
compounds trans-8 and cis-9. Although it was possible to equilibrate the latter mixture to a more 
desirable ~4:6 ratio upon the action of tetrabutylammonium bromide in MeCN (or acetone), a more 
desirable route involved cis-diastereoselective epoxidation of the crude mixture of 8 and 9 with 
trifluoroperacetic acid. It was found that the resulting 9:1 mixture of diepoxides 10 and 11 was also 
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amenable for equilibration under the influence of an ammonium bromide in acetone, to give the 
mirror 1:9 ratio of 10 to 11.
46
 The desired all-cis-diepoxide 11 could thus be obtained in pure form 
after selective crystallization from the mixture in methanol.  
 
Scheme 3.  
O O
Br
O
Br
(85-90%)(50%)
NBS
AIBN
6 7
O
Br
O O
Br
O
H2O2
CF3COOH
8 9
1110
OH
O
O
HOO
(73%)
+
ratio 9:1
(equilibr. 
to 4:6)
+
ratio 9:1
(equilibr. 
to 1:9)  
 
Having the cis-diepoxide 11 in hand three alternative routes were described to synthesize 2-DOS. 
Firstly, treatment of 11 with tetraethyl ammonium acetate in acetone led to nucleophilic substitution 
of the bromide and after subsequent deacetylation, alcohol 12 (Scheme 4). Application of Suami's 
hydrazinolysis/hydrogenation procedure gave aminocyclitol 1 in 75-80% yield.
31
 The total yield of 
compound 1 starting from 1,4-cyclohexadiene in 7 steps is approximately 24%. Similarly, 
subjection of 12 to methylhydrazine led to (±)-hyosamine (13), the N-methyl derivative of 2-DOS, 
in a yield of approximately 70%. The diazidocyclitol 14 could also be obtained from 12 by reaction 
with sodium azide but in this case the overall yield is only 2.1% for the 6 steps. 
 
Scheme 4.  
11 O
OH
O
(75-80%)
1. RHN-NH2
12
(91%)
(7%)
NaN3
HO
OH
OH
N3 N3
1 R = H
ZnSO4
14
HO
OH
OH
H2N NHR
13 R = Me
1. Et4NOAc
2. NH3
2. Ra-Ni
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A third variation on the theme provided by the same research group involves conversion of 
monoepoxide 9 to the p-nitrophenylether 15 with tetraethylammonium 4-nitrophenolate (Scheme 
5). Subsequent stereoselective epoxidation to diepoxide 16 followed by opening of both epoxides 
with sodium azide led to a much improved yield of 50% and an overall yield of the protected 
2-DOS derivative 17 in 5 steps and 6.6%. Final removal of the p-nitrophenyl group was not 
reported. 
 
Scheme 5.  
O
p-NO2PhO
O
p-NO2PhO
(50%)
O
m-CPBA
(96-98%)
15 16
9
NaN3,
ZnSO4
(50%) HO
p-NO2PhO
OH
N3 N3
17
Et4NOPhp-NO2
 
 
1.4 Desymmetrization 
None of the syntheses of 2-DOS discussed above led to enantiopure material. The reason for this is 
that despite its five stereocenters, 2-DOS (or any symmetrically protected variant of it) is a meso 
compound, due to the presence of an internal plane of symmetry (although an unlikely optical 
rotation of 41.8° has been reported).
37
 Obviously, if synthesis of 2-DOS itself is the prime goal, 
molecular symmetry makes life easier. However, if 2-DOS is to serve as a scaffold for 
incorporation in an enantiopure aminoglycoside (analogue), a desymmetrized variant is a 
prerequisite.  
A most convenient approach toward an enantiopure derivative of 2-DOS, since it is so 
readily obtained by hydrolysis of neomycin, involves resolution. Nevertheless, the first (enzymatic) 
resolution of 2-DOS was not reported until 1996, by Orsat et al.,47 and involved the conversion of 
meso 2-DOS 1 into 18 through the combined action of the catalase subtilisin BPN' and 
diallylcarbonate in HEPES buffer (Scheme 6). The product (18) was obtained (1 week, room 
temperature) in a yield of 76% and with excellent selectivity (>99% e.e.). 
 
Scheme 6.  
NH2
H
N
OH
OHHO
O
O
 subtilisin BPN'
1
18
(76%, e.e. >99%)
O
O
2
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Nearly at the same time, another example of 2-DOS resolution was provided by incubation of a 
suspension of N,N'-di(phenylacetyl) protected 2-DOS (19) in a 4:1 phosphate buffer: DMF mixture 
(18 days, 25-35 °C) with Penicillin amidase to give, after acetylation, the N-acetyl,N'-phenylacetyl 
protected derivative 20 with high enantioselectivity (Scheme 7).
48
 
 
Scheme 7.  
1. Penicillin 
    amidase
(76%, 
e.e. >97%)
NHAcPhAcHN
OAc
OAcAcO
NHAcPhPhAcHN
OH
OHHO
19 20
2. Ac2O
 
 
More recently, Wong et al. described the desymmetrization of a diazido derivative of 2-DOS by 
either an enzymatic or a chemical approach.
49
 Thus, 2-DOS was converted into the diazido triacetyl 
derivative (21) by a Cu
2+
-catalyzed diazotransfer with triflyl azide, followed by treatment with 
acetic anhydride (Scheme 8). Enzymatic resolution of 21 relied on enantioselective deacetylation 
using a resin-immobilized lipase Novozym 435 (immobilized Candida antarctica), providing 22 in 
71% yield (although the e.e. was not mentioned). 
 
Scheme 8.  
1
1. TfN3, CuSO4
(75%)
N3N3
OAc
OAcAcO
N3N3
OAc
OAcHO
Candida 
antarctica
(71%)
21 22
2. Ac2O
 
 
An alternative chemical desymmetrization approach utilized the chiral dispiroketal protection-
desymmetrization protocol of Ley and coworkers.
50
 After deacetylation of 21, the resulting triol 23 
was treated with (2R,2R')-bis-diphenyl-6,6'-bis(3,4-dihydro-2H-pyran, PDHP) and catalytic 
camphorsulfonic acid in refluxing chloroform, followed by acetylation to give 24 as the major 
isomer in 50% (Scheme 9). Deacetylation provided 25, a suitable substrate for selective 
glycosylation at the 4-position in a dedicated synthesis of aminoglycosides, but 25 was found to be 
of little value as carbohydrate acceptor due the inreactivity of the (sterically hindered) free 
hydroxyl. 
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Scheme 9.  
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O
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1.5 Enantiopure 2-DOS (derivatives) from the chiral pool 
Apart from strategies employing resolution, a large number of synthetic routes toward enantiopure 
2-DOS (derivatives) that have appeared in the literature are based on chiral starting materials such 
as neomycin, N-acetyl-D-glucosamine, D-mannose,58 and D-glucose.54 
 Canas-Rodriguez reported the first synthesis of an asymmetric (protected) form of 2-DOS 
starting from neamine (3).
51
 Oxidative cleavage of compound 26 with sodium periodate followed 
by E2-elimination upon treatment of the resulting dialdehyde with triethylamine gave 28 (Scheme 
10). For reasons of purification the crude reaction mixture was subsequently treated with sodium 
borohydride after which alcohol 28 could be isolated in 25% yield or, preferably, as the acetate 29. 
The overall yields starting from neomycin B are 8.7% and 17% for compounds 28 and 29, 
respectively. We have adapted this methodology for the preparation of more conveniently protected 
N-Cbz protected 2-DOS (not depicted) and found the procedure works just as well.52 
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Yoshikawa designed a route toward 2-DOS centered on nitro-aldol reaction and a one-step 
elimination-reduction sequence of an acetoxy residue (Scheme 11).
53
 To this end, Fisher 
glycosidation of N-acetyl-D-glucosamine (30) was followed by selective protection of the primary 
hydroxyl by a trityl group, benzylation and acidic detritylation to give 31. Subsequent Jones 
oxidation with CrO3 with concomitant hydrolysis at the anomeric center, Pb(OAc)4 cleavage of the 
masked glycol at O5, O6 followed by Henry reaction of the intermediate dialdehyde with 
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nitromethane gave the all-equatorial 32 with remarkable stereoselectivity. Selective protection of 
the 1,3-hydroxylamide using Ac2O-NaOAc in THF was followed by NaBH4-induced elimination of 
the acetoxy group and reduction leading to nitroaminocyclitol 34. The overall yield of these 9 steps 
is 9.6%. The configurational identity of 34 was unambiguously established via reduction of the 
nitro group, N-acetylation, debenzylation and O-acetylation to afford the known 2-DOS 
pentaacetate 36. 
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Da Silva et al. developed a route toward 2-DOS which appears to be inspired by the biosynthetic 
pathway of 2-DOS from D-glucose.
54,55
 Oxime 40 was obtained from the α-methyl glycoside 37 via 
the carbohydrate-inose Ferrier rearrangement (38→39, Scheme 12).
56,57
 Direct reduction of oxime 
40 with LiAlH4 was unsuccessful but benzylation of the oximino group prior to reduction led to a 
mixture of epimeric amines along with the O-benzylhydroxylamine (not depicted) in a 90% 
combined yield (ratio 1:9:1). Acetylation of the desired trans-epimer 42 followed by conversion to 
the mesylate and reaction with sodium azide led to protected azido 2-DOS 43. Staudinger reaction 
with triphenylphosphine gave the protected 2-DOS derivative (44) in an overall yield of 4.9% 
starting from protected methyl glycoside 37. 
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Scheme 12.  
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Baer and coworkers
58
 developed two (similar) routes toward enantiopure 2-DOS analogues, both 
starting from D-mannose (45, Scheme 13). Via a known Henry reaction, D-mannose was first 
converted into 1-deoxy-1-nitro-D-glycero-D-galacto-heptitol hexaacetate (46).59 Elimination-
reduction with sodium borohydride followed by O-deacetylation gave the pentanol (not depicted) 
which was regioselectively acetonated. Mesylation or triflation afforded the sulfonates 48 and 49 in 
an overall yield from D-mannose of 20-25%. 
 
Scheme 13.  
(72%)
 R= SO2Me (62%)
 R= SO2CF3 (±73%)
46 X = OAc
47 X = H
NaBH4
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O
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1. NaOMe
2. DMP, H+
 
 
Compounds 48 and 49 were the starting materials for two alternative routes. First of all, following 
route A (Scheme 14), mesylate 48 was selectively deacetonated at the 6,7-position with 
trifluoroacetic acid and subsequently cleaved with sodium periodate to afford compound 51. 
Nitroaldol cyclization of the sugar effected by sodium methoxide in methanol led to a mixture of 
epimeric cyclitols that could be separated by chromatography to give predominantly diastereomer 
52 (70% yield). Conversion of 52 into 53 could be executed by two routes, either involving 
deacetonation with TFA prior to nucleophilic introduction of an azide (72% for 2 steps), or by 
reaction of 52 with sodium azide under phase transfer catalysis in benzene/water (52→54) followed 
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by acid hydrolysis (72% yield). Unfortunately, in both cases nucleophilic displacement was 
accompanied by partial epimerization at the carbinol positions, necessitating tedious 
chromatographic separation. Final hydrogenolysis of 53 with Adam's catalyst to 2-DOS was 
straightforward. The alternative route B involves the preparation of azido derivative 55 from triflate 
49 prior to Henry-aldol cyclization. In similar steps as above, nitro alcohol 54 was obtained, along 
with its epimer, in 62% overall yield (54 was isolated by crystallization performed under dynamic 
epimerization conditions). An alternative route from 54 to 1 was also presented involving 
hydrogenation to the 4,5-isopropylidene protected 2-DOS 54 prior to deacetonation. The total yield 
for both routes starting from D-mannose is around 13%. It is of interest to note that the enantiopure 
alcohol 54 is potentially suitable for the preparation of aminoglycoside analogues by O-
glycosylation. 
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1.6 Conclusion 
An efficient route to 2-DOS may serve as a practical starting point for the assembly of 
aminoglycoside-type libraries in the development of novel RNA-ligands. As such, the syntheses 
discussed in this chapter are not of sole academic interest since they lead to a valuable starting 
material for biological and medicinal purposes. It is apparent, however, that the above described 
synthetic sequences aiming at 2-DOS are characterized by a wide variety of strategies. Apart from 
that, nearly each route starts from its own unique starting material (with the exception of neomycin) 
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and, more importantly, leads to a unique 2-DOS analogue, rather than 2-DOS itself, in most of the 
cases. A few observations can be readily made. First of all, by far the highest overall yield to 
acquire ‘naked’ 2-DOS is by degradation of the relatively cheap and commercially available 
aminoglycoside neomycin. Although the synthetic elegance of the approach is poor, with 75% of 
starting material degraded to waste, the ease and straightforwardness of the procedure outperforms 
any of the de novo syntheses. Therefore, if plain 2-DOS is required, acid hydrolysis of neomycin 
obviously is the method of choice (apart from direct acquisition of 2-DOS). The syntheses shown in 
this chapter start from a large diversity in starting material, both in structure and in price. However, 
for cost-effective synthesis of 2-DOS, or an analogue thereof, the price of the starting material is 
only one of the factors to be taken into consideration. Apart from that, the number of synthetic 
steps, costs of reagents and purification, intermediate yields and applicability to large scale are only 
some of the additional factors that define the value of a synthetic sequence. Obviously, ‘naked’ 
2-DOS or a symmetrically protected variant thereof can be readily obtained, but the practicality of 
these meso compounds (or any other analogue) depends entirely on an individual’s particular goal.  
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Synthesis of a protected enantiomerically pure  
2-deoxystreptamine derivative from D-allylglycine
1
 
 
 
 
 
Abstract 
A diastereoselective synthetic route from D-allylglycine to the enantiopure (protected) 
2-deoxystreptamine (2-DOS) derivative 14 is presented. Key steps involve two consecutive chain 
extensions with crucial stereodirective roles for the amino protective groups, as well as ring closure 
by olefin metathesis, face selective dihydroxylation, cyclic sulfate formation and finally opening 
with azide. The resulting 2-DOS derivative is ideally protected for the preparation of 4,5- or 
4,6-linked aminoglycoside antibiotics. 
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 Part of this chapter has been published in: G. F. Busscher, F. P. J. T. Rutjes, F. L. van Delft, 
Tetrahedron Let. 2004, 45, 3629-3632. 
 
Chapter 2 
 24 
2.1  Introduction 
Since the discovery of streptomycin in 1944, the family of aminoglycosides has grown steadily into 
a powerful class of antibiotics with a broad antibacterial spectrum and proven efficacy, particularly 
in combination with other drugs.1 Nevertheless, extensive use of the aminoglycosides is limited due 
to the associated toxicities, most notably nephrotoxicity and ototoxicity, and to a lesser extent 
neuromuscular blockade.2 Another, more alarming drawback of the aminoglycosides is the global 
development of microbial resistance with the most common mechanism being structural 
modification by bacterial enzymes. These circumstances necessitate the development of new and 
innovative aminoglycoside antibiotics and several reports on the derivatization of existing 
aminoglycosides have appeared in the literature in recent years.3 To be fully flexible in the design 
and preparation of novel aminoglycoside-type structures, however, de novo synthesis from 
individually prepared components is required. Consequently, our research has focused on the 
synthesis of enantiomerically pure derivatives of 2-deoxystreptamine (2-DOS), an aminocyclitol 
ring that constitutes the core structure of the majority of clinically useful aminoglycosides (Figure 
1) and, as may well be speculated, is crucial for binding of the aminoglycosides to their target A-
site RNA.4  
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Figure 1. Representative aminoglycoside antibiotics, both 4,5- and 4,6-linked to 2-DOS. 
 
Although several synthetic routes towards 2-DOS are known in the literature, all require many 
synthetic steps and offer minimal flexibility in protective groups.
5
 Moreover, only two of these 
routes afford an asymmetric analogue of 2-DOS, starting from either D-mannose
6
 or D-glucose.
7
 
The most practical method to obtain this aminocyclitol moiety is by degradation of neomycin,
8,9,10
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but the “naked” meso-compound thus obtained still requires desymmetrization as well as protective 
group manipulations before incorporation into new aminoglycoside entities can be ensured. In 
contrast, we here wish to report a synthesis of an orthogonally protected, enantiopure 2-DOS 
derivative which is highly suitable to serve as a scaffold for new aminoglycoside entities, either 4,5- 
or 4,6-linked. 
It was envisioned that the final protected 2-DOS derivative A could be obtained from the 
cyclohexane precursor B via epoxidation and nucleophilic ring opening. Compound B in turn can 
be retrosynthetically traced back via ring closing metathesis and vinyl addition to the masked 
aldehyde C. The latter thiazole-protected syn β-amino alcohol C was expected to result in a few 
steps from D-allylglycine.  
 
[N] NH2
HO OP1
OP2
NH2
OP1
OP2
N
S
NH2
OP1
NH2
OHO
A B C D-allylglycine  
Figure 2. Retro-synthetic analysis of protected 2-DOS 
 
Our synthesis starts from enantiomerically pure D-allylglycine, a non-proteinogenic amino acid that 
is readily available in our group.
11
 Thus, the methyl ester of D-allylglycine
12
 was subjected to 
conditions explored by Dondoni and co-workers,13 involving introduction of thiazole as a masked 
aldehyde. Our first attempt to obtain the thiazolyl β-amino alcohol 2a (Scheme 1) started with 
Boc-protected allylglycine methyl ester 1a, which gave upon partial reduction and addition of 
2-(trimethylsilyl)thiazole (2-TST) the syn-amino alcohol 2a. Not unexpectedly, however, alcohol 2a 
was obtained13 with a d.e. of only 70% which led us to follow a slightly different procedure 
involving double protection of the amino function (Boc, PMB) as in 1b and reversal of the 
sequence of events, e.g. first reaction with 2-lithiothiazole (2-LTT) and then NaBH4 reduction of 
the resulting ketone. To our satisfaction, the syn β-amino alcohol 2b was now obtained with a d.e. 
of >95%.
13
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Scheme 1.  
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Reagents and conditions: (a) AcCl, MeOH, 2 h, ∆ then Boc2O, dioxane, rt, 18 h (90%); (b) AcCl, MeOH, ∆, 
2 h then Et3N, p-MeOC6H4CHO or naphtylaldehyde, CH2Cl2, rt, 18 h then NaBH4, MeOH, 30 min, 0 °C then 
Boc2O, dioxane, rt, 18 h (1b 89%, 1c 60%); (c) DIBAL-H, toluene, -78 °C, 2 h, 2-TST, CH2Cl2, -20 °C, 48 h 
then Bu4NF.3H2O, THF, rt, 1 h (70% d.e., 70%); (d) 2-LTT, Et2O, -78 °C to -45 °C, 6 h then NaBH4, MeOH, 
0 °C, 30 min; (e) DDQ, CH2Cl2/MeOH (4/1), drop H2O, rt, o.n.; (f) NaH, DMF, 0 °C. 
 
Next, benzyl protection of the free hydroxyl was investigated but it was found that standard 
conditions (sodium hydride followed by benzyl bromide) led to 2-oxazolidinone 3 (Scheme 1). 
However, inverting the order of addition of NaH and BnBr cleanly gave the O-benzylated 
derivative 4 (Scheme 2) which was subjected to the thiazole deblocking protocol,13 followed by 
condensation of the resulting aldehyde 5 with vinylmagnesium bromide. Unfortunately, the 
nucleophilic chain extension was characterized by low stereoselectivity revealing a 1:1 mixture of 
syn and anti-diastereomers 6a and 6b which did not improve upon varying the reaction conditions 
(temperature, solvents, additives). 
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Reagents and conditions: (a) BnBr, DMF, 0 °C then NaH, 1 h; (b) CAN, NaHCO3, MeCN/H2O (4/1), rt, 30 
min; (c) 4Å MS, MeOTf, MeCN, rt, 25 min then NaBH4, MeOH, 0 °C, 10 min then CuCl2.2H2O, CuO, 
MeCN/H2O, 10/1, rt, 15 min; (d) vinylMgBr, THF, -78 °C, 4 h. 
 
A crucial role of the amino protection was again suspected and therefore it was decided to remove 
the p-methoxybenzyl group of 4 (→7) with CAN prior to Grignard addition. Buffering of the CAN 
solution with NaHCO3 was required to prevent a drop in yield, the monoprotected amine 7 was now 
obtained in a yield of 67%. Attempts to increase the yield, for instance via deprotection with DDQ, 
were not fortunate since only starting material was recovered. A route proceeding via the 
naphtylmethyl protected urethane 1c, based on the premise that a naphtylmethyl group could be 
removed easier was also not successful due to the fact we were unable to remove the 
naphthylmethyl group with DDQ (Scheme 1).
14
 Nevertheless, having the monoprotected urethane 7 
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in hand, addition of vinylmagnesium bromide after thiazole unmasking (7→8) could be attempted. 
Gratifyingly, the diastereoselectivity of the addition now proceeded with a much improved syn:anti 
ratio of 4:1, leading to compounds 9a and 9b, respectively. (Scheme 2). 
 
Scheme 3.  
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Reagents and conditions: (a) 2nd generation Grubbs’ catalyst (mono-substituted imidazolylidene ligand), 
CH2Cl2, rt, 2 h; (b) TBDMSOTf, Et3N, CH2Cl2, rt, 2 h; (c) several methods e.g. m-CPBA, CH2Cl2, rt, 48 h, rt or 
oxone, chlorocyclohexanone, NaHCO3, MeCN/H2O 3:2, 24 h; (d) NaN3, NH4Cl, MeOH. 
 
After silica gel separation of the diastereomers, ring-closing metathesis proceeded smoothly and the 
free hydroxyl of the cyclic product 1015 was protected with a TBDMS group to afford 11 in 84% 
yield (Scheme 3). Despite the presence of the bulky silyl group, however, epoxidation of compound 
11 with several reagents, such as m-CPBA, oxone and in situ formed dioxirane16 led in all cases to 
inseparable mixtures of diastereomers varying from 1:1 to 3:1 (12). Matters became more 
complicated when we tried to open the diastereomeric epoxides with sodium azide, leading to the 
formation of four isomeric azido alcohols (13).  
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Reagents and conditions: (a) RuCl3.H2O, NaIO4, EtOAc/MeCN/H2O (3/3/1), 0 °C, 3 min; (b) SOCl2, 
pyridine, EtOAc, 0 °C, 30 min then NaIO4, RuCl3.H2O, CH2Cl2/MeCN/H2O (2/2/3), 0 °C, 1 h; (c) LiN3, 
DMF, ∆, 4 h then H2SO4, THF, H2O, rt, 30 min. 
 
Therefore, attention was focused on the application of cyclic sulfate technology, since it is known 
that the reactivity of cyclic sulfates and epoxides towards nucleophiles is similar in nature but 
differs in selectivity.17 Another advantage is that the ring-opening of five-membered cyclic sulfates 
proceeds much faster than with epoxides probably due to the better leaving group ability.18 Thus, 
the double bond of 11 was dihydroxylated19 (11→14, Scheme 3), which occurred with exclusive 
facial selectivity, followed by reaction with thionyl chloride and oxidation to form the cyclic sulfate 
15 in 80% yield.20 Much to our satisfaction, opening of the cyclic sulfate with lithium azide 
proceeded completely regioselectively to give, after subsequent sulfate hydrolysis, the protected 
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2-DOS 16 in enantiomerically pure form. The latter compound, after glycosylation of the free 
hydroxyl, is ideally suited for the preparation of either 4,5- or 4,6-linked aminoglycoside analogues 
after subsequent desilylation or debenzylation, respectively. 
 
2.2 Concluding remarks 
In conclusion, we believe that the synthesis described above is a versatile route towards 
orthogonally protected 2-DOS in enantiomerically pure form in 14 steps and an overall yield of 
6.1%. The aminocyclitol building block obtained is suitable for incorporation into new 
aminoglycoside entities.  
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2.4 Experimental Section 
General methods 
All reactions were carried out under inert atmosphere of dry nitrogen or argon. Standard syringe techniques 
were applied to the transfer of dry solvents and air- or moisture sensitive reagents. Rf values are obtained 
using thin layer chromatography (TLC) on silica gel-coated plates (Merck 60 F254) with the indicated 
solvent mixture and compounds were detected with UV light, ammonium molybdate solution, potassium 
permanganate, ninhydrin, or with anisaldehyde. Melting points were analyzed with a Büchi melting point B-
545. IR spectra were recorded on an ATI Mattson Genesis Series FTIR spectrometer; absorption reported in 
cm-1. GC was performed on a Hewlett Packard 5890, containing a HP1 column (25 m * 0.32 mm * 0.17 
µm), FID detection, and equipped with a HP3393A integrator. NMR spectra were recorded on a Bruker 
DMX 300 (300 MHz), and a Varian 400 (400 MHz) spectrometer in CDCl3 solutions (unless otherwise 
reported) using TMS as internal standard; chemical shifts are given in ppm. Coupling constants are reported 
as J-values in Hz. Peak assignment in 13C spectra are based on 2D-GHSQC and GHMBC spectra. 
Enantiomeric purities were determined on a Shimadzu HPLC, with indicated column and solvent mixture. 
Column or flash chromatography was carried out using ACROS silica gel (0.035–0.070 mm, and ca 6 nm 
pore diameter). Automated parallel syntheses were performed with the Anachem synthesis robot (Gilson 
SK233). Optical rotations were determined with a Perkin Elmer 241 polarimeter. Mass spectra were 
measured with a Fisons (VG) Micromass 7070E apparatus and/or a Finnigan MAT900S. MALDI-TOF-MS 
spectra were measured on a Bruker Biflex III machine, with dihydroxybenzoic acid (DHB) as matrix. 
Elemental analyses were carried out using a Carlo Erba Instruments CHNS-O EA 1108 element analyzer. 
Solvents were distilled from appropriate drying agents prior to use. Unless stated otherwise, all chemicals 
were purchased and used as such. The microwave reactions were carried out in a CEM Discover microwave. 
 
(4R)-N-(tert-Butoxycarbonyl)-N-(4-methoxybenzyl)allylglycinemethylester (1b)  
AcCl (18 mL) was added dropwise to cold MeOH (ice bath) (118 mL). The reaction 
mixture was stirred for 5 min before D-allylglycine was added (10.0 g, 87.0 mmol). After 
refluxing for two hours the reaction mixture was concentrated. The obtained allylglycine methylester (5.0 g, 
25 mmol) was dissolved in CH2Cl2 (200 mL) under an argon atmosphere. To this solution was added 
p-methoxybenzaldehyde (5.60 mL. 104 mmol), Et3N (6.50 mL, 104 mmol) and MgSO4 (6.00 g). The 
MeO O
NPMBBoc
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reaction mixture was stirred for 18 hours and filtered through celite and evaporated. The crude mixture was 
dissolved in MeOH and cooled with an ice bath. NaBH4 (1.90 g, 50.0 mmol) was added and the reaction 
mixture was stirred for 30 min. After the addition of acetone solvents were evaporated. The reaction mixture 
was washed with sat. aq. NaHCO3, brine and extracted with EtOAc, and dried with Na2SO4, the crude 
product was dissolved in dioxane (40 mL) and di-tert-butyldicarbonate (6.00 g, 104 mmol) was added to the 
reaction mixture. After stirring for another 18 hours the solvents were evaporated and the crude product was 
purified by flash chromatography (EtOAc/n-heptane, 1/5), to obtain 1b (13.0 g, 89%, 3 steps) as a colorless 
oil. Rf 0.7 (EtOAc/n-heptane, 3/2). [α]D
20 +31 (c 0.68; CH2Cl2). IR υmax film: (cm
-1) 2979, 1732, 1496, 1365, 
1167, 1052. 1H NMR (CDCl3, 300 MHz, ppm): δ 7.22 (br s, 2H), (d, 2H), 5.78-5.51 (m, 1H), 5.15-4.89 (m, 
2H), 4.78-4.29 (m, 2H), 3.90-3.71 (m, 1H), 3.80 (s, 3H), 2.60 (s, 3H), 2.89-2.62 (m, 1H), 2.61-38 (m, 1H), 
1.55 (s, 9H). 13C NMR (CDCl3, 100 MHz, ppm) δ: 130.5, 118.0, 114.3, 114.0, 70.2, 69.7, 55.9, 52.5, 38.2, 
29.1, 29.0. HRMS (CI) m/z calcd for C19H27O5N (M)
+: 350.1967, found: 350.1967. 
 
(1R,2S)-2-[2-N-(tert-Butoxycarbonyl)-N-(4-methoxybenzyl)amino]-1-hydroxy-3-
allylpropyl]-1,3-thiazole (2b)  
To a cold (-78 °C) solution of BuLi (6.05 mL, 9.68 mmol, 1.6 M solution in hexane) in 
Et2O (30 mL) was added dropwise a solution of 2-bromothiazole (806 µl, 8.94 mmol) in 
the same solvent (30 mL). After the yellow solution had been stirred for 30 min at -78 °C a solution of the 
ester 1b (2.5 g, 7.5 mmol) in Et2 O (30 mL) was added slowly. The solution was allowed to warm to -65 °C 
and was stirred at this temperature for 4 h. after which sat. aq. NaHCO3 was added (30 mL). The mixture was 
allowed to warm up to room temperature over 20 min and the layers were separated. The aqueous layer was 
extracted with Et2O (2 × 30 mL). The combined organic extracts were washed with sat. aq. NaCl (6 mL), 
dried (Na2SO4) and concentrated. Flash chromatography (EtOAc/n-heptane, 1/5) to yield the ketone 2b (2.6 
g, 92%) as a yellow oil. To a cold (-78 °C) stirred solution of this ketone (2.6 g, 6.6 mmol) in MeOH was 
added NaBH4 (506 mg, 14 mmol). The mixture was stirred for 30 min and diluted with acetone (5 mL) and 
concentrated. The residue was washed with sat. aq. NaHCO3 (3 mL) and extracted with Et2O (2 × 30 mL), 
dried (Na2SO4) and concentrated. Flash column chromatography (EtOAc/n-heptane, 2/3) gave the pure 
alcohol 2b (2.6 g, 89%) as a white solid. Rf 0.4 (EtOAc/n-heptane, 2/3). [α]D
20 -65 (c 0.445; CH2Cl2). IR υmax 
film: (cm-1) 2976, 2360, 2340, 1656, 1513, 1247, 1164, 729. 1H NMR (CDCl3, 400 MHz, ppm) δ: 7.70 (d, 
1H, J = 3.2 Hz, Th), 7.32-7.69 (m, 3H, arom), 6.79 (d, 2H, J = 8.5 Hz, arom), 5.50 (m, 1H, allyl), 5.14-4.89 
(m, 3H, allyl and CH), 4.35 (d, J = 14.9 Hz, 1H, CH2), 3.79 (s, 4H, OMe and CH), 3.51 (d, J = 14.9 Hz, 1H, 
CH2), 2.78 (m, 1H, CH2a), 2.36(m, 1H, CH2b), 1.44 (s, 9H, t-Bu).
 13C NMR (CDCl3, 100 MHz, ppm) δ: 
159.3, 158.3, 142.9, 134.7, 130.0, 119.0, 118.4, 114.2, 82.0, 74.7, 65.4, 55.9, 55.0, 36.1, 32.6, 29.7, 23.44, 
14.89. MS (CI) m/z: 405 (M+H). Elemental analysis: calculated for (C21H28O4N2S) (405.535) C 62.35, H 
6.98, N 6.92, found C 61.67, H 7.12, N 6.63.  
 
(1R,2S)-2-[N-(tert-Butoxycarbonyl)-N-(4-methoxybenzyl)amino]-1-hydroxy-3-allyl-
1-(1,3-thiazol-2-yl)propylbenzyl (4)  
BnBr (4.3 mL, 36 mmol) and compound 2b (7.5 g, 18 mmol) were dissolved in DMF and 
cooled to 0 °C. Sodium hydride (741 mg, 18 mmol) was then added to the reaction 
mixture. After stirring for half an hour the reaction mixture was quenched with saturated 
NH4Cl and extracted with 2-propanol/EtOAc (10/1) and washed with H2O (4 times) and brine and dried 
(Na2SO4). Flash column chromatography (EtOAc/n-heptane, 1/5) gave 4 (8.1 g, 90%) as a colorless oil. Rf 
0.2 (EtOAc/n-heptane, 1/5). [α]D
20 -33 (c 1.60; CH2Cl2). IR υmax film: (cm
-1) 2974, 1688, 1512, 1245, 1165, 
735. 1H NMR (CDCl3, 400 MHz, ppm) temp 55 °C: δ 7.75 (d, J = 2.4, 1H), 7.43-7.24 (m, 8H, arom), 6.75 
(m, 2H, PMB), 5.64-5.23 (m, 1H, allyl), 5.12-4.03 (m, 8H, 2CH and allyl, 2CH2), 3.75 (s, 3H, OMe), 2.40 
(m, 1H, CH2), 2.11 (m, 1H, CH2), 1.37 (s, 9H, t-Bu).
 13C NMR (CDCl3, 100 MHz, ppm): δ 142.9, 134.9, 
128.6, 128.5, 20.22, 117.5, 133.8, 72.6, 55.8, 34.5, 29.1. HRMS (CI) m/z calcd for C28H34O4N2S (M)
+: 
494.2239, found: 494.2243. HPLC (OD-H, 1.0 mL/min, i-PrOH/hexane, 1/99, 1 µL): retention times (min): 
26.162 (ee > 98%). 
OH
NPMBBoc
N
S
OBn
NPMBBoc
N
S
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(1R,2S)-2-[N-(tert-Butoxycarbonyl)-amino]-1-hydroxy-3-allyl-1-(1,3-thiazol-2-yl) 
propyl Benzyl (7)  
To a solution of 4 (2.46 g, 4.98 mmol) in 50 mL of MeCN/H2O (4/1) at rt was added 
NaHCO3 (4.53 g, 14.9 mmol) and ceric ammonium nitrate (CAN; 29.6 g, 14.9 mmol). 
The reaction was stirred vigorously for 30 min, neutralized with Et3N (a few drops), and 
concentrated to dryness. The residue was extracted with EtOAc and washed with H2O, dried (Na2SO4) and 
concentrated. Flash column chromatography gave (1.23 g, 67%). Rf 0.2 (EtOAc/n-heptane, 1/5). [α]D
20 -5.3 
(c 0.68; CH2Cl2). IR υmax film: (cm
-1) 3448, 1711, 1496, 1365. 1H NMR (CDCl3, 300 MHz, ppm): δ 7.75 (d, J 
= 2.4 Hz, 1H), 7.43-7.24 (m, 6H), 5.61-5.22 (m, 1H), 5.22-4.45 (m, 3H), 4.67 (d, J = 14.8 Hz, 1H), 4.47 (d, J 
= 14.8 Hz, 1H, CH), 4.09 (m, 1H, CH), 2.48-2.18(m, 2H, CH2), 1,38 (s, 9H, t-Bu).
 13C NMR (CDCl3, 75 
MHz, ppm): δ 170.1, 155.5, 142.6, 1347.3, 134.6, 128.4, 119.7, 117.9, 79.4, 79.0, 72.3, 53.8, 36.9, 28.5. 
HRMS (CI) m/z calcd for C20H26O3N2S (M)
+: 374.1664, found: 374.1664.  
 
(2R,3S)-3-[N-(tert-Butoxycarbonyl)amino]-2-[(benzyl)oxy]-4-allylbutanal (8)  
A mixture of compound 7 (1.00 g, 2.67 mmol), activated 4 Å powdered molecular sieves 
and anhydrous MeCN (26 mL) was stirred at rt for 10 min after which methyl 
trifluoromethanesulfonate (497 µL, 3.47 mmol) was added. The suspension was stirred for 
15 min and concentrated to dryness. The residue was dissolved in MeOH, cooled to 0 °C, 
and treated with NaBH4 (222 mg, 5.94 mmol). The mixture was stirred at rt for 20 min, diluted with acetone, 
filtered through Celite, and concentrated. The residue was dissolved in H2O/CH3CN (1/10), CuO (1.96 g, 
21.3 mmol) and CuCl2·H2O (358 mg, 4.54 mmol) were added. The mixture was stirred for 15 min and then 
filtered through celite. MeCN and most of the water were evaporated (bath temperature not exceeding above 
40 °C) to give a brown syrup. The residue was triturated with Et2O and the liquid face was pipetted through a 
pad of Florisil (100-200 mesh) to afford a colorless solution (708 mg, 83%). Rf 0.5 (EtOAc/n-heptane, 3/2). 
IR υmax film: (cm
-1) 3444, 2975, 1708, 1498, 1365, 1250, 1167, 1053. 1H NMR (CDCl3, 400 MHz, ppm): δ 
9.64 (s, 1H), 7.42-723 (m, 5H), 5.81-5.61 (m, 1H), 5.09-4.96 (m, 2H), 4.99( br d, J = 1.6 Hz, 1H), 4.79 (d, J 
= 11.4 Hz, 1H), 4.47 (d, J = 11.4 Hz, 1H), 4.21-4.4.11 (m, 1H), 3.92 (s, 1H), 2.34 (t, J = 14.4 Hz, 2H), 1.39 
(s, 9H). 13C NMR (CDCl3, 100 MHz, ppm): δ 155.3, 17.1, 134.0, 128.5, 118.6, 83.4, 79.8, 73.1, 65.9, 50.5, 
36.7, 28.6, 15.4.  
 
(3S,4S,5R)-5-(tert-Butyloxycarbonyl)amino-4-(benzyloxy)-1,7-octadiene-ol (9a)  
To a cold solution -78 °C of compound 8 (0.815 g, 2.55 mmol) in THF was added 
vinlylmagnesium bromide (10.2 mL, 10.2 mmol). The solution was stirred for 4 h and 
quenched with NH4Cl. The solvent was evaporated and extracted with Et2O and water, dried 
Na2SO4, the solvents were evaporated to yield compound 9a as a colorless liquid (0.963 g, 56%). Rf 0.5 
(EtOAc/n-heptane, 2/3). [α]D
20 +27.3 (c 1.89; CH2Cl2). IR υmax film: (cm
-1) 2976, 1707, 1502, 1171.1H NMR 
(CDCl3, 400 MHz, ppm): δ 7.48-7.25 (m, 5H, arom), 6.19-6.40 (m, 1H, =CH-), 5.82-5.62 (m, 1H, =CH-), 
5.72 (d, 1H, J = 10.5 Hz, =CH2), 5.12 (d, 1H, J = 17.3 Hz, =CH2), 5.11-5.02 (m, 2H, =CH2), 4.77 (d, 2H, J = 
11.3 Hz, CH2), 4.66 (d, 2H, J = 11.0 Hz, CH2), 4.80 (br s, 1H, CH), 4.23-4.15 (m, 1H, CH), 4.09-3.80 (m, 
1H, CH), 2.31 (br t, 2H, J = 7.2 Hz, CH2), 1.41 (s, 9H, t-Bu).
 13C NMR (CDCl3, 75 MHz, ppm): δ 135.0, 
128.9, 128.8, 118.1, 118.0, 79.9, 75.6, 73.7, 51.0, 38.5, 29.1. HRMS (CI) m/z calcd for C24H30O4N (M)
+: 
348.2174, found: 348.2167. 
 
(1R,5S,6S)-6-benzyloxy-5-hydroxy-cyclohex-3-enyl-1-amino(tert-butyloxycarbonyl) (10) 
To a mixture of compound 9a (20 mg, 5.7 mmol) in CH2Cl2 was added the mono-substituted 
imidazolylidene ligand (3 mg, 5 mol%) The mixture was stirred for 2 h at rt and evaporated 
dried (Na2SO4). Column chromatography (EtOAc/n-heptane, 1/5) gave 10 (18 mg, 98%). as a 
white solid. Rf 0.4 (EtOAc/n-heptane, 1/1). [α]D
20 +20.0 (c 0.57; CH2Cl2). Mp: 126 °C. IR υmax 
film: cm-1 3342, 1681, 1531, 1168, 734. 1H NMR (CDCl3, 400 MHz, ppm): δ 7.43-7.19 (m, 5H, arom), 5.79-
5.40 (m, 2H, CH=CH), 4.92-4.68 (m, 3H, Bn and CH), 4.32 (br s, 1H, NH), 4.05-3.78 (m, 1H, CH), 3.47 (q, 
J = 6.0 Hz, 1H, CH), 2.68-2.42 (m, 1H, CH2), 2.20-1.95 (m, 2H, CH2 and OH), 1.44 (s, 1H, 9H, t-Bu). 
13C 
NMR (CDCl3, 100 MHz, ppm): δ 155.9, 138.6, 128.8, 128.1, 126.9, 82.0, 73.4, 71.5, 31.6, 28.6. HRMS (CI) 
m/z calcd for C18H26NO4 (M+H)
+: 320.1861, found: 320.1860. 
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(1R,5S,6S)-6-benzyloxy-5-(tert-butyldimethylsilyl)oxy-3-cyclohexenyl-1-(tert-
butyloxycarbonyl)amine (11)  
Compound 10 (167 mg, 0.523 mmol) was dissolved in CH2Cl2 (5 mL) and cooled to -20 
°C then tert-butyldimethylsilyl trifluoromethanesulfonate (156 µl, 0.676 mmol) and 
DIPEA (127 µl, 0.732 mmol) were added to the reaction mixture. After stirring for 30 min the mixture was 
quenched with sat. aq. NaHCO3 and dried with Na2SO4, evaporated and purified by flash column 
chromatography (EtOAc/n-heptane, 1/10) gave (186 mg, 84%) of compound 11 as a white solid. Rf 0.68 
(EtOAc/n-heptane, 2/3). [α]D
20 +12.6 (c 0.27; CH2Cl2). mp 78 °C. IR υmax film: (cm
-1) 2956, 2885, 1714, 
1513, 1114, 840. 1H NMR (CDCl3, 400 MHz, ppm): δ 7.19-39 (m, 5H, Bn), 5.69-5.82 (m, 1H, H5), 5.49-5.68 
(m, 1H, H4), 4.62 (dd, J = 12.0 Hz, 2H, CH2Bn), 4.18 (m, 2H, H3 and H1), 3.48 (dd, J = 3.5 Hz, 1H, H2), 
2.34-2.53 (m, 1H, H6), 2.18-1.99 (m, 1H, H6), 1.37 (s, 9H, t-Bu), 0.86 (s, 9H, t-Bu), 0.03 (s, 6H, 2Me).
 13C 
NMR (CDCl3, 100 MHz, ppm); δ 160.5, 143.3, 133.5, 132.8, 131.9, 83.9, 83.2, 77.4, 73.6, 36.9, 33.8, 30.8, 
22.9, 0.4, 0.0. HRMS (CI) m/z calcd for C24H40O4NSi (M+H)
+: 434.2727, found: 434.2781.  
 
(1R,2R,3S,4S,5R)-5-(tert-Butyloxycarbonyl)amino-4-benzyloxy-3-[(tert-
butyldimethylsilyl)oxy]cyclohexane-1,2-diol (14)  
To a vigorously stirred solution of the alkene 11 (15 mg, 0.046 mmol) in EtOAc and 
CH3CN (200 µl, 1:1) at 0 °C (ice bath) was added a solution of RuCl3·H2O (cat) and 
NaIO4 (15 mg, 0.069 mmol) in distilled H2O. The two fase system was stirred vigorously for 3 min and 
quenched with sat. aq. solution of Na2SO3. The aqueous face was separated and extracted with EtOAc. The 
combined organic abstracts were dried (Na2SO4) and concentrated. Flash column chromatography 
(EtOAC/n-heptane, 1/5) gave (15 mg, 70%) of the diol (14) as colorless oil. Rf 0.1 (EtOAc/n-heptane, 2/3). 
[α]D
20 +12.8 (c 0.445; CH2Cl2). IR υmax film: (cm
-1) 2925, 2358, 1778, 1697, 1508, 1135, 1081, 838. 1H NMR 
(CDCl3, 400 MHz, ppm): δ 7.36-7.12 (m, 5H), 4.71 (d, J = 11.6 Hz, 2H), 4.53 (d, J = 11.6 Hz, 2H), 4.21 (m, 
1H, CH), 4.1 (m, 1H, CH), 3.97 (m, 1H), 3.75 (m, 1H), 3.44 (m, 1H), 3.27 (br d, J = 9.8 Hz, 1H), 2.02-1.89 
(m, 2H), 1.42 (s, 9H, t-Bu), 0.88 (s, 9H, t-Bu), 0.03 (s, 6H, SiMe2). 
13C NMR (CDCl3, 100 MHz, ppm): δ 
154.8, 136.7, 128.3, 79.4, 73.7, 72.8, 72.3, 64.7, 60.6, 48.1, 30.1, 28.7, 26.0, 18.1, 14.6, -4.7. HRMS (CI) m/z 
calcd for C24H42O6NSi (M+H)
+: 468.2781, found: 468.2785. 
 
(1R,2S,3R,4S,5R)-5-(tert-Butyloxycarbonyl)amino-4-benzyloxy-3-[(tert-
butyldimethylsilyl)oxy]cyclohexane-1,2-sulfate (15)  
To a solution of diol 14 (23 mg, 0.024 mmol) and thionyl chloride (1.8 µL, 0.025 
mmol) in EtOAc was added a solution of pyridine (4.1 µL, 0.051 mmol). The mixture 
was stirred and was not allowed to rise above rt. When TLC analysis showed complete formation of the 
cyclic sulfate the mixture was diluted with EtOAc and extracted with H2O. The organic phase was dried 
(Na2SO4) and concentrated. The residue was dissolved in a mixture of CH2Cl2, MeCN and water (2:2:3), 
NaIO4 (10 mg, 0.048 mmol) and RuCl3·H2O (catalytic) were added and the mixture was stirred for 1h at 20 
°C. The mixture was filtered and the filtrate was diluted with CH2Cl2, the organic layer was extracted with 
water, dried (MgSO4) and concentrated. Flash column chromatography (EtOAc/n-heptane, 1/5) gave 
compound 15 as a white solid (20 mg, 80%). Rf 0.5 (EtOAc/n-heptane, 2/3). IR υmax film: (cm
-1) 2923, 1687, 
1328, 1212, 840. 1H NMR (CDCl3, 400 MHz, ppm): δ 7.48-7.25 (m, 5H, Bn), 5.18-5.12 (m, 1H, CH), 4.70 
(dd, 2H, J = 11.7 Hz, CH2), 4.71-4.70 (m, 1H, CH), 4.25-4.18 (m, 1H, CH), 3.74-68 (m,1H, CH), 3.52-3.33 
(m, 1H, CH), 2.63 (dt, 1H, CH2), 1.40 (s, 9H, t-Bu), 1.48-1.40 (m, 1H, CH2), 0.91 (s, 9H, t-Bu), 0.15 (s, 3H, 
SiMe), 0.08 (s, 3H, SiMe). 
 
(1R,2S,3S,4R,6S)-6-azido-4-(tert-butyloxycarbonyl)amino-3-benzyloxy-2-[(tert-
butyldimethylsilyl)oxy]cyclohexane-1-ol (16)  
Compound 15 (10 mg, 0.019 mmol) was dissolved in DMF (500 µL). The reaction 
mixture was heated to 80 °C and LiN3 (2.4 mg, 0.046 mmol) was added to the reaction 
mixture. The reaction mixture was heated until TLC analysis showed conversion of the cyclic sulfate into 
baseline material. After stirring for 2 h, the reaction mixture was evaporated and dissolved in THF. A drop of 
water and H2SO4 (5 µL) were added and the reaction mixture was quenched with NaHCO3 and extracted 
with EtOAc, dried Na2SO4 and purified by flash column chromatography (EtOAc/n-heptane, 1/5) to yield the 
diol 16 (6 mg, 60%) as a white solid. Rf 0.3 (EtOAc/n-heptane, 2/3). [α]D
20 – 21.0 (c 0.10; CH2Cl2). IR υmax 
OBn
NHBoc
TBDMSO
OBn
NHBoc
OTBDMS
O
O
S
O
O
OBn
NHBoc
OTBDMS
N3
HO
OBn
NHBoc
OTBDMS
HO
HO
Chapter 2 
 32 
film: (cm-1) 2928, 2103, 1689, 1169, 1069, 610. 1H NMR (CDCl3, 400 MHz, ppm): δ 7.43-7.24 (m, 5H, 
arom), 4.50 (dd, J = 7.8, 11.4 Hz, 2H, CH2), 3.72-3.44 (m, 4H, CH), 3.22-3.11 (m, 1H, CH), 2.62-47 (m, 1H, 
CH2), 2.32-2.26 (m, 1H, CH2), 1.40 (s, 9H, t-Bu), 0.93 (s, 9H, t-Bu), 0.32 (s, 6H, SiMe2). HRMS (CI) m/z 
calcd for C24H41O5N4Si (M)
+: 493.2846, found: 493.2847. 
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Preparation of a 1,3-diazidocyclitol as a versatile  
2-deoxystreptamine precursor
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Abstract 
Synthesis of a direct 2-deoxystreptamine (2-DOS) precursor, a common structure in the majority of 
clinically important aminoglycosides, is presented. The synthetic route described in this chapter 
starts from p-benzoquinone and cyclopentadiene and comprises a Pd(0)-catalyzed rearrangement 
and a retro-Diels–Alder reaction by flash vacuum thermolysis. Final stereoselective introduction of 
the desired trans-azidoalcohol was explored with a variety of methods e.g. via an Yb(III)-directed 
regioselective epoxide opening, via diepoxide opening, or via dihydroxylation, cyclic sulfate 
forming and opening with lithium azide. The obtained orthogonally protected diazidocyclohexitol 
(DACH) derivatives 22 and 24 are suitable 2-DOS precursors, conveniently protected for 
incorporation in new aminoglycoside entities.  
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3.1 Introduction 
Since the discovery of the aminoglycoside antibiotic streptomycin in 1944,
1
 the family of 
aminoglycosides has steadily grown into a powerful class of antibiotics with a broad antibacterial 
spectrum and proven efficacy particularly against aerobic Gram-negative bacteria. Nevertheless, 
extensive clinical use of the aminoglycosides is limited, mostly due to the associated nephro- and 
ototoxicities.
2
 Another disadvantage is the global development of microbial resistance as the result 
of structural modification by bacterial enzymes; aminoglycoside phosphotransferases (APH), 
adenyltransferases (AAD or ANT) and acetyltransferases (AAC).
3,4
 These circumstances validate 
research into novel aminoglycoside analogues which do not display the undesirable features but 
maintain a strong bactericidal effect. This notion has already awakened the chemical community 
and the number of papers along this line is rapidly increasing.
5
 Surprisingly, however, none of these 
reports describes an efficient way to prepare the core diaminocyclohexanetriol 2-deoxystreptamine 
(2-DOS, Figure 1) common to (nearly) all of the known aminoglycoside antibiotics.
5 
 
OHHO
OH
NH2H2N
OH
O O
OH
O
2-deoxystreptamine
1
2
3
4
5
6
A B
[PG]
 
Figure 1. Retrosynthetic analysis of 2-DOS. 
 
Synthetic routes toward 2-DOS that have appeared in literature require numerous synthetic steps 
and offer minimal flexibility in protective groups
6,7,8 
or require expensive starting material (see 
Chapter 1). As a result, to date the most practical method to synthesize 2-DOS is by degradation of 
natural neomycin.
9,10,11
 However, the initially obtained “naked” meso compound still demands 
desymmetrization as well as extensive protective group manipulations before successful 
incorporation in aminoglycoside entities can be ensured. Based on this reasoning we set out to 
investigate a practical synthetic route toward a 2-DOS precursor that is suitable to serve as scaffold 
for either 4,5- or 4,6-linked aminoglycoside antibiotics. 
 
3.2 Unexpected cage structures en route to 2-DOS 
As becomes clear from Figure 1, the target molecule 2-DOS shows a remarkable structural 
simplicity particularly due to the internal plane of symmetry. An obvious retrosynthetic approach 
therefore suggests introduction of both the amino functionalities by dual nucleophilic opening of 
diepoxide A. This diepoxide has been described in literature, but it is unstable and the synthetic 
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route leading to it is by no means straightforward.
6,12
 Unfortunately, obtention of A by epoxidation 
of cyclohexane-2,5-dien-1-ol (not drawn) seemed not feasible to us since the inherent instability of 
the latter molecule precludes its use in chemical synthesis. In chapter 2 we described the synthesis 
of an enantiopure and fully orthogonally protected 2-DOS by using a stepwise approach starting 
from D-allylglycine.
13 
The latter route provides a highly useful 2-DOS scaffold for the preparation 
of new aminoglycoside antibiotics but in this chapter we reasoned a shorter route toward a versatile 
2-DOS precursor would be valuable. 
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Reagents and conditions: (a) MeOH, 0-5 °C, 2.5 h; (b) NaBH4, CeCl3·7H2O, MeOH, 0-5 °C, 1 h; (c) 
PdCl2(dppf), HCO2NH4, MeCN, ∆, 45 min; (d) H2O2, 0.2 M NaOH, CH2Cl2/MeOH, 1/1, rt, 30 min; (e) 
NaBH4, CeCl3·7H2O, MeOH, -78 °C, 30 min. 
 
Our synthesis starts from the readily accessible Diels–Alder condensation product 1 of 
cyclopentadiene and p-benzoquinone (Scheme 1). Reduction under Luche conditions according to a 
known protocol
14,15
 led to diol 2 which was converted into the enone 3 via a 1,4-hydrogen 
migration catalyzed by in situ formed Pd(0), according to Takano et al.16,17 In our hands, however, 
it was not possible to reproduce the reported yield under the described conditions (PdCl2(PPh3)2 in 
MeCN), since an appreciable amount (16%) of starting material remained (Table 1, entry 1). We 
therefore further investigated the optimal reaction conditions for this transformation, the parallel 
syntheses were performed with a synthesis robot (Figure 2). In DMF we saw minor amounts of 3 or 
no product formed (entry 5, 6), which also applied to the use of other sources of palladium in 
MeCN (entry 2, 4). On the contrary, with PdCl2(dppf) as catalyst we found only minor residual 
starting material and a much improved yield of 3 (entry 3). 
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Figure 2. System used for optimization of the 
palladium catalyzed reaction. 
 
 
 
Table 1. Optimization of the palladium(0)-
catalyzed 1,4-hydrogen migration a 
 solvent catalyst 
2 
yield 
(%)b
3 
yield 
(%)b 
1 MeCN PdCl2(PPh3)2 16 71 (49)
2 MeCN PdCl2(MeCN)2 -
c -c 
3 MeCN PdCl2(dppf) 9 89 (77)
4 MeCN Pd(OAc)2(dppe) 100 - 
5 DMF PdCl2(PPh3)2 100 - 
6 DMF PdCl2(dppf) 69 29  
a standard procedure is used, with given catalyst, 
and solvent. b GC yield (isolated yield).c 
decomposition. 
Having established the palladium(0)-catalyzed hydrogen migration, the next step is a nucleophilic 
epoxidation reaction. Thus, reacting α,β-unsaturated ketone 3 with hydrogen peroxide under basic 
conditions afforded epoxide 4 in a yield of 89% (Scheme 1). The following step, reduction of the 
ketone to alcohol 5 proved troublesome and was inevitably accompanied by varying amounts of the 
Payne-rearranged product (6). Optimal conditions to keep this side-reaction to a minimum involved 
reduction under Luche conditions
15
 at -78 °C to afford alcohol 5 and 6 in a favorable 7:1 ratio of 
isomers, which could be easily separated by column chromatography. To investigate the energy 
difference AM1 molecular mechanics were performed. The molecular mechanics, using 
MOPAC/AM1, and quantum mechanics using B3LYP 6-31G*, show that there is little energy 
difference between Payne-rearranged product 6 and starting compound 5, predicting ∆E = 1.8 and 
0.75 kcal/mole, respectively. In order to define whether the epoxides 5 and 6 are in a dynamic 
equilibrium under the basic conditions applied, each epoxy alcohol was individually treated with 
sodium hydride. It turned out that only the transoid-epoxy alcohol (5) (partially) rearranged to the 
regioisomeric 1,2-cisoid-epoxy alcohol 6, whereas the reverse reaction did not take place. The 
results indicate that, although it stops at a certain ratio of inverted and non inverted product, the 
Payne rearrangement is not in equilibrium.
 
The results found here are in agreement with the 
reported (un)stability of an α,β-epoxy-cyclopentanol instead of the above mentioned α,β-epoxy-
cyclohexanol.
18
 The reason for the rearrangement not to proceed beyond a certain point remains 
unclear at this moment. 
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Although we were satisfied with the fact that Payne rearrangement could be kept to a minimum 
under an appropriate protocol, we discovered that the conversion of 4 to 5 requires additional 
caution, due to the high acid-sensitivity of the desired product 5,
19
 purification on silica gel led to 
the formation of two new products. The structure of the latter inseparable compounds could not be 
fully established but since spectroscopic analysis revealed the presence of an alcohol, the unknown 
product was converted into its p-nitrobenzoate derivative, since p-nitrobenzoates are known to 
crystallize easily (Scheme 2). Subsequent separation by selective crystallization of the p-
nitrobenzoate derivatives, followed by X-ray analysis revealed that the rather striking tetracyclic 
structures 9 and 12 had been formed (Figure 3).
20
 
 
Scheme 2.  
9
O
OH OH
HO
H
H
a b
H-shift
path a
path b
  α-ketol 
  rearr.
OHO
OH
O
alkyl-shift
O
HO
a
a
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10 11
5
Op-NO2BzO
O
p-NO2BzO 12
H
H
silica 
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-H
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Reagents and conditions: (a) p-NO2-BzCl, Et3N, DMAP, CH2Cl2. 
 
             
9     12 
Figure 3. Platon visualization25 of the X-ray structures of 9 and 12. 
 
We suggest that the mechanism leading to 9 and 12 involves acid activation (silica gel) of the 
epoxide of 5 which has the double bond π-electrons ideally positioned for nucleophilic attack. The 
resulting intermediate carbocation 7 undergoes one of two possible rearrangements, involving either 
an H-shift (path a) or alkyl-shift (path b). Although the α-hydroxy aldehyde 10 as such could not be 
identified, it seems likely that formation of the nitrobenzoate 12 can be explained via α-ketol 
rearrangement of 10 to the more stable ketone 11. In addition, when epoxyalcohol 5 was stirred in 
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CH2Cl2 in the presence of silica gel the same rearrangement takes place. To prove that the free 
hydroxyl has no influence in the predicted mechanism we protected the free hydroxyl of compound 5 with an 
acetyl group. Stirring of the latter in CH2Cl2 with silica gel for 48 hours followed by removal of the acetyl 
group with potassium cyanide in MeOH gave again the cage structures 8 and 11. Gratifyingly, 
rearrangement could be completely suppressed by pre-eluting the column with 1% Et3N to give 5 in 
a final isolated yield of 80% (Scheme 1). 
 
3.3 Retro-Diels–Alder reaction by flash vacuum thermolysis and epoxide 
 opening 
Having the tricyclic structure 5 in hand, the desired retro-Diels–Alder reaction could be 
investigated. Such reactions, typically executed in high-boiling ethereal solvents, are often 
accompanied by side-products and the solvent is inherently difficult to remove. These 
disadvantages can be elegantly circumvented by application of flash vacuum thermolysis (FVT, 
Figure 4).
21
 The first attempt to afford epoxyalcohol 13 yielded only 22% of the desired product and 
75% starting material (Table 2, entry 1). In the next attempt a raise in thermolysis temperature 
(500→550 °C) gave a yield of 62% and only 3% of the starting material remained. However this 
reaction furnished beside these two products a reasonable amount of a side product, the identity of 
which we have not been able to establish (entry 2).  
 
 
Figure 4. Flash vacuum thermolysis set-up. 
 
After a few more optimization reactions (entry 3, 4, 5) it was found that the best result was obtained 
with sublimation at 80 °C, thermolysis at 600 °C and the pressure around 0.04 mbar to afford 
compound 13 cleanly in 84% yield (entry 6). 
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Table 2. Optimization of the flash vacuum thermolysis reactiona 
H
H
O
O
5
OH
OH
FVT
13
0.04 mbar
 
 sublimation 
(°C) 
thermolysis 
(°C) 
yield (5) 
(%)a 
yield (13)
(%)a 
UFOb 
(%) 
1 120 500 75 22 3 
2 120 550 3 62 35 
3 100 500 39 30 31 
4 80 500 45 45 10 
5 80 550 13 81 5 
6 80 600 - 96 (84) 4 
a GC yield (isolated yield)b Unidentified flying object 
 
In the following steps the hydroxyl was protected with a tert-butyldimethylsilyl group and the 
epoxide was converted to azido alcohol 15 (Scheme 3). The free hydroxyl was now acetylated and 
the remaining double bond was epoxidized, via in situ dioxirane formation reported by Yang et al,22 
leading to predominantly the trans-epoxide 17 (71%) and a minor amount of the cis-isomer 18 
(ratio 4:1). The cyclohexene ring bearing a free hydroxyl was also epoxidized, in this case with 
m-CPBA. Giving the trans and cis epoxide (19 and 20) in a yield of 72% and 18%, respectively. 
Epoxidation could also be performed with the in situ formed dioxirane but although this reaction 
proceeds faster, it neither gave a better ratio between cis and trans epoxide, nor a better yield. 
 
Scheme 3. Synthesis of epoxides 17-20 
O
dOR
N3(85%)
b
 (85%)
R = H (72%)
OTBDMS OTBDMS
OR
N3
OTBDMS
O
a
 R = H (18%)
OR
N3
OTBDMS
O+
14
15
16
 (77%) c R = H
R = Ac
 R = Ac (71%) R= Ac (14%)
13
17
19
18
20  
Reagents and conditions: (a) TBDMSCl, DIPEA, DMAP, CH2Cl2, rt, 5 h; (b) NaN3, NH4Cl, MeOH, ∆, 40 h; 
(c)Ac2O, DMAP, CH2Cl2,rt, 1h; (d) Oxone®, chlorocyclohexanone, NaHCO3, MeCN/H2O 3:2, 1 h; (d) or m-
CPBA, CH2Cl2, rt, 24 h, rt.  
 
The final step, involving another regioselective epoxide opening of epoxide 17 or 19, proved to be 
more troublesome (Table 3). Our first attempt to open epoxide 17 with NaN3 in MeOH 
predominantly led to the formation of azido alcohol 23 and only to a lesser extent to the preferred 
regioisomer 22 (entry 1), presumably due to a favored trans-diaxial opening of the epoxide as 
dictated by the Fürst-Plattner rule.
23
 Opening with sodium azide and lithium perchlorate did not 
improve matters since after prolonged stirring mainly starting material was recovered (48h)  
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(entry 2). After some unsuccessful variation of reaction conditions, a paper by Delgado et al. 
stimulated us to investigate chelation-controlled Yb(OTf)3-catalyzed azidolysis of epoxides (Figure 
5).
24
 Much to our satisfaction, under the suggested conditions with sodium azide, ytterbium(III) 
triflate and triethylamine, the 1,3-diazidocyclitol (1,3-DACH) 24 was formed as the only 
regioisomer (Table 3, entry 5), most likely from nucleophilic attack at the all-axial conformer, 
formed by chelation of ytterbium(III) with both the free (deprotonated) hydroxyl and the epoxide 
(Figure 5). The likeliness of such a mechanism was substantiated when we observed that 
application of the Yb(OTf)3-catalyzed procedure to the protected derivative 17 did not lead to any 
reaction (entry 3). 
 
Table 3. Optimization of the epoxide opening of 17 and 19 
TBDMSO
HO
RO
N3
N3 TBDMSO
N3
RO OH
N3
2322
OH
TBDMSO
H
RO
H
N3
24 25
R = Ac
R = H
R = Ac
R = H19R = H
21R = TMS
R = Ac17
 
 
s.m.
a 
conditions solvent 
  
22:23b 
isolated  
yield 22 (%) 
1 17 NaN3, NH4Cl, 80 °C MeOH     9:32 21 
2 17 NaN3, LiClO4 80 °C toluene - -
c 
3 17 NaN3, Yb(OTf)3, Et3N, 60 °C toluene - -
c 
  conditions solvent 
  
24:25b
yield 24 (%) 
4 19 NaN3, NH4Cl, 80 °C MeOH     1:2 10 
5 19 NaN3, Yb(OTf)3, Et3N, 80 °C toluene >95:5 49 
6 19 NaN3, Yb(OTf)3, 60 °C MeOH - -
 
7 19 TMSN3, Yb(OTf)3, Et3N, 60 °C toluene - -
d 
8 19 
(Me2N)2C=NH2N3, Yb(OTf)3, Et3N, 60 
°C 
toluene  18 
9 19 NaN3, Yb(OTf)3, Et3N, 280 W, 135 °C toluene >95:5 70
e 
10 19 NaN3, Yb(OTf)3, Et3N, 80 °C, 4Å MS toluene >95:5 82
e 
a s.m. = starting material b regioisomeric ratio determined by 1H NMR c mainly starting material 17 d major 
compound 21 (in 70% yield) e BORSM = based on recovered starting material. 
 
Unfortunately, conversion was never complete, since after 4 days of refluxing substantial amounts 
of starting material remained and only 49% of the product could be isolated. Replacement of the 
sodium azide by TMSN3 was not a fortunate choice since the silylated product 21 was obtained 
(entry 7). Replacement of the sodium azide with tetramethylguanidinium azide yielded the product 
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in a disappointing yield of 18% accompanied by several side products (entry 9). Replacement of 
toluene by MeOH was again not fortuitous, but by carrying out the reaction in a microwave at 280 
W and at 135 °C (entry 9), product 24 was obtained in a yield of 70%. Finally, the optimal result 
was achieved by addition of molecular sieves to the reaction mixture, to give a yield of 82%. The 
structural identity of 24 was unequivocally established by X-ray analysis (Figure 6).
20
 
 
Figure 5.  Figure 6. Platon visualization 25 of the X-ray 
structure of 24.  
 
The convenience of the diazido derivative 24 above carbamate-protected 2-DOS is reflected in its 
excellent solubility in organic solvents and straightforward spectral analysis. Finally, the 
applicability of 24 as a versatile scaffold for the preparation of new 4,6-linked aminoglycoside type 
compounds
6e,7
 was established by its smooth conversion into 2-DOS. To this end, the TBDMS 
protective group was removed with 1N HCl in methanol, since attempted desilylation with TBAF 
surprisingly resulted in formation of the TBDMS migration to a neighboring hydroxyl (26). The 
next step was hydrogenation which yielded 2-DOS in 95% yield for the two steps (Scheme 4). 
Comparison of spectral data of the diacetate derivative 28 with reported data
26
 provided further 
evidence of the structural identity of 24. 
 
Scheme 4. Conversion of 24 into 2-DOS 
26
24
2-DOS
(quant) (95%)
a or b b  c
28
OR
N3
OH
HO
N3
OH
NH2
OH
HO
H2N
27
OH
NHAc
OH
HO
AcHN
R= TBDMS
R= H
 (96%)
 
Reagents and conditions: (a) TBAF, THF, 0 °C, 30 min; (b) 1N HCl, MeOH, rt, 16 h; (b) Pd-C, H2, MeOH, 
16 h; (c) Ac2O, Et3N, MeOH/H2O, 1/1, 3h. 
O
O
Yb
3+
TBDMSO
N3
H
H
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3.4 Synthesis of 2-DOS via the diepoxide 
A potentially more direct route toward 2-DOS follows direct epoxidation of the double bond of the 
TBDMS protected FVT product 14. It was reasoned that the obtained diepoxide could be 
subsequently ring opened with sodium azide in a single step. Thus, starting from the protected 
epoxy alcohol 14, the double bond was epoxidized with m-CPBA to obtain the diepoxide 29 in 70% 
yield (Scheme 5). Although formation of the trans diepoxide could not be completely 
circumvented, the cis and trans epoxide were formed in a ratio of 9:1 (in favor of the desired 
cis-diastereomer), corroborated by a crystal structure of the major diepoxide.  
 
Scheme 5. Dual epoxide opening toward 24 
(10%, 
3 steps)
O
OTBDMS
O
OH
OTBDMS
HO
HN NH
a
(70%)
b c,d
OH
OTBDMS
HO
N3 N3
29
14
30 24  
Reagents and conditions: (a) m-CPBA, NaHCO3, CH2Cl2, rt, 48 h; (b) hydrazine, EtOH, ∆, 4 h; (c) 
Amberlite IRA 400, Ra-Ni, H2, H2O/MeOH, 1/1, 16 h; (d) TfN3, ZnCl2, Et3N, CH2Cl2/MeOH/H2O, 3/10/3, 
rt, 3 h. 
 
Figure 7. Platon visualization 25 of the X-ray structure of 29. 
 
Opening with sodium azide under ammonium chloride catalysis led to the formation of mainly the 
wrong regioisomers which was not surprising based on our earlier findings. More surprisingly, 
opening of epoxide 29 with sodium azide in the presence of zinc sulfate gave the 2-DOS derivative 
in a disappointing yield of 15% and the other regioisomer as the main product in a yield of 54%, 
opposite to the reported findings of Prinzbach.
 27
 Little success was also met when the diepoxide 
was opened with sodium azide under Yb(OTf)3-catalyzed conditions because after prolonged 
stirring (7 days, 80 °C) only opening of a single epoxide and minor amounts of the diol were 
observed. A more successful strategy involved opening with hydrazine which has the inherent 
advantage that the second nucleophilic addition proceeds intramolecularly, and hence with proper 
regiochemistry. Subsequent reduction of the resulting crude product with Ra-Ni in the presence of 
basic Amberlite gave the TBDMS protected 2-DOS and two other unidentified side-products. The 
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last step, diazotransfer catalyzed by ZnCl2, gave the corresponding diazido derivative 24 in a 
disappointing yield of 10% for three steps.
28
 In conclusion, in 10 steps and an overall yield of 2.2% 
the 1,3-DACH 24 was synthesized.  
 
3.5 Synthesis of orthogonally protected 2-DOS via dihydroxylation and cyclic 
 sulfate formation 
Since it was found impossible to drive the epoxide opening of 19 to completion, an approach 
involving cyclic sulfate methodology, applied successfully earlier in chapter 2, was followed. Thus, 
the double bond of intermediate 16 was reacted with catalytic osmium tetroxide, but even after 
prolonged stirring no conversion of starting material was observed,
29
 even when a stoichiometric 
amount of osmiumtetroxide was used. Therefore, cyclohexene 16 was reacted with ruthenium(III) 
chloride and sodium periodate, leading to the desired diol in a yield of 88% (Scheme 6).
30
 However, 
since these conditions can easily lead to over–oxidation –by oxidative cleavage of the resulting 
diol– we were hesitant to employ these conditions on a large scale. Therefore, other dihydroxylation 
methods were explored. For example, it is known that the presence of CH3SO2NH2 in the OsO4 
catalyzed dihydroxylation reaction leads to shorter reaction times, occasionally 50-fold catalysis is 
observed, by accelerating the osmate ester hydrolysis.
31,32
 Therefore, alkene 16 was reacted with 
OsO4 in the presence of 1 equiv. of sulfonamide, leading to the quantitative isolation of diol 31. The 
last transformations to obtain 2-DOS involve reaction of the diol with thionylchloride and oxidation 
to cyclic sulfate 32, followed by opening of the corresponding sulfate with lithium azide. Following 
such a sequence of events yielded the orthogonally protected 2-DOS precursor (22) cleanly, but in a 
rather low 43% yield.
33
 To prove the stereochemistry of compound 22, the free hydroxyl was 
acetylated to give diacetylated structure 33, spectral data of which were in full agreement with the 
spectra obtained by acetylation of compound 24. 
 
Scheme 6. Conversion of 16 toward orthogonally protected 2-DOS analogue 22 
R = H
R = Ac
OAc
N3
OTBDMS
OAc
N3
OTBDMS
RO
N3
HO
HO
OAc
N3
OTBDMS
O
O
S
O
O
16
a b,c d
(88%
to quant.)
(43%, 
3 steps)
31 32
22
 (87%)e
33  
Reagents and conditions: (a) RuCl3, NaIO4, EtOAc/MeCN/H2O (3/3/1), 0 °C, 3 min (88%) or OsO4, 
CH3SO2NH2, t-BuOH/H2O (1/1) (quant.); (b) SOCl2, pyridine, EtOAc, 0 °C, 30 min. (c) NaIO4, RuCl3.H2O, 
CH2Cl2/MeCN/H2O (2/2/3), 0 °C, 1 h; (d) LiN3, wet DMF, ∆, 4 h then H2SO4, THF, H2O, rt, 30 min (43% 
for 3 steps) (e) Ac2O, DMAP, Et3N, CH2Cl2, 1h, (87%). 
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3.6 Concluding remarks 
Several synthetic routes of 2-DOS proceeding via a retro-Diels–Alder reaction were developed 
successfully; DACH 24 was synthesized in 10 steps and an overall yield of 16% (§3.3), and via the 
diepoxide opening of (29) in 10 steps and an overall yield of 2.2% (§3.4). The orthogonally 
protected 2-DOS entity 22 was synthesized in 13 steps and an overall yield of 8.8% (§3.5). The 
most straightforward route proceeds via epoxide opening but the last step is not ideal since the 
reaction fails to go to completion under a variety of conditions. Synthesis of the diepoxide and dual 
opening of the corresponding epoxides has no advantages over the previous route. Similarly, 
application of cyclic sulfate methodology does not improve the overall yield but opens possibilities 
for desymmetrization earlier in the synthesis, since the final product is not necessarily meso. The 
obtained diazidocyclitols, which can be obtained at gram-scale following a route presented here, are 
suitable 2-DOS precursors and moreover conveniently protected for incorporation in new 
aminoglycoside entities.  
Finally, an interesting intramolecular electrophilic cyclisation reaction was discovered 
serendipitously, leading to unique and highly bridged cage structures.  
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3.8 Experimental Section 
(1R,2S,3R,6S,7R,8S)-Tricyclo[6.2.1.0
2,7
]undeca-4,9-diene-3,6-diol (2)  
Freshly distilled cyclopentadiene (bp 42 °C; 15.3 mL, 0.185 mol) was added dropwise in 25 
min to a solution of p-benzoquinone (20 g, 0.185 mol) in MeOH (100 mL) at 0-5 °C. The 
mixture was stirred for 2.5 h at room temperature. The brown liquid was diluted with MeOH to 
460 mL and CeCl3.7H2O (138 g, 0.370 mol) was added to the solution. The reaction mixture 
was cooled to 0-5 °C and NaBH4 (14.0 g, 0.370 mol) was added slowly. The mixture was stirred for an 
additional 1 h at room temperature. The reaction was quenched with water, filtered extracted with EtOAc 
and dried (Na2SO4), and the solvent was evaporated. Recrystallization from acetone gave 2 (26 g, 80%) as 
pink crystals. Mp: 157 °C. IR υmax film: (cm
-1) 3251, 2980, 2943, 2926, 1352, 1270, 1054. 1H NMR (CD3OD, 
300 MHz, ppm): δ 5.76 (br s, 2H, H4, and H5), 5.25 (br s, 2H, H9 and H10), 4.39 (dd, J = 5.1, 12.6 Hz, 2H, H3 
HO
OH
H
H
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and H6), 3.00 (br s, 2H, H1 and H8), 2.80 (t, J = 3.3 Hz, 2H, H2 and H7), 1.29 (br s, 2H, H11); in agreement 
with literature.34 
 
(±)-(1R,2R,7R,8S)-Tricyclo[6.2.1.0
2,7
]undeca-4,9-dien-3-one (3)  
To a solution of 2 (5.1 g, 29 mmol) and HCO2NH4 (2.7 g, 42 mmol) in degassed MeCN (280 
mL), was added 1 mol% PdCl2(dppf) (230 mg, 0.282 mmol). The solution was refluxed for 45-
90 min. The reaction was diluted with Et2O, washed with brine, and dried (Na2SO4). After 
evaporation of the solvent the crude product was purified by flash chromatography (EtOAc/n-heptane, 1/5) 
to give 3 (3.5 g, 77%) as a yellow oil. The reaction conditions were optimized with automated parallel 
syntheses performed with the Anachem synthesis robot (Gilson SK233).35 1H NMR (CDCl3, 300 MHz, 
ppm): δ 6.66 (dt, J = 4.0, 10.3 Hz, 1H, CH), 6.12 (ddd, J = 2.9, 5.6, 15.8 Hz, 2H, CH), 5.86 (dt, J = 10.4, 2.4 
Hz, 1H, CH), 3.38 (br s, 1H, CH), 3.03 (br s, 1H, CH), 2.91 (dd, J = 10.1, 3.9 Hz, 1H, CH), 2.76 (dt, J = 
10.1, 3.5 Hz, 1H, CH), 2.60 (dddd, J = 20.6, 10.2, 3.9, 2.4 Hz, 1H, CH), 2.02 (ddd, J = 20.5, 6.0, 3.4 Hz, 1H, 
CH), 1.42 (dt, J = 1.8, 8.4 Hz, 1H, CH), 1.34 (d, J = 8.4 Hz, 1H, CH); in agreement with literature.36 
 
(±)-(1R,2R,4S,5S,7R,8S)- 4,5-Epoxytricyclo[6.2.1.0
2,7
]undec-9-en-3-one (4)  
35% H2O2 (8.6 mL) and 0.2 M aqueous NaOH (10.6 mL) were added to a solution of 3 (3.4 g, 
21 mmol) in a mixture of CH2Cl2/MeOH (1:1, 200 mL) at room temperature. After the reaction 
had been stirred stirring for 30 min the reaction mixture was diluted with CH2Cl2 (300 mL). 
Washing with brine, drying (Na2SO4), gave the crude product which was purified by flash chromatography 
(EtOAc/n-heptane, 1/5), to obtain 4 (3.3 g, 89%) as a colorless oil. 1H NMR (CDCl3, 400 MHz, ppm): δ 6.22 
(dd, J = 2.8, 5.5 Hz, 1H, H10), 5.89 (dd, J = 5.6, 2.8 Hz, 1H, H9), 3.42 (t, J = 4.1 Hz, 1H, H4), 3.16 (dd, J = 
1.0 4.5 Hz, 1H, H2), 3.10 (br s, 1H, H1), 2.90 (dd, J = 10.4, 3.4 Hz, 1H, H5), 2.82-2.75 (m, 2H, H6exo, and H8), 
2.38 (ddd, J = 14.7, 6.8, 3.6 Hz, 1H, H7), 1.44 (d, J = 8.4 Hz, 1H, H11), 1.33 (dd, J = 14.7, 10.8 Hz, 1H, 
H6endo), 1.25 (d, J = 8.4 Hz, 1H, H11). 
13C NMR (CDCl3, 100 MHz, ppm): δ 209.6, 138.5, 134.1, 57.6, 54.5, 
50.6, 47.6, 45.5, 42.9, 36.3, 27.4; in agreement with literature.36 
 
(±)-(1R,2R,3S,4R,5S,7R,8S)-4,5-Epoxytricyclo[6.2.1.0
2,7
]undec-9-en-3-ol (5)  
To a cold solution -78 °C of 4 (3.21 g, 18.2 mmol) in MeOH (46 mL) was added NaBH4 (689 
mg, 18.2 mmol) and CeCl3·7H2O (6.77 g, 18.2 mmol). The reaction was stirred until 
conversion was completed. The mixture was quenched with ammonium chloride, extracted 
with Et2O, washed with brine and dried (Na2SO4). The crude mixture was purified by means of flash 
chromatography (EtOAc/n-heptane, 1/5 and 1% Et3N) to yield (2.59 g, 80%) of compound 5 as colorless oil. 
Rf 0.4 (EtOAc/n-heptane, 1/3). IR υmax film: (cm
-1) 3442, 2958, 1439, 1338, 1255, 816, 729. 1H NMR 
(CDCl3, 400 MHz, ppm): δ 6.40 (dd, J = 5.7, 3.1 Hz, 1H, H10), 6.06 (dd, J = 5.7, 3.1 Hz, 1H, H9), 4.46 (m, 
1H, H3), 3.12 (m, 2H, H4, and H5), 2.93 (br s, 1H, H1), 2.77 (br s, 1H, H8), 2.46-2.38 (m, 1H, H7), 2.30-2.24 
(m, 2H, H2, and H6exo), 1.45 (dt, J = 8.1, 1.9 Hz, 1H, H11), 1.34 (dd, J = 14.4, 11.7 Hz, 2H, H6endo, and H11), 
1.11 (br d, 1H, OH). 13C NMR (CDCl3, 75 MHz, ppm): δ 137.8, 134.0, 68.9, 51.8, 50.9, 50.7, 46.1, 45.7, 
40.8, 36.1, 26.9. HRMS (CI) m/z calcd for C11H15O2 (M+H)
+: 179.1072, found: 179.1068. 
 
(±)-(1R,2R,3S,4R,5S,7R,8S)-5,6-Epoxytricyclo[6.2.1.0
2,7
]undec-9-en-4-ol (6)  
To a solution of 5 (20 mg, 0.11 mmol) in Et2O (1.5 mL) was added NaH (2.7 mg, 0.11 mmol) 
at room temperature. The reaction was followed with TLC (EtOAc/n-heptane, 2/3). After 
stirring for 3 days water was added and the product was extracted with Et2O, dried (MgSO4). 
Analysis with TLC and NMR showed 100% conversion to 6. Rf 0.30 (EtOAc/n-heptane, 1/3). 
IR υmax film: cm
-1 3406, 2960, 1437, 1342, 1049, 735. 1H NMR (CDCl3, 200 MHz, ppm): δ 6.23 (dd, J = 5.7, 
2.9 Hz, 1H, H10), 6.06 (dd, J = 5.7, 3.2 Hz, 1H, H9), 4.23 (m, 1H, H5), 3.25 (m, 1H, H3), 3.00 (m, 2H, H1 and 
H4), 2.70 (br s, 1H, H8), 2.47 (dt, J = 9.8, 2.6 Hz, 1H, H2), 2.35-2.19 (m, 1H, H7), 1.72-1.61 (m, 2H, H6exo and 
OH), 1.42 (m, 1H, H11), 1.29-1.21 (m, 2H, H11 and H6endo). HRMS (CI) m/z calcd for C11H15O2 (M+H)
+: 
179.1072, found: 179.1071. 
 
(±)-(1S,2R,4R,6R,7R,8S,9R)-10-Oxotetracyclo[5.3.1.0
2,6
.0
4,8
]undec-9-yl 4-nitrobenzoate 
(9)  
IR υmax film: (cm
-1) 2959, 1724, 1527, 1269, 718. 1H NMR (CDCl3, 400 MHz, ppm): δ 8.29 
(d, J = 8.9 Hz, 2H, arom), 8.22 (d, J = 8.9 Hz, 2H, arom), 7.23 (s, 1H, CH), 5.61 (d, J = 6.0 
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Hz, 1H, CHOH), 3.00 (t, J = 6.0 Hz, 1H, CH), 2.79-2.51 (m, 3H, CH), 2.41 (s, 1H, CH), 1.85 (d, J = 13.0 
Hz, 1H, CH2), 1.71-1.62 (m, 3H, CH2), 1.52-1.41 (m, 1H, CH2), 1.37 (d, J = 10.2 Hz, 1H, CH2). 
13C NMR 
(CDCl3, 100 MHz, ppm): δ 164.1, 131.1, 123.7, 74.5, 53.0, 48.2, 42.8, 38.8, 37.0, 36.9, 34.5. MS (CI) m/z: 
328 (M+H)+. Crystal structure has been deposited at the Cambridge Crystallographic Data Centre, CCDC 
226045. 
 
(±)-(1R,2R,3R,4S,6R,7R,8R)-2-Oxo-2-{tetracyclo[4.3.0.0
2,4
.0
3,8
]non-7-yl}ethyl 
4-nitrobenzoate (12)  
IR υmax film: (cm
-1) 2961, 1720, 1526, 1346, 1275, 1100, 717. 1H NMR (CDCl3, 400 MHz, 
ppm): δ 8.31-8.27 (m, 4H, arom), 5.50 (q, J = 6.0 Hz, 2H, CH2), 2.74 (s, 1H, CH), 2.62 (s, 1H, 
CH), 2.61 (s, 1H, CH), 2.42 (d, J = 8.4 Hz, 1H, CH), 2.07 (d, J = 8.8 Hz, 1H, CH2), 2.00-1.98 
(m, 1H, CH), 1.88 (s, 2H, CH2), 1.70-1.60 (m, 2H, CH2, CH), 1.40-31 (m, 1H, CH). 
13C NMR (CDCl3, 100 
MHz, ppm): δ 131.2, 123.7, 69.2, 55.0, 50.0, 46.1, 37.8, 33.1, 31.1, 30.2, 22.9. MS (CI) m/z: 328 (M+H)+. 
Crystal structure has been deposited at the Cambridge Crystallographic Data Centre, CCDC 226044. 
 
(±)-(1S,5S,6R)-5,6-Epoxycyclohex-2-en-1-ol (13)  
The thermolysis oven was preheated to 600 °C. A solution of 5 (430, 2.41 mmol) in Et2O was 
brought into the sublimation flask, and Et2O was evaporated. The vacuum gauge was carefully 
opened until vacuum reached 0.04 mbar, after which the collecting cooler was charged with CO2/acetone (-
78 °C). The sublimation oven was heated to 80 °C at this stage. The reaction was finished when no starting 
material remained in the sublimation flask. The crude mixture was purified by flash chromatography 
(Et2O/n-pentane, 1/2). Compound 13 (226 mg, 84%) was obtained as a colorless liquid. Rf 0.3 (EtOAc/n-
heptane, 2/1). IR υmax film: cm
-1 3390, 1419, 1011, 929, 986, 798, 710. 1H NMR (CDCl3, 400 MHz, ppm): δ 
5.7-5.66 (m, 1H, CH), 5.6-5.57 (m, 1H, CH), 4.48 (br s, 1H, CH), 3.31 (br s, 1H, CH), 3.25 (br s, 1H, CH), 
2.63-2.48 (m, 2H, CH), 1.84 (br s, 1H, OH). 13C NMR (CDCl3, 100 MHz, ppm): δ 124.8, 124.7, 63.0, 53.06, 
50.2, 25.1. 
 
(±)-(3S,4S,5S)-3-[(tert-Butyldimethylsilyl)oxy]-4,5-epoxycyclohex-1-ene (14)  
To a solution of 13 (655 mg, 5.84 mmol) in CH2Cl2 (30 mL) was added DIPEA (1.43 mL, 8.17 
mmol), TBDMSCl (1.06 g, 7.59 mmol), and DMAP (71.0 mg, 0.584 mmol) at 0 °C. The solution 
was stirred 5 h at room temperature. Water was added, and the product was extracted with 
CH2Cl2, dried (Na2SO4) and concentrated under reduced pressure. The crude product was purified by flash 
chromatography (EtOAc/n-heptane, 1/10), to yield 14 (1.12 g, 85%) as a colorless oil. Rf 0.6 (EtOAc/n-
heptane, 1/3). IR υmax film: (cm
-1) 2952, 2927, 2856, 1254, 1068, 837. 1H NMR (CDCl3, 400 MHz, ppm): 
5.58-5.49 (m, 2H, 2CH), 4.49 (br s, 1H, CH), 3.30 (br s, 1H, CH), 3.15 (br s, 1H, CH), 2.54 (br s, 2H, CH2), 
0.92 (s, 9H, t-Bu), 0.14 (s, 3H, Me), 0.12 (s, 3H, Me). 13C NMR (CDCl3, 100 MHz, ppm): δ 125.1, 123.2, 
63.7, 54.1, 50.7, 25.9, 24.9, 18.3, -4.5, -4.6. HRMS (EI) m/z calcd for C12H22O2Si (M)
+: 226.1389, found: 
226.1381. C11H19O2Si (M-Me): 211.1154, found: 211.1152.  
 
(±)-(1S,2S,6R)-6-Azido-2-[(tert-butyldimethylsilyl)oxy]cyclohex-3-en-1-ol (15)  
To a solution of 14 (3.05 g, 13.5 mmol) in MeOH (50 mL) was added NaN3 (1.75 g, 26.9 mmol) 
and NH4Cl (1.29 g, 24.1 mmol). The reaction was stirred under reflux for 40 h. MeOH was 
evaporated, CH2Cl2 was added, the solution was washed with brine, dried (Na2SO4). The solvent 
was evaporated and the crude product was purified by flash chromatography (EtOAc/n-heptane, 1/10), to 
obtain 15 as a colorless oil (4.2 g, 85%). IR υmax film: (cm
-1) 2109, 1253, 1088, 837, 779. 1H NMR (CDCl3, 
400 MHz, ppm): δ 5.59-5.55 (m, 1H, CH), 5.50 (d, J = 10.1 Hz, 1H, CH), 4.22-4.20 (m, 1H, CH), 3.60-3.57 
(m, 2H, 2CH), 2.50-2.44 (m, 1H, CH), 2.46 (s, 1H, OH, disappears with a drop of D2O), 2.14-2.07 (m, 1H, 
CH), 0.91 (s, 9H, t-Bu), 0.13 (s, 3H, MeSi), 0.12 (s, 3H, MeSi). 13C NMR (CDCl3, 100 MHz, ppm): δ 130.0, 
124.1, 76.9, 73.9, 60.7, 31.0, 25.8, 18.1, -4.5. MS(CI): 270 (M+H). HRMS (EI) m/z calcd for C12H23O2SiN3 
(M)+: 269.1559, found: 269.1551. 
 
(±)-(1S,2S,6R)-6-azido-2-[(tert-butyldimethylsilyl)oxy]-cyclohex-3-ene-5-olacetate (16)  
To a solution of 15 (63 mg, 0.234 mmol) in CH2Cl2 (2 mL), were added Ac2O (44 µl, 0.468 
mmol), Et3N (65 µl, 0.468 mmol), and DMAP (cat.) at room temperature. The reaction was 
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stirred for 1 h. Brine was added and the product was extracted with CH2Cl2, and dried with Na2SO4. After 
evaporation of the solvent, the crude product was purified by flash chromatography (EtOAc/n-heptane, 
1/10), to obtain 16 (56 mg, 77%). IR υmax film: (cm
-1) 2929, 2102, 1754, 1253, 1222, 940, 837. 1H NMR 
(CDCl3, 400 MHz, ppm): δ 5.64-5.59 (m, 1H, H-5), 5.52 (d, J = 10.2 Hz, 1H, H-4), 5.06 (dd, J =10.9, 7.8 Hz, 
1H, H-2), 4.34 (ddd, J = 7.7, 3.6, 1.8 Hz, 1H, H-3), 3.62 (td, J = 10.7, 5.9 Hz, 1H, H-1), 2.50 (dt, J = 5.4, 
17.6 Hz, 1H, H-6a), 2.25-2.13 (m, 1H, H-6b), 2.15 (s, 3H, Ac), 0.87 (s, 9H, t-Bu), 0.09 (s, 3H, Me), 0.06 (s, 
3H, Me). 13C NMR (CDCl3, 100 MHz, ppm): δ 170.4, 130.6, 124.5, 71.7, 59.5, 31.3, 26.0, 21.5, 18.3, -4.2, -
4.4. HRMS (CI) m/z calcd for C14H26O3SiN3 (M+H)
+: 312.1743, found: 312.1754. 
 
(±)-(1R,2S,3S,4R,5R)-1-azido-3-[(tert-butyldimethylsilyl)oxy]-4-epoxy-cyclohexane-2-
ylacetate (17)  
To a solution of 16 (37 mg, 0.12 mmol), and chlorocyclohexanone (0.12 mmol, 16 mg) in 
MeCN and water (3:2, 3 mL) was added in small portion during 1 hour oxone (0.12 mmol, 73 
mg) and NaHCO3 (0.36 mmol, 30 mg). The solution was stirred at room temperature for another hour and 
quenched with water, extracted twice with CH2Cl2, dried with Na2SO4, concentrated, and purified by flash 
chromatography to yield compound 17 as a colorless oil (27 mg, 71%). The ratio between cis and trans-
epoxide is 1:4. IR υmax film: (cm
-1) 2929, 2104, 1759, 1369, 1221, 1107, 841, 779. Rf 0.25 (EtOAc/n-heptane, 
1/10). 1H NMR (CDCl3, 400 MHz, ppm): δ 4.84 (dd, J = 11.0, 8.1 Hz, 1H, H2), 3.96 (d, J = 8.1 Hz, 1H, H-
3), 3.41 (td, J = 11.1, 5.1 Hz, 1H, H-1), 3.30 (br s, 1H, H-5), 3.04 (d, J = 3.5 Hz, 1H, H-4), 2.56 (ddd, J = 
14.8, 5.1, 2.0 Hz, 1H, H-6a), 2.13 (s, 3H, Ac), 1.90 (ddd, J = 14.8, 11.3, 1.6 Hz, 1H, H-6b), 0.89 (s, 9H, t-
Bu), 0.14 (s, 3H, Me), 0.08 (s, 3H, Me). 13C NMR (CDCl3, 100 MHz, ppm): δ 170.5, 71.5, 57.1, 56.0, 53.6, 
30.5, 26.1, 21.6, 18.5, -4.1, -4.4. HRMS (CI) m/z calcd for C14H25O4SiN3 (M+H)
+: 328.1692, found: 
328.1684.  
 
(±)-(1S,2R,3R,4R,6R)-6-Azido-2-[(tert-butyldimethylsilyl)oxy]-3,4-epoxycyclohexan-1-ol 
(19)  
To a solution of 15 (3.61 g, 13.4 mmol) in CH2Cl2 (180 mL) at room temperature, was added 
m-CPBA (5.76 g, 33.4 mmol). After stirring overnight the suspension was diluted with 
CH2Cl2, filtered, washed with water, and twice with a phosphate buffer (pH 7.5) to get rid of the excess 
benzoic acid. The crude product was dried (Na2SO4), concentrated under reduced pressure, and purified by 
flash chromatography (EtOAc/n-heptane, 1/5) to give (2.74 g, 72%) of compound 19 as a colorless 
crystalline solid and (0.684 g, 18%) of compound 20. Spectral data 19: Rf 0.4 (EtOAc/n-heptane, 1/5). IR 
υmax film: (cm
-1) 2956, 2927, 2860, 2110, 1709, 841. 1H NMR (CDCl3, 400 MHz, ppm): δ 3.82 (d, 1H, 3, J = 
7.2 Hz, CH), 3.42-3.32 (m, 3H, CH), 3.01 (d, 1H, J = 3.7 Hz, CH), 2.53 (ddd, J = 1.9, 3.1, 6.9 Hz, 1H, CH2), 
2.40 (d, J = 2.6 Hz, 1H, OH), 1.79 (ddd, J = 1.3, 10.4, 11.9 Hz, 1H, CH2) 0.93 (s, 9H, t-Bu), 0.18 (s, 3H, 
MeSi), 0.16 (s, 1H, MeSi). 13C NMR (CDCl3, 100 MHz, ppm): δ 73.2, 57.4, 56.4, 53.1, 28.9, 25.9, 18.2, -4.5, 
-4.6. HRMS (CI) m/z calcd for C12H24O3SiN3 (M+H)
+: 286.1587, found: 286.1577.  
 
(±)-(1S,2R,3S,4S,6R)-6-Azido-2-[(tert-butyldimethylsilyl)oxy]-3,4-epoxycyclohexan-1-ol 
(20)  
Rf 0.3 (EtOAc/n-heptane, 1/5). IR υmax film: (cm
-1) 2954, 2105, 1769, 1374, 1247, 837, 780, 
608. 1H NMR (CDCl3, 400 MHz, ppm): δ 3.76 (d, J = 8.1 Hz, 1H), 3.44 (t, J = 9.8 Hz, 1H), 
3.20 (q, J = 10.6, 18.2 Hz, 1H), 3.08-2.98 (m, 2H), 2.24-2.14 (m, 1H), 1.75-1.65 (m, 1H), 0.78 (s, 9H), 0.01 
(s, 6H). 13C NMR (CD3OD, 100 MHz, ppm): δ 75.2, 62.4, 58.8, 52.4, 30.7, 26.5, 19.2, -3.9, -4.4. HRMS (CI) 
m/z calcd for C12H24O3SiN3 (M+H)
+: 286.1587, found: 286.1577. 
 
(±)-(1R,2S,3S,4S,6R)-4,6-Diazido-2-[(tert-butyldimethylsilyl) oxy]cyclohexane-3-acetyl-
1,3-diol (22)  
To a solution of 17 (40 mg, 0.14 mmol) in MeOH (2 mL) was added NaN3 (26 mg, 0.56 
mmol) and NH4Cl (18 mg, 0.50 mmol). The reaction mixture was refluxed for 48 h. and the 
solvents were evaporated. The crude was dissolved in EtOAc and washed with H2O several times. The crude 
product was dried (Na2SO4), concentrated under reduced pressure, and purified by flash chromatography 
(EtOAc/n-heptane, 1/10) to give (9 mg, 21%) of compound 19 as a colorless oil. The wrong regio isomer 
was also isolated as a colorless oil (32 mg, 74%). Spectral data 19: Rf 0.06 (EtOAc/n-heptane, 1/10). IR υmax 
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film: (cm-1) 2932, 2357, 2103, 1748, 1376, 1255, 841. 1H NMR (CDCl3, 400 MHz, ppm): δ 4.88 (t, 1H, J = 
9.2 Hz), 3.66-3.31 (m, 4H), 2.41 (s, 1H), 2.31 (m, 1H), 2.11 (s, 3H), 1.45 (dt, 1H), 0.88 (s, 9H), 0.16 (s, 3H), 
0.11 (s, 3H). 13C NMR (CDCl3, 100 MHz, ppm): δ 168.8, 74.7, 74.0, 59.3, 58.3, 31.4, 25.3, 20.8, 17.7, -4.3, -
4.9. HRMS (CI) m/z calcd MS C14H26O4N6Si (M+H)
+: 371.1864, found: 371.1863.  
 
(1R,2r,3S,4R,6S)-4,6-Diazido-2-[(tert-butyldimethylsilyl) oxy]cyclohexane-1,3-diol (24) 
A solution of the epoxide (19) (448 mg, 1.66 mmol) in 22 mL toluene is added dropwise 
under argon over Yb(OTf)3 (515 mg, 0.83 mmol) and MS 4Å (500 mg) at room temperature. 
NaN3 (1.08 g, 16.6 mmol) and Et3N (3.47 ml, 24.9 mmol) are added and the reaction is 
stirred at 80 °C for 4 days. The reaction mixture is cooled, filtered and evaporated. The 
crude product was purified by flash chromatography (EtOAc/n-heptane, 1/10), to give compound 24 as white 
crystals (321 mg, 82% based on recovered starting material 114 mg). Rf 0.2 (EtOAc/n-heptane, 1/10). Mp: 
104 °C. IR υmax film: (cm
-1) 2932, 2098, 1247, 1130, 841. 1H NMR (CDCl3, 400 MHz, ppm): δ 3.35 (s, 5H), 
2.41 (s, 2H, OH), 2.18 (m, 1H), 1.38 (m 1H), 0.92 (s, 9H), 0.16 (s, 6H). 13C NMR (CDCl3, 75 MHz, ppm): δ 
76.2, 59.7, 31.7, 25.7, 18.1, -4.5.HRMS (CI) m/z calcd for C12H25O3SiN6 (M+H)
+: 329.1758, found: 
329.1754. Anal. calcd for C12H24O3N6Si: C 43.88, H 7.37, N 25.59; found: C 43.84, H 7.04, N 25.11. Crystal 
structure have been deposited at the Cambridge Crystallographic Data Centre, CCDC 226046. 
 
(±)-(1S,2S,3R,4S,6R)-4,6-Diazido-1-[(tert-butyldimethylsilyl)oxy]cyclohexane-2,3-
diol (26)  
Compound 24 (30 mg, 0.0 93 mmol) was dissolved in THF (1mL). The mixture was 
cooled to 0 °C and TBAF (1 M solution, 100 µL) was added. After stirring for 30 
minutes the reaction mixture was diluted with Et2O, filtered, washed with water, and 
brine. The crude product was dried (Na2SO4), concentrated under reduced pressure, and purified by flash 
chromatography (EtOAc/n-heptane, 1/10) to give (30 mg, quant.) of compound 26 as a colorless oil. 1H 
NMR (CDCl3, 400 MHz, ppm): δ 3.45-3.25 (m, 5H), 2.86 (br s, 1H, OH), 2.51 (br s, 1H, OH), 2.43-2.12 (m, 
1H, CH2), 1.45-1.12 (m, 1H, CH2), 0.93 (s, 9H, t-Bu), 0.19 (s, 3H, Me), 0.15 (s, 3H, Me). 
 
(1R,2r,3S,4R,6S)-4,6-Diazidocyclohexanetriol (27)  
Compound 24 (30 mg, 0.093 mmol) was dissolved in a 1N HCl solution in MeOH (1 mL). 
The reaction mixture was stirred at room temperature overnight. EtOAc was added and the 
reaction mixture was washed with NaHCO3 and dried (Na2SO4), to give after flash 
chromatography (EtOAc) the 4,6-diazidocyclohexanetriol (quant.). Rf 0.4 (EtOAc). IR υmax film: (cm
-1) 3369, 
2923, 2100, 1359, 1260, 1113, 1080, 1023, 668, 616, 556. 1H NMR (CD3OD, 400 MHz, ppm): δ 3.38 (m, 
2H, CH), 3.18-3.27 (m, 3H, CH), 2.09 (dt, J = 4.4 Hz, 1H, CH2), 1.25 (q, J = 12.6 Hz, 1H, CH2); in 
agreement with literature.37  
 
2-Deoxystreptamine  
To a solution of 4,6-diazidocyclohexanetriol 27 (20 mg, 0.093 mmol) in MeOH was added 
Pd/C (spatula). After the mixture had been stirred for 14 h under 3 bar of H2, Pd/C was 
filtered off and the filtrate was concentrated to yield 2-deoxystreptamine (14 mg, 95%). IR 
υmax film: (cm
-1) 3345, 2917, 2362, 2094, 1559, 1541, 1095, 988. 1H NMR (CD3OD, 400 
MHz, ppm): δ 3.13 (m, 1H, CH), 3.02 (t, J = 9.5 Hz, 2H, CH), 2.68-2.54 (m, 2H, 2CH), 1.98 (dt, J = 4.3, 4.1 
Hz, 1H, CH2) 1.16 (q, J = 12.1 Hz, 1H, CH2).
38 
 
N,N'-diacetyl-2-deoxystreptamine (28)  
2-Deoxystreptamine (0.086 mmol, 14 mg) was dissolved in MeOH/H2O
 (1/1) and Ac2O 
(0.172 mmol, 16 µl) and Et3N (0.172 mmol, 24 µl) were added. The reaction mixture as 
stirred for 3 h and then concentrated in vacuo and co-evaporated a few times with D2O, 
to yield the diacetyl compound (20 mg, 96%). 1H NMR (D2O, 400 MHz, ppm): 3.82-3.71 (m, 2H, CH), 3.49-
3.38 (m, 3H, 3CH), 2.03 (dt, J = 4.3 Hz, 1H, CH2), 2.01 (s, 6H, CH3), 1.42 (q, J = 12.5 Hz, 1H, CH2). 
13C 
NMR (D2O, 75 MHz, ppm): δ 174.8, 77.0, 75.5, 50.9, 33.8, 23.4; in agreement with literature.
39 
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(1R,2R,3r,4S,5S)-3-[(tert-Butyldimethylsilyl)oxy]-1,2-4,5-disepoxycyclohexane (29) 
Compound 14 (50 mg, 0.22 mmol) was dissolved in CH2Cl2 (2 mL) m-CPBA (56 mg) and 
NaHCO3 (18 mg) were added to the reaction mixture. The reaction was stirred at room 
temperature for 48 hours. The reaction mixture was diluted with water and extracted with 
CH2Cl2. The organic layer was washed twice with a phosphate buffer solution, dried with Na2SO4 and the 
solvents were evaporated. Two diastereomers xa (cis) and xb (trans) were formed in a ratio of 9:1. Both 
products were separated by column chromatography (EtOAc/n-heptane 1/10), to yield compound 29 (37 mg, 
70%) as a white powder: Rf 0.16 (EtOAc/n-heptane, 1/5), Mp 85.2 °C. IR υmax film: (cm
-1) 2956, 2929, 2856, 
2358, 1739, 1438, 1257, 1095, 1012, 802. 1H NMR (CDCl3, 400 MHz, ppm): δ 4.53 (s, 1H, CH), 3.12 (brs, 
2H, epoxide), 3.01 (br s, 2H, epoxide), 2.67 (dd, J = 0.9, 16.4 Hz, 1H), 2.32 (dd, J = 3.1, 6.0 Hz, 1H), 0.94 
(s, 9H, tBu), 0.17 (s, 6H, Me). 13C NMR (CDCl3, 100 MHz, ppm): δ 67.4, 57.5, 54.6, 30.6, 23.1, 23.0, 0.01. 
CI/MS m/z (M+C2H5)
+ 271. Anal. calcd for C12H22O3Si: C 59.46, H 9.15; found: C 59.30, H 9.11.  
 
(1R,2S,3r,4R,5S)-3-[(tert-Butyldimethylsilyl)oxy]-6,7-diazo-dicyclo[3,2,1]octane (30) 
Compound 29 (50 mg, 0.21 mmol) was dissolved in EtOH (5 mL) and hydrazine (50 µL, 1.6 
mmol) was added. The reaction was refluxed for 4 hours and the solvent was removed under 
reduced pressure to obtain 30. Rf 0.0 (EtOAc/n-heptane, 1/3). 
1H NMR (CD3 OD, 400 MHz, 
ppm): δ 3.60 (s, 1H, CH), 3.59 (s, 2H, CH), 3.42 (br s, 2H, CH), 2.70 (d, 1H, CH2), 1.47 (dt, J = 6.0 Hz, 1H, 
CH2), 0.94 (s, 9H, tBu), 0.15 (s, 6H, Me). HRMS (EI) m/z calcd MS C12H26O3N2Si (M)
+: 274.1713, found: 
274.1710. 
 
(1R,2r,3S,4R,6S)-4,6-Diazido-2-[(tert-butyldimethylsilyl) oxy]cyclohexane-1,3-diol (24) 
Dissolve 30 (54 mg, 0.20 mmol) in MeOH/H2O, 1/1 (30 mL). Amberlite IRA 400 (OH
-) 
(~20 mg) and Raney Nickel 2800 catalyst (~1.5 mL, slurry) are added. This is placed under 
an atmosphere of 3 bar H2 for 16 hours. Filtrate the suspension over Celite and remove the 
solvent under reduced pressure. The crude compound (55 mg, 0.20 mmol) and ZnCl2 (cat) 
were dissolved in H2O (1.5 mL). Et3N (170 µL, 0.60 mmol) and carefully MeOH (5.0 mL) were added. 
Followed by addition of a 0.6 M TfN3 in CH2Cl2 (1.5 mL). The reaction mixture was stirred for three hours 
after which the solvents carefully evaporated. Purify the product by flash column chromatography (EtOAc/n-
heptane, 1/10) to obtain 1 (6 mg, 10% in three steps). Rf 0.6 (EtOAc/n-heptane, 1/3). Spectral data in 
agreement with pervious.  
 
Dihydroxylation with OsO4 
Compound (16) was dissolved in a mixture of H2O and acetone (2/1, 0.1 M solution). To this mixture was 
added NMO (1equiv) and OsO4 (1 mol %- 100 mol %). The mixture was stirred at room temperature. 
 
Dihydroxylation with OsO4 and methanesulfonamide 
OsO4 (0.2 mL mg, 0.03 mmol) was dissolved in a mixture of H2O and t-BuOH (1/1, 2 mL solution) and 
methanesulfonamide (3 mg, 0.03 mmol). To this mixture was added compound (16) (10 mg, 0.032 mmol). 
The mixture was stirred at room temperature for 5h, solid sodium sulfite was added and the mixture was 
stirred for 30 min. EtOAc was added to the reaction mixture, and after separation of the layers, the aqueous 
phase was further extracted with the EtOAc (3 X 5 mL). The combined organic extracts were dried with 
Na2SO4 and concentrated to give the diol and the ligand. This crude product was purified by flash 
chromatography (EtOAc/hexanes; 1/5) to afford the 1,2-diol 31 (12 mg, quant.).  
 
Dihydroxylation with the NaIO4 
To a cold 0 °C solution of EtOAc and MeCN (1/1, 1 mL) was added compound 16 (60 mg, 0.19 mmol) and 
RuCl3.H2O (2.7 mg, 0.013 mmol) and NaIO4 (56 mg, 0.28 mmol) in H2O (1 mL). The reaction was stirred for 
3 min and quenched with saturated Na2S2O3, extracted twice with EtOAc, dried with Na2SO4, evaporate the 
solvents, and purify by flash chromatography (EtOAc/n-heptane, 1/3) to yield compound 31 as a colorless oil 
(59 mg, 88%). 
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(±)-(1R,2R,3S,4S,5R)-5-azido-3-[(tert-butyldimethylsilyl)oxy]cyclohexane-4-acetyloxy-
1,2-diol (31)  
Rf 0.36 (EtOAc/n-heptane, 2/3). IR υmax film: (cm
-1) 2928, 2111, 1722, 1238, 836. 1H NMR 
(CDCl3, 400 MHz, ppm): δ 4.87 (t, J = 9.8 Hz, 1H, CH), 4.13 (br s, 1H, CH) 3.86 (t, J = 9.2 
Hz, 1H, CH), 3.52 (dq, J = 2.2, 5.6 Hz, 1H, CH), 3.49 (dt, J = 2.6, 3.1 Hz, 1H, CH) 2.48 (br 
s, 1H, OH), 2.31 (br s, 1H, OH), 2.29 (dt, J = 3.7 Hz, 1H, CH2), 2.25 (s, 3H, Me), 1.61 (m, 1H, CH2), 2.15 (s, 
9H, t-Bu), 0.13 (s, 3H, Me), 0.09 (s, 3H, Me). 13C NMR (CDCl3, 100 MHz, ppm): δ 169.9, 76.2, 75.3, 72.7, 
67.9, 58.3, 32.8, 26.0, 21.6, 18.4, -3.8, -4.0. HRMS (CI) m/z calcd MS C14H27O5N3Si (M+H)
+: 346.1803, 
found: 346.1798. 
 
(±)-(1R,2S,3R,4S,5R)-5-azido-1,2-sufate-3-[(tert-butyldimethylsilyl)oxy]cyclohexane-
4-acetyloxy-1,2-diol (32)  
To a solution of the diol (50 mg, 0.14 mmol) and thionyl chloride (18 µl, 0.14 mmol) in 
dry EtOAc was added pyridine (25 µl, 0.29 mmol). The mixture was stirred and not 
allowed to rise above rt. When TLC analysis showed complete conversion the mixture was diluted with 
EtOAc and extracted with H2O. The organic phase was dried with Na2SO4 and concentrated. The residue was 
dissolved in a mixture of CH2Cl2, MeCN and H2O (2:2:3, 1 mL), NaIO4 (61 mg, 0.28 mmol) and RuCl3×H2O 
(catalytic) were added and the mixture was stirred for 1h at 20 °C. The mixture was filtered and the filtrate 
was diluted with CH2Cl2, the organic layer was extracted with water, dried (MgSO4) and concentrated. Flash 
column chromatography (EtOAc/n-heptane, 1/5) yielded compound 32 as a white solid. 1H NMR (CDCl3, 
400 MHz, ppm): δ 5.24 (m, 1H), 4.91 (t, J = 9.7 Hz, 1H), 4.72 (dd, J = 4.8, 7.6 Hz, 1H), 4.24 (dd, J = 7.6, 
9.5 Hz, 1H), 3.80 (m, 1H), 2.57-2.23 (m 1H), 2.17 (s, 3H) 1.89 (dt, J = 3.7 Hz, 1H), 0.86 (s, 9H), 0.16 (s, 
3H), 0.10 (s, 3H). HRMS (CI) m/z calcd MS C14H25O7N3SiS (M+H)
+: 408.1261, found: 408.1257.  
 
(±)-(1R,2S,3S,4R,6S)-4,6-Diazido-2-[(tert-butyldimethylsilyl) oxy]cyclohexane-3-
acetyloxy-1-ol (22)  
Compound 32 (18 mg, 0.044 mmol) was dissolved in DMF (1 mL). The reaction mixture 
was heated top 80 °C and LiN3 (18 mg, 0.11 mmol) was added to the reaction mixture. The 
reaction mixture was heated until TLC analysis showed conversion of the cyclic sulfate into baseline 
material. After stirring for 2 h, the reaction mixture was evaporated and dissolved in THF. A drop of water 
was added and H2SO4 (5 µL) was added to the reaction mixture. The reaction mixture was quenched after 30 
min. with NaHCO3 and extracted with EtOAc, dried with Na2SO4 and purified by flash column 
chromatography (EtOAc/n-heptane, 1/5) gave (23 mg, 43% for 2 steps) as an oil. Spectra in agreement with 
previous. 
 
(1R,2r,3S,4R,6S)-4,6-Diazido-2-[(tert-butyldimethylsilyl) oxy]cyclohexane-1,3-
acetyldiol (33)  
Compound 22 (13 mg, 0.035 mmol) was dissolved in CH2Cl2 (0.8 mL) and add Et3N (8 µL, 
0.07 mmol) and Ac2O (8 µL, 0.07 mmol) and DMAP (cat). Stir for 3 hours, dilute with 
CH2Cl2, wash with brine and dry with Na2SO4. Evaporation of the organic solvent and purification by flash 
column chromatography (EtOAc/n-heptane, 1/5) yields 33 as colorless oil (13 mg, 87%).  
Compound 24 (100 mg, 0.30 mmol) was dissolved in CH2Cl2 (3 mL) and Et3N (84 µL, 0.75 mmol), Ac2O 
(72 µL, 0.75 mmol) and DMAP (cat) were added. The reaction mixture was stirred for 2 hours, diluted with 
CH2Cl2, washed with brine and dried with Na2SO4. Evaporation of the organic solvent and purification by 
flash column chromatography (EtOAc/n-heptane, 1/10 to 1/5) yields 33 as colorless oil (117 mg, 93%).  
33: Rf 0.24 (EtOAc/n-heptane, 1/5). IR υmax film: (cm
-1) 2951, 2930, 2857, 2098, 1746, 1372, 1250, 1215, 
1144, 1096, 1067, 1032, 979, 896, 878, 836, 779. 1H NMR (CDCl3, 300 MHz, ppm): δ 4.97 (dd, J = 9.2, 
10.2 Hz, 2H), 3.69 (t, J = 9.3 Hz, 1H), 3.40 (ddd, J =12.5, 10.2, 4.5 Hz, 2H), 2.30 (td, J = 4.5, 13.1 Hz, 1H), 
2.17 (s, 6H), 1.62 (dd, J = 12.6, 25.8 Hz, 1H), 0.85 (s, 9H), 0.08 (s, 6H). 13C NMR (CDCl3, 100 MHz, ppm): 
δ 169.6, 77.4, 77.1, 76.8, 75.7, 72.2, 58.7, 31.8, 25.5, 22.8, 21.3, 17.8, -4.3. HRMS (EI) m/z calcd for 
C16H29O5SiN6 (M+H)
+: 413.1969, found: 413.19706. 
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Table 4. Crystallographic data and parameters for compounds 9, 12, 24 and 29  
Compound 9 12 24 29 
Empirical formula C18H17NO5 C18H17NO5 C12H24N6O3Si C12H22O3Si 
Molecular mass 327.33 327.33 328.46 242.39 
Temperature, K 208(2) 208(2) 208(2) 293(2)  
Wavelength, Å 0.71073 0.71073 0.71073 0.71073  
Crystal system triclinic monoclinic monoclinic monoclinic 
Space group P-1 C2/c P 21/c P 21/a 
Unit cell dimension (Å, °)     
A 7.0838(4) 41.943(3) 11.7487(7) 12.565(4) 
B 14.5357(7) 7.1885(6) 8.6317(7) 7.882(3) 
C 16.0758(9) 10.2993(8) 17.4180(12) 14.321(6) 
α 71.249(5) 90.000 90 90 
β 78.019(5) 97.023(7) 92.494(6) 90.80(3) 
γ 78.019(5) 90.000 90 90 
Volume (Å3) 1532.27(14) 3082.0(4) 1764.7(2) 1418.1(9) 
Z 4 8 4 4 
Density (calculated, mg/m3) 1.419 1.411 1.236 1.135 
µ, mm-1 0.104 0.104 0.154 0.158 
F(000) 688 1376 704 528 
Crystal size, mm 0.19x0.15x0.03 0.26x0.26x0.03 0.26x0.14x0.06 0.29 x0.20x0.12 
θ range (°) 3.53 - 27.50 3.19 - 27.50 3.70 - 27.50 5.01 - 27.54 
Reflections collected 43104 41867 36090 20820 
Independent reflections [Rint] 7002 [0.1121] 3541 [0.1077] 4034 [0.1059] 3248 [0.0597] 
Refinement method Full-matrix least-squares on F2 
Data/restraint/parameters 7002 / 0 / 569 3541 / 0 / 278 4034 / 0 / 240 3248 / 0 / 233 
Goodness-of-fit on F2 1.025 1.029 1.081 1.032 
R1, ωR2 indices  0.0608, 0.0967 0.0685, 0.1520 0.0830, 0.1740 0.0606, 0.1200  
R1, ωR2 indices (all data) 0.1413, 0.1162 0.1378, 0.1799 0.1509, 0.2030 0.1094, 0.1378 
Largest diff peak and hole, e. 
A-3 
0.200 and -
0.254 
0.532 and -0.244 0.987 and -0.271 0.241 and -0.180 
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Desymmetrization 
of 1,3-diazidocyclohexitols 
 
 
 
 
Abstract 
Several methodologies are explored to obtain enantiopure and orthogonally protected 
1,3-diazidocyclohexitols (1,3-DACHs), via resolution of a racemic intermediate of the synthetic 
route or via resolution of a meso 5-O-protected precursor, for example by asymmetric alkylation, 
asymmetric allylic alkylation or enzymatic resolution. A straightforward synthesis of 5-O-benzyl 
protected 1,3-diazido-4,5,6-cyclohexanetriol is developed, starting from commercially available 
kanamycin.  
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4.1 Introduction 
The core structure of all clinically important aminoglycoside antibiotics is formed by an 
aminocyclitol termed streptamine. In particular, a monodeoxygenated version of streptamine, 
termed 2-deoxystreptamine or 2-DOS, features in natural or semi-synthetic aminoglycosides and as 
such appears indispensable for the development of any new aminoglycoside-type antibiotic or, more 
generally speaking, for RNA-specific high affinity ligands. Indeed, recent structural studies toward 
novel aminoglycoside entities with omission of 2-DOS led to low bacterial activity.
1
 An important 
reason therefore to synthesize 2-DOS is that it may serve as a worthwhile scaffold in the 
development of new and innovative antibiotics. 
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Figure 1. Asymmetrically substituted 2-deoxystreptamine in two common aminoglycosides. 
 
In the preceding chapter we have synthesized two different 1,3-diazidocyclohexitol (1,3-DACH) 
precursors, 1 and 2. Cyclic sulfate methodology yielded the racemic 2-DOS precursor 2, whereas 
the other meso 2-DOS precursor 1 was obtained via a more straightforward strategy, by epoxide 
opening. This chapter describes the exploration of several methods to desymmetrize the 2-DOS 
precursors 1 and 2, with particular attention on methodology to desymmetrize meso diol 1, since in 
theory a 100% yield with 100% enantiomeric excess can be achieved starting from a meso 
compound.  
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Figure 2. 1,3-DACHs 1 and 2 synthesized in chapter 3. 
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4.2 Asymmetric palladium-catalyzed 1,4-hydrogen migration  
In the synthetic route toward 2-DOS described in chapter 3, the earliest occasion for 
desymmetrization of an intermediate lies in the resolution of ene-1,4-diol 3 (Scheme 1), prepared in 
two steps from 1,4-benzoquinone and cyclopentadiene. As described by Takano and co-workers, 
meso diol 3 can be converted into the enantiopure tricyclic enone 6 –the proper enantiomer for our 
purpose (vide infra)– in a few steps (Scheme 1):2,3 first enantioselective acetylation with lipase PS, 
then protection of the remaining hydroxyl with a pivaloyl group (3→4), followed by selective 
deacetylation (4→5) and finally palladium-mediated hydrogen migration to yield enantiopure 
ketone 6 in an overall yield of 51% for the 4 steps.
4
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Reagents and conditions: (a) lipase PS, vinylacetate, MeCN, 30 °C; (b) PivCl, DMAP, Et3N, CH2Cl2; (c) 
K2CO3, MeOH; (d) Pd2Cl2(PPh3)2, HCO2NH4, MeCN; (e) given Pd source, Trost ligand (S,S)-7, MeCN. 
 
We reasoned that ketone 6 could possibly also be obtained in enantioselective fashion by a 
1,4-hydrogen migration in the presence of a chiral ligand (Scheme 1),
5
 particularly since catalysis 
of palladium-mediated reactions with enantiopure phosphine ligands is precedented. Thus, in an 
initial attempt compound 3 was subjected to the isomerization conditions (Pd(dba)2, MeCN, 60 °C) 
explored in chapter 3, in the presence of Trost ligand (S,S)-7. In our first attempt, enantiopure 
ketone (+)-6 was obtained in moderate yield (45%) but with excellent enantiomeric excess (97%).
6
 
However, besides (+)-6 formation of another product was observed, in a ratio of 45:55 in favor of 
the side-product (Table 1, entry 1). Unfortunately, the side-product could not be isolated possibly 
due to instability. A few different reaction conditions were investigated but since none of the 
attempts led to an improval of product yield (entry 2-4), this methodology was abandoned. 
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Table 1. Enantioselective Pd-catalyzed 1,4-hydrogen migration 
 hydrogen 
donor  
catalyst temperature time (+)-6 
yield 
(%)a 
u.c.b
yield 
(%)a 
1 -     Pd(dba)2 60 °C   3 h 45 55 
2 -     Pd(dba)2 ∆   40 min 45 55 
3 HCO2NH4     Pd(OAc)2 60 °C   3 h 23 77 
4 -     PdCl2(C3H5)2 ∆   30 min 28 72 
a GC yield b unidentified compound 
4.3 Asymmetric dihydroxylation 
In the early 90’s Sharpless et al. developed a highly useful protocol for the asymmetric 
dihydroxylation (ADH) of a wide variety of olefines. The discovery of both the phthalazine class of 
ligands
7
 and the acceleration of osmate ester hydrolysis of organic sulfonamides have led to one 
general procedure for diol formation from a wide range of alkenes with good to excellent 
enantiomeric excesses. Since our synthetic route toward 2-DOS involved the dihydroxylation of an 
alkene (vide chapter 3), asymmetric dihydroxylation was explored as a possible means to obtain an 
enantiopure 2-DOS precursor. Thus, the double bond of intermediate 8 was reacted under Sharpless 
asymmetric dihydroxylation conditions
8
 with AD-mix β, to yield the dihydroxylated product 9 in a 
satisfactory yield of 84% (BORSM 96%), but with disappointing enantiomeric excess (21%) as 
determined by HPLC.
7
 Because no proof of absolute stereochemistry could be obtained, the 
stereochemical constitution was assigned by analogy (Scheme 2).
9
 The rather low e.e. of the ADH 
stimulated us to investigate whether double stereodifferentiation was playing a role and, 
consequently, if dihydroxylation under the action of AD-mix α would lead to a significantly 
different e.e. However, also upon reaction with AD-mix α product 9 was isolated in an enantiomeric 
excess of only 9% (yield 71%, BORSM 89%). Since these findings strongly suggest that the facial 
selectivity of the dihydroxylation is predominantly determined by the constitution of the starting 
material this route was further discarded. 
 
Scheme 2.  
OTBDMS
8 (±)
SiMe2H SiMe2H
OH
OH
Ref 9
N3
AcO
OTBDMS
9
N3
AcO
OH
OH
a a
(40-65% e.e.)
(84%, 
21% e.e.)  
Reagents and conditions: AD-mix, CH3SO2NH2, t-BuOH/H2O (1/1), 0 °C, 24h, AD-mix β; 84% yield, 21% 
e.e., AD-mix α; 71% yield, 9% e.e. 
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4.4 1,3-DACHs from kanamycin 
So far, attempts to obtain an enantioselective, protected 2-DOS precursor were based on the 
synthetic route described in the previous chapter. The latter route (§3.3), a 10-step sequence from 
cheap starting materials, was amenable to scale-up to afford several grams of 2-DOS in a few weeks 
time. Nevertheless, by far the simplest procedure to obtain 2-DOS remains the hydrolytic 
degradation of a natural aminoglycoside. Generally neomycin B trisulfate, since it is readily 
obtained by Streptomyces fermentation.10 Thus, acidic degradation of neomycin yields ‘naked‘ 
2-DOS in an overall yield of 40% in two steps.
11
 However, since neomycin is an aminoglycoside 
4,5-linked at 2-DOS it is not well suitable for the preparation of 4,6-protected 2-DOS analogues. 
The synthesis described in this paragraph therefore starts from commercially available kanamycin B 
sulfate (5.20 €/mmol) which is more costly than neomycin,
12 
but as will become clear below, can be 
converted into versatile scaffolds 13 or 14 in three straightforward steps.  
The first step in our synthesis is a Zn-catalyzed diazotransfer onto kanamycin B, to give the 
corresponding azides, according to Wong and co-workers.
13 
The free alcohols of the resulting 
tetraazide 10 were protected with an allyl or benzyl protective group, to give fully protected 
trisaccharide 11 or 12, respectively. Subsequent acetal hydrolysis was performed with hydrochloric 
acid (Scheme 3) to afford the benzyl or allyl protected DACHs 13 and 14 in an overall yield of 39% 
and 40%, respectively. Other methods were also investigated i.e. hydrobromic acid, sulfuric acid 
and Amberlite IR-120 (H
+
), but did not lead to satisfactory yields of the desired products. 
 
Scheme 3.  
kanamycin B
sulfate
OHHO
N3 N3
OR
(70%)
(68%)
OAcAcO
N3 N3
OR
+
+
a b
c d
(75 %)
(78 %)
 (92%)
(75 %)
10
 (89%)
15  R= Bn 
16  R= All
13 R= Bn
14 R= All
11 
12 R= All
R= Bn
O
N3 N3
OO
HO
OH
N3
N3
OH
O
N3
HO OH
OH
O
N3 N3
OO
RO
OR
N3
N3
OR
O
N3
RO OR
OR
OMeO
RO
OR
N3
N3
MeO O
N3
RO OR
OR
Reagents and conditions: (a) TfN3, ZnCl2, Et3N, CH2Cl2/MeOH/H2O, 3/10/3, rt, 3 h; (b) NaH, TBAI, AllBr or 
BnBr, DMF, 0 °C-rt, 16 h; (c) 1 N HCl/MeOH, ∆, 16 h; (d) Ac2O, Et3N, DMAP, CH2Cl2, rt, 3 h. 
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Since both compounds 13 and 14 are meso, an important advantage of the route described here is 
that the obtained diazido entities can be directly subjected to enzymatic resolution. Moreover, the 
diazido derivatives described here display distinct advantages over carbamate-protected 2-DOS, as 
reflected in excellent solubility in organic solvents and straightforward spectral analysis.  
 
4.5 Enantioselective acylation of 1,3-DACHs 
Asymmetric acylation is a versatile strategy in synthetic organic chemistry for the preparation of 
small chiral compounds. Such methodology, described by Oriyama and co-workers in the 
desymmetrization of various meso diols, is based on enantioselective acylation with benzoyl 
chloride in the presence of chiral diamine derived from (S)-proline and typically proceeds with high 
yield and enantioselectivity.
14,15
 For instance, asymmetric benzoylation of cis 1,2-cyclohexanediol 
under proline catalysis affords the enantiopure monobenzoylated product in 89% yield and 93% 
e.e.. We reasoned that adaptation of asymmetric acylation to our 1,3-DACHs could be a promising 
route to obtain monoprotected, enantiopure product. To this end, chiral diamine (20) was 
synthesized according to literature
16
 and the dideoxystreptamine precursor (17)
17
 was reacted under 
conditions described above. The reaction mixture was stirred overnight at -5 °C and 
monobenzoylated product 18 was obtained in a yield of 78% (Table 2, entry 1). Surprisingly, when 
the same reaction conditions were used for the DACHs protected with either a TBDMS or an allyl 
group no reaction was observed, even when the reaction was performed with AcCl (entry 4 and 5). 
Presumably also in this case acetylation was prevented by steric hindrance of the 5-O protective 
group, a presumption which is further substantiated by the unsuccessful acetylation of the 2-DOS 
precursors in the presence of DIPEA and AcCl (entry 6), and only slight acceleration by DMAP 
(entry 7). Only under the influence of Ac2O, Et3N and DMAP a smooth reaction was observed 
(entry 8), but no further enantioselective acylation was further pursued because it is clear that the 
accelerating potential of 20 lags that of DMAP by far. 
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Table 2. Acylation of 1,3-DACH 
HO OH
N3 N3
R
17 R = H
R2O OR3
N3 N3
R
a
14 R = OAll
1 R = OTBDMS
18 R = H R2 = Bz R3 = H (78%)
19 R = OTBDMS R2 = Ac R3 = Ac (93%)
20
N
N
 
 
 Conditions reactant yield 
(%) 
1 BzCla    17 78 a 
2 BzCla    1 no reaction 
3 BzCla    14 no reaction 
4 AcCla    1 no reaction 
5 AcCla    14 no reaction 
6 AcCl, DIPEA, CH2Cl2    1 no reaction 
7 AcCl, DMAP, CH2Cl2    1 slow
b 
8 Ac2O, Et3N, DMAP, 
CH2Cl2 
   1 93 c 
a Reagents and conditions: diamine 20, BzCl or AcCl (ratio 1.5:1), 4 Å MS, EtCN, -78 °C. b prolonged 
stirring yielded (72 h) mainly starting material.c BORSM. 
 
4.6 Pd-catalyzed asymmetric allylic alkylation (AAA) 
Pd-catalyzed asymmetric allylic alkylation has recently been developed for the resolution of allylic 
alcohols via chiral π-allyl palladium complexes.18,19 Grover and co-workers, for example (Scheme 
4) reported an enantioselective alkylation of BnOH with a secondary carbonate in the presence of 
(R)-BINAP, with good conversion and high enantiomeric excess (65-88%).20 We realized that 
adaptation of such a strategy might possibly also be applied in inverse mode for the resolution of 
chiral alcohols with achiral allyl carbonates, which could be directly applied in the 
desymmetrization of 2-DOS precursors.  
 
Scheme 4.  
Ph Ph
OCO2-t-Bu
Ph Ph
OBn
*
a
(yield >98% 
e.e. 65-88%)
BnOH +
Ph Ph
PdL*
 
Reagents and conditions: (a) Pd2(dba)3, (R)-BINAP, THF, 55 °C. 
 
Thus, in a pilot experiment TBDMS protected 1,3-DACH 1 was reacted with allyl ethyl carbonate 
in the presence of Pd(dba)2 and 1,4-(diphenylphosphino)butane (DPPB) to give monoallylated 
compound 21 and diallylated compound 23 in a yield of respectively 51% and 18% (Scheme 5 and 
Table 3, entry 1). No reaction was observed under Ph3P-catalysis instead of DPPB, suggesting that 
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the reaction is only activated by bidentate ligands. The successful monoallylation stimulated us to 
investigate the desymmetrization of 2-DOS precursors with several chiral phosphine ligands (Table 
3).  
 
Scheme 5.  
a
N3N3
OR
OHHO
N3N3
OR
OO
O OEt
O
+
N3N3
OR
OHO
23 R= TBDMS21 R= TBDMS1 R= TBDMS
22 R= Bn 24 R= Bn13 R= Bn
Reagents and conditions: (a) Pd2(dba)3, 1,4-(diphenylphosphino)butane, THF, 55 °C. 
 
Firstly, under (S,S)-DIOP catalysis the monoallylated product 21 was obtained in a slightly reduced 
yield of 41%, accompanied by trace amounts of diallyl ether 23 (4%, entry 2). Prolonged stirring 
(entry 3) led to improved yields of both mono- and diallylated products but in a worse ratio. In the 
presence of (R)-BINAP only little conversion occurred (entry 4).  
 
Table 3. Optimization of the Pd-catalyzed asymmetric allylic alkylation 
PPh2Ph2P
O O
PPh2
PPh2
(R)-BINAP (26)(S,S)-DIOP (25)
N
H
N
H
OO
PPh2Ph2P
(S,S)-anthracenyl 
ligand (27)
 
 diol phosphine ligand time 
(h) 
temp 
(°C) 
starting 
material 
(%) 
monoallyl 
(%) 
diallyl 
(%) 
ee 
(%) 
1 1      DPPB 1 70 - 51 18 - 
2 1 25 5 20 - 41 4 - 
3 1 25 24 20 - 62 26 - 
4 1 26 5 20 30 25a - - 
5   13       DPPB 2 40 10 35a 22a - 
6   13 25 2 40 30 44a <5a <1 
7   28       DPPB 4 40 31 75a - - 
8   28 27 4 40 40 59a - 22 
a BORSM. 
 
The fact that we found only minor amounts of the diallylated compounds was taken as an indication 
of the enantioselectivity of the reaction. Unfortunately, it turned out rather cumbersome to define 
the enantiopurity of 21 with HPLC due to the lack of a UV-chromophore. For this reason the 
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monoallylation was repeated with benzyl-protected 2-DOS (13), to give under DIOP catalysis the 
monoallylated product (22) in a yield of 44%. Unfortunately, HPLC analysis on a chiral ODH 
column showed that the product was obtained with no enantioselectivity (<1% e.e., entry 6). 
Another disadvantage is that in all reactions small amounts of base-line material were observed by 
Staudinger reduction effected by the phosphine ligand.
21
 
 Most recently, a paper by Trost and co-workers showed that an asymmetric allylation with 
the anthracenyl ligand (27) gave the best yields and selectivities among four other ligands,
22
 which 
stimulated us to investigate desymmetrization potential of ligand 27. However, in order to avoid the 
undesirable Staudinger reaction, 1 was first reduced under hydrogen atmosphere, followed by 
protection of the amines to give Cbz-protected 28 (Scheme 6). Allylation under the optimized 
conditions gave no conversion at room temperature, but when the reaction was heated to 40 °C 
monoallylated protected 2-DOS 29 was formed in a yield of 59% with no detectable formation of 
the diallylated compound. To our surprise, HPLC analysis revealed that product was formed with 
only moderate enantioselectivity (22% e.e., entry 8) and the strategy of enantioselective allylation 
was further abandoned. 
 
Scheme 6.  
N3N3
OTBS
OHHO
a, b NHCbzCbzHN
OTBS
OHHO
c NHCbzCbzHN
OTBS
OHO
1 28 29
(86%)
 
Reagents and conditions: (a) Pd/C (10%), H2, MeOH, 3 bar, o.n.; (b) CbzCl, Et3N, MeOH, rt, o.n.; (c) 
anthracenyl ligand (27), allyl ethyl carbonate, Pd2(dba)3, toluene, 40 °C, 3h. 
 
4.7 Enzymatic resolutions of 1,3-DACHs 
The hydrolysis or formation of the C-O bond of an ester, lactone or carbonate by a hydrolase is 
amongst the most useful enzyme-catalyzed reactions in organic synthesis.
23
 Hydrolases and in 
particular lipases are established tools on laboratory as well as on industrial scale, primarily because 
of their ability to be highly active under (buffered) aqueous conditions but also in the presence of an 
organic cosolvent.
24
 The most widely used class of hydrolases are lipases, for example pig pancreas 
lipase, pseudomonas sp. lipase, Candida antarctica lipase, Candida cylindracea lipase (CCL) and 
Porcine pancreas lipase (PPL). A further potent application of lipases lies in the resolution of 
alcohols, either by enantioselective hydrolysis of acetate esters or by acetylation of alcohols with an 
acetate donor (Scheme 7). Application of the latter potential of hydrolases for our purpose lies in 
the desymmetrization of meso 2-DOS.  
Chapter 4 
 62 
Scheme 7.  
HO
N3
R
OH
N3
HO
N3
R
OAc
N3
R = H
AcO
N3
R
OAc
N3
c
R = H (99%)R = H (70%)
R = OAll
R = OBn
R = OTBDMS
 R = OAll (88%)
R = OBn
R = OTBDMS
R = OAll (89%)
R = OBn (92%)
R = OTBDMS (93%)
a b
31
32
33
34
17
1
13
14
30
19
15
16
 
Reagents and conditions: (a) Ac2O, DMAP, Et3N, CH2Cl2, rt; (b) lipase, phosphate buffer, pH 6-7, 27-37 °C; 
(c) lipase, vinyl acetate, toluene, 27-37 °C. 
 
Initial experiments were performed with the dideoxy analogue (30) with several lipases and it was 
found that out of 11 different enzymes (Table 5, experimental section) two were able to hydrolyze 
the substrate, i.e. Candida antarctica lipase (CAL) and Candida cylindracea lipase (CCL). Much to 
our satisfaction the monohydrolyzed product was formed in a high yield of 95% and 99%, 
respectively, and excellent selectivity (both >99% e.e.), which compares favorably with the 
reported 22% yield with Novozym 435.
25
 
 Unfortunately, upon application of the desymmetrization conditions to the O-TBDMS-
protected 2-DOS precursor 19, no hydrolysis products were obtained with any of the available 
enzymes (Table 5), most likely due to the fact that the (large) TBDMS group prohibits access to the 
enzyme’s active site. The allyl and benzyl protected 2-DOS precursors were also subjected to effect 
hydrolysis but again neither of the enzymes were able to remove an acetyl group (Table 5). 
 Because it was not possible to desymmetrize the 2-DOS derivatives 15, 16 and 19 by a 
commercially available enzyme, 17 esterases provided by Diversa Corporation, San Diego were 
screened next. Thus, the TBDMS-protected 1,3-DACH 19 was dissolved in a mixture of MeCN and 
phosphate buffer (pH 7.5) and the esterases were added. After incubation for 5d, reactions were 
filtered, solvents were evaporated and analyzed by 
1
H NMR spectroscopy to show that again neither 
of the enzymes had been able to hydrolyze the starting material. In a final attempt, resolution was 
attempted of allyl protected 2-DOS 16 and it was rewarding to find that 6 esterases (out of 17) were 
indeed able to hydrolyse the substrate (Table 4), although in four cases complete deprotection 
occurred (entry 1,2,4,6) and under the influence of one esterase a mixture of starting material, 
monodeprotected product and diol was obtained (entry 3). Much to our delight, a single, 
monoacetylated product (34) was obtained (entry 5) in a yield of 88% and, more importantly, with 
excellent enantioselectivity (>99%.) under the action of esterase 5. The absolute stereochemistry of 
34 has not yet been established. 
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Table 4. Desymmetrization of allyl protected DACH 16 
 enzymes specific  
activitya 
conversion 
(%) 
ratio 
14:34 
e.e. 
(%) 
1 Diversa esterase 1 2.642 73 1:0  
2 Diversa esterase 2 243.422 36 1:0  
3 Diversa esterase 3 17.279 n.d. n.d.b  
4 Diversa esterase 4 5.084 19 1:0  
5 Diversa esterase 5 0.032 67 0:1 >99% 
6 Diversa esterase 6 8.3 100 1:0  
a activity: units/mg protein, 1 unit=1 µmol/min of pNP released from 5 mM p-NP-butyrate, pH 7.5, 37 °C b 
three products 14, 16 and 34 ratio could not be determined. 
 
4.8 Concluding remarks 
In the presence of an enantiopure bidentate phosphine ligand, Pd-catalyzed 1,4-hydrogen migration 
of the previously prepared meso diol-3 successfully led to enantiopure ketone (+)-6 with high 
enantiomeric excess, although the yield was suppressed by the formation of a hitherto unidentified 
side-product. Sharpless asymmetric dihydroxylation of a late-stage intermediate of the route 
presented in chapter 3 yielded the desired diol in high yield (96%) but with moderate enantiomeric 
excess. A new route toward 2-DOS precursors was developed from kanamycin A, to give in three 
steps a benzyl or allyl protected meso 2-DOS analogue in overall yields of 39% and 40%, 
respectively. Desymmetrization of the TBDMS, benzyl and allyl diazidocyclitols by asymmetric 
acylation was not successful due to low reactivity of the hydroxyls. A Cbz-protected 2-DOS 
derivative could be desymmetrized by asymmetric allylic alkylation in reasonable yield but the 
enantiomeric excess was low (22%). Finally, enzymatic resolution of a dideoxystreptamine 
precursor was successfully achieved in high yield 99% and with excellent enantiomeric excess 
(99%), under the action of Candida Cylindracea lipase. The latter enzyme, however, turned out 
inactive for protected 2-DOS analogues, and only a single esterase obtained from Diversa was able 
to desymmetrize an allyl protected diazido cyclitol, to give the desired product in a most gratifying 
yield of 88% and with excellent enantiomeric excess (>99%). The latter product shows promise as 
an orthogonally protected building scaffold for the development of enantiopure, novel 2-DOS based 
RNA-ligands. 
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4.10 Experimental Section 
(+)-(1R,2R,7R,8S)-Tricyclo[6.2.1.0
2,7
]undeca-4,9-dien-3-one (6)  
To a solution of 3 (50 mg, 0.28 mmol) in MeCN (3 mL), was added (S,S)-Trost ligand 7 (12 
mg, 0.017 mmol, 6 mol%), and optionally HCO2NH4 (27 mg, 0.43 mmol). Under an argon 
atmosphere 5 mol% palladium complex was added. The reaction was stirred for given time at 
60 °C or reflux. Spectral data are in agreement with the data shown in chapter 3. The reaction was monitored 
by GC. For entry 1 of the crude mixture was purified by column chromatography (EtOAc/n-heptane, 1/5), 
and 4 was obtained with an optical purity of 97% ee by HPLC (chiralpak AD, elution with n-hexane/IPA 
99/1, flow: 1 mL/min); retention times (min): 14.00 and 18.45.  
  
(+ or -)-(1R,2R,3S,4S,5R)-5-azido-3-[(tert-butyldimethylsilyl)oxy]cyclohexane-4-
acetyloxy-1,2-diol (9) 
A 25-mL round-bottomed flask, equipped with a magnetic stirrer, was charged with 5 mL 
of t-BuOH, 5 mL of water, and 1.4 g of AD-mix-α or AD-mix-β.6 Stirring at room 
temperature produced two clear phases; the lower aqueous phase appears bright yellow. 
Methanesulfonamide (95 mg, 1 equiv based on 1 mmol of olefin) was added at this point. The mixture was 
cooled to 0 °C whereupon some of the dissolved salts precipitated. One mmol of olefin was added at once, 
and the heterogeneous slurry was stirred vigorously at 0 °C for 24 h (progress was monitored by TLC). 
While the mixture was stirred at 0 °C, solid sodium sulfite (1.5 g) was added and the mixture was allowed to 
warm to room temperature and stirred for 30-60 min. EtOAc (10 mL) was added to the reaction mixture, and 
after separation of the layers, the aqueous phase was further extracted with the organic solvent (3 X 5 mL) 
and the combined organic layers were washed with 2 N KOH). The combined organic extracts were dried 
with Na2SO4 and concentrated to give the diol and the ligand. This crude product was purified by flash 
chromatography (EtOAc/hexanes; 1/5 the ligand does not move in this solvent system) to afford the 1,2-diol. 
Spectroscopic data were in agreement with the data obtained in chapter 3. An optical purity of 21% ee by 
HPLC (chiralpak AD-H, elution with n-hexane/IPA 98/2, flow: 1 mL/min); retention times (min): 17.19 and 
22.26.  
 
General procedure for the synthesis of the triflylazide solution in CH2Cl2 (0.6 M) 
A solution of NaN3 (8.19 g, 126 mmol) in H2O (20 mL), was cooled to 0 °C and CH2Cl2 was added (20 mL). 
Tf2O (11 mL, 63 mmol) was added slowly to the vigorously stirring solution, and the reaction mixture was 
stirred for 2 hours at 0 °C after which it was quenched carefully with NaHCO3 (sat. aq.) until CO2 evolution 
ceases. The organic phase was collected and the aqueous phase was washed with CH2Cl2 (2x 15 mL) the 
combined organic phases were washed with sat. NaHCO3. To give a solution of approximately 0.6 M triflyl 
azide in CH2Cl2 (50 mL).
13 
 
General procedure for the acetylation  
Protected aminocyclitol was dissolved in CH2Cl2 and Et3N (4 equiv) and Ac2O (4 equiv) and DMAP (cat) 
were added to the reaction. The reaction was stirred for 4 hours, diluted with CH2Cl2, washed with brine and 
dried with Na2SO4, followed by evaporation of the organic solvent and purified by flash column 
chromatography. 
 
OTBDMS
N3
AcO
OH
OH
H
H
O
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3,4’,6’,6’’-Tetrazido-kanamycin A (10)  
Kanamycin-A sulfate (3.86 g, 6.62 mmol) and ZnCl2(cat.) were 
dissolved in H2O (80 mL). Et3N (11.0 mL, 79.2 mmol) and, carefully, 
MeOH (266 mL). Triflylazide in CH2Cl2 (0.6 M, 80 mL) was added to 
the vigorously stirring solution at once, the solution becomes colorless. 
After stirring for three hours the solvents were carefully evaporated and 
the product was purified by flash chromatography (EtOAc/MeOH, 9/1), to give 10 as a colorless oil (2.07 g, 
75%). Rf 0.4 (MeOH/EtOAc, 1/9). IR υmax film: (cm
-1) 2473, 2359, 2114, 1384, 1234, 1188, 1150, 1030, 953, 
612, 565, 494. 1H NMR (MeOD, 400 MHz, ppm): δ 5.27 (d, J = 3.8 Hz, 1H), 5.22 (d, J = 3.8 Hz, 1H), 4.19-
3.98 (m, 2H), 3.82-3.33 (m, 15H), 2.38 (dt, J = 4.0, 12.9 Hz, 1H), 1.56 (dt, J = 12.4, 12.4 Hz, 1H). 13C NMR 
(MeOD, 75 MHz, ppm): δ 102.2, 99.6, 84.8, 81.6, 75.6, 74.7, 73.7, 73.3, 73.2, 72.2, 71.9, 69.7, 68.4, 62.1, 
61.9, 60.8, 52.7, 33.4. HRMS (FAB) m/z calcd for C18H29O11N12 (M+H)
+: 589.2079, found 589.2088. 
 
Tetrazido-hepta-O-benzyl-kanamycin A (11)  
Compound 10 (502 mg, 0.85 mmol) was dissolved in DMF. TBAI (0.2 
g, cat) was added and the reaction was cooled to 0 °C. NaH (0.400 g, 
5.76 mmol) and BnBr (2.0 mL, 16 mmol) were added. The reaction was 
stirred for 4h at rt. The reaction was quenched with NH4Cl (sat) and 
extracted with i-PrOH/EtOAc (1/9, 10 mL). Wash three times with 
water and evaporate the organic solvent. Flash column chromatography (EtOAc/n-heptane, 1/5), to yield 
compound 11 as a white foam (75%). [α]D
20 +97.4 (c 0.42; CH2Cl2). IR υmax film: (cm
-1) 3029, 2902, 2100, 
1743, 1495, 1452, 1361, 1259, 1068, 1028, 910, 736, 697, 580. 1H NMR (CDCl3, 400 MHz, ppm): δ 7.45-
6.81 (m, 35H), 5.56 (d, J = 3.7 Hz, 2H), 5.04 (d, J = 12.0 Hz, 1H), 4.89-4.47 (m, 9H), 4.42 (d, J = 12.0 Hz, 
1H), 4.30 (ddd, J = 2.4, 4.6, 9.9 Hz, 1H), 4.21-4.09 (m, 3H), 4.16 (t, J = 18.8 Hz, 1H), 3.77-3.22 (m, 14H), 
3.11 (dd, J = 1.8, 11.0 Hz, 1H), 2.84 (dd, J = 2.4, 11.0 Hz, 1H), 2.39 (td, J = 4.4, 13.1 Hz, 1H), 1.65 (dd, J = 
12.4, 25.0 Hz, 1H). 13C NMR (CDCl3, 75 MHz, ppm): δ 138.2-137.2, 128.4-127.1, 125.6, 97.2, 96.0, 82.6, 
81.8, 79.3, 78.4, 76.8, 76.7, 76.6, 76.0, 75.6, 75.1, 74.5, 74.5, 74.1, 73.6, 73.2, 70.9, 70.0, 67.7, 65.5, 60.5, 
59.5, 51.4, 32.4. HRMS (FAB) m/z calcd for C67H71O11N12 (M+H)
+: 1219.5365, found: 1219.5366.  
 
(1R,2r,3S,4R,6S)-4,6-Diazido-2-O-benzyl-cyclohexane-1,3-diol (13)  
AcCl (1.5 mL) was added to MeOH (15 mL) at 0 °C. The obtained 1 N HCl/MeOH was 
added to 11 (200 mg, 0.24 mmol) and the reaction mixture was refluxed over night. The 
reaction was quenched with NaHCO3 (sat.) and extracted with EtOAc. Flash column 
chromatography (EtOAc/n-heptane, 1/3), to yield 7 as a white solid (31 mg, 70%). Rf 0.11 (EtOAc/n-
heptane, 1/3). Mp 130.9 °C. IR υmax film: (cm
-1) 3430, 2359, 2105, 1454, 13565, 1127, 1025, 744, 700. 1H 
NMR (CDCl3, 400 MHz, ppm): δ 7.49-7.28 (m, 5H), 4.83 (s, 2H), 3.51-3.31 (m, 4H), 3.24 (t, J = 7.8 Hz, 
1H), 2.19 (dt, J = 13.2, 3.9 Hz, 1H), 1.27 (dt, J = 13.2, 12.9 Hz, 1H). 13C NMR (CDCl3, 75 MHz, ppm): 
128.8, 128.0, 83.4, 75.7, 60.5, 32.1. HRMS (EI) m/z calcd for C13H16O3N6 (M+H)
+: 304.1284, found: 
304.1294. 
 
(1R,2r,3S,4R,6S)-1,3-Di-O-acetyl-4,6-diazido-2-O-benzyl-cyclohexane (15)  
Acetylation of 13 (45 mg, 0.15 mmol) via general procedure and purification by flash 
column chromatography (EtOAc/n-heptane, 1/3) to yield 15 (53 mg, 92%). Rf 0.53 
(EtOAc/n-heptane, 1/1). IR υmax film: (cm
-1) 2099, 1745, 1564, 1453, 1372, 1218, 1065, 
1034, 897, 862, 746, 699. 1H NMR (CDCl3, 300 MHz, ppm): δ 7.48-7.18 (m, 5H), 5.06 (t, J 
= 9.9 Hz, 2H), 4.60 (s, 2H), 3.52-3.39 (m, 3H), 2.29 (dt, J = 13.5, 4.1 Hz, 1H), 2.02 (s, 6H), 1.57 (dt, J = 
13.0, 12.1 Hz, 1H). 13C NMR (CDCl3, 75 MHz, ppm): 169.2, 128.4, 127.6, 79.6, 74.9, 58.6, 32.1, 21.0. 
HRMS (EI) m/z calcd for C17H20O5N6 (M+Na)
+: 411. 
 
Tetrazido-hepta-O-allylkanamycin A (12)  
Compound 10 (517 mg, 0.88 mmol) was dissolved in DMF, TBAI (0.2 
g, cat.) was added, after which the reaction was cooled to 0 °C. NaH 
(545 mg, 7.85 mmol) and allylbromide (1.0 mL, 12 mmol) were added. 
The reaction mixture was stirred for 2 h at rt. Quenched with NH4Cl and 
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extracted with 2-propanol/EtOAc (1/9, 10 mL) and washed three times with water, dried with Na2SO4 and 
evaporated. Flash column chromatography (EtOAc/n-heptane, 1/5) to yield 12 as yellow oil (596 mg, 78%). 
Rf 0.35 (EtOAc/n-heptane, 1/3). IR υmax film: (cm
-1) 2871, 2360, 2339, 2250, 2103, 1351, 1262, 1075, 1031, 
996, 913, 734, 668, 646, 412. 1H NMR (CDCl3, 400 MHz, ppm): δ 5.90-5.78 (m, 7H), 5.55 (d, J = 3.7 Hz, 
1H), 5.47 (d, J = 3.8 Hz, 1H), 5.31-5.12 (m, 14H), 4.45 (d, J = 10.0 Hz, 1H), 4.37-3.84 (m, 14H), 3.85-3.62 
(m, 2H), 3.58-3.22 (m, 14H), 2.35 (d, J = 8.0 Hz, 1H), 1.21 (t, J = 4.8 Hz, 1H). 13C NMR (CDCl3, 75 MHz, 
ppm): δ 134.9, 134.6, 134.5, 134.4, 134.3, 134.0, 133.9, 118.6, 117.7, 117.0, 116.5, 116.5, 115.7, 97.3, 96.0, 
82.6, 81.6, 79.0, 78.2, 75.9, 74.3, 74.2, 74.0, 73.6, 72.6, 72.6, 70.7, 69.9, 68.3, 65.2, 61.0, 59.3, 51.6, 32.7.  
 
(1R,2r,3S,4R,6S)-4,6-Diazido-2-O-allyl-cyclohexane-1,3-diol (14)  
AcCl (1.5 mL) was added to MeOH (15 mL) at 0 °C. The obtained 1 N HCl/MeOH was 
added to 12 (200 mg, 0.23 mmol) and the reaction was refluxed for 16 hours. Quench with 
NaHCO3 (sat.) and extract with EtOAc. Wash with water and dry with MgSO4 and evaporate 
the solvent. Purify by flash column chromatography (EtOAc/n-heptane, 1/3), to obtain 14 as 
a white solid (58 mg, 68%). Rf 0.11 (EtOAc/n-heptane, 1/3). IR υmax film: (cm
-1) 3408, 2920, 
2100, 1732, 1451, 1348, 1260, 1070, 1028, 925, 571, 443, 424. 1H NMR (CDCl3, 400 MHz, ppm): δ 6.01-
5.86 (m, 1H), 5.23-5.11 (m, 4H), 4.18 (dt, J = 1.4, 5.6 Hz, 2H), 3.50-3.38 (m, 3H), 2.20 (dt, J = 4.6, 13.3 Hz, 
1H), 1.38 (dt, J = 12.6, 13.2 Hz, 1H). 13C NMR (CDCl3, 75 MHz, ppm): δ 134.5, 117.8, 83.2, 76.2, 74.5, 
60.5, 32.2. HRMS (CI) m/z calcd for C9H14O3N6 (M+)
+: 254.1128, found: 254.1116. 
 
(1R,2r,3S,4R,6S)-1,3-Di-O-acetyl-2-O-allyl-4,6-diazido-cyclohexane (16)  
Acetylation of 14 (30 mg, 0.12 mmol) via general procedure and purification by flash 
column chromatography (EtOAc/n-heptane, 1/3) to yield 16 (36 mg, 89%) as a colorless 
oil. Rf 0.53 (EtOAc/n-heptane, 1/1). IR υmax film: (cm
-1) 2920, 2098, 1744, 1557, 1373, 
1219, 1152, 1064, 1034, 926, 615, 447. 1H NMR (CDCl3, 400 MHz, ppm): δ 5.75 (ddt, J = 
17.3, 10.4, 5.7 Hz, 1H), 5.32-5.11 (m, 2H), 5.01 (t, J = 9.9 Hz, 2H), 4.07 (dt, J = 1.4, 5.6 
Hz, 2H), 3.45 (m, 3H), 2.28 (dt, J = 13.3, 4.6 Hz, 1H), 2.13 (s, 6H), 1.54 (dt, J = 13.2, 12.6 Hz, 1H). 13C 
NMR (CDCl3, 75 MHz, ppm): δ 169.5, 134.0, 117.2, 79.1, 74.8, 73.8, 58.2, 31.8, 20.8. HRMS (CI) m/z calcd 
for C13H18O5N6 (M+H)
+: 339.1417, found: 339.1428. 
 
(1R,2r,3S,4R,6S)-1,2,3-Tri-O-acetyl-4,6-diazidocyclohexane  
Kanamycin derivative (10) (100 mg, 0.17 mmol) was dissolved in an 1 N HCl/MeOH 
solution (1.4 mL). The reaction mixture was refluxed overnight and quenched with 
saturated NaHCO3. The solvents were evaporated and the crude reaction mixture was 
purified by flash column chromatography (EtOAc/n-heptane, 1/1), to obtain the triol as an oil. The oil was 
dissolved in Ac2O (0.5 mL, 5 mmol) and one drop of BF3.Et2O was added to reaction mixture. The reaction 
mixture was stirred 10 min and quenched with water and extracted with EtOAc, dry with Na2SO4 and 
evaporate the solvents. Purify by flash column chromatography (EtOAc/n-heptane, 1/3) to obtain a colorless 
oil (10 mg, 20%). 1H NMR (CDCl3, 400 MHz, ppm): δ 5.09-4.81 (m, 3H), 3.61-3.55 (m, 2H), 2.33 (dt, J = 
4.6, 13.6 Hz, 1H), 2.04 (s, 6H), 2.01 (s, 3H), 1.58 (q, J = 12.8 Hz, 1H); in agreement with literature.26 
 
(1R,2S,4R,5S)-1,2:4,5-Diepoxycyclohexane  
To a cold suspension (0 °C) of m-CPBA (77% pure, 18 g, 75 mmol) in CH2Cl2 (150 mL) was 
added a solution of 1,4-cyclohexadiene (3.6 mL, 37 mmol) in CH2Cl2 (50 mL). This mixture 
was stirred at 0 °C for 8 hours and at room temperature for 16 hours. The mixture was filtrated and washed 
with phosphate buffer (pH 7.0). Flash chromatography (toluene/acetone, 7/1) to yield the compound as a 
white solid. Rf 0.06 (EtOAc/n-heptane, 1/10). IR υmax film: (cm
-1) 2991, 2906, 1717, 1470, 1418, 1354, 1263, 
1022, 834. 1H NMR (CDCl3, 300 MHz, ppm): δ 3.07 (s, 4H), 2.74 (d, J = 22.4 Hz, 2H), 2.25 (d, J = 22.4 Hz, 
2H); in agreement with literature.27  
 
(1R,3S,4S,6R)-1,3-Diamino-cyclohexane-4,6-diol  
The diepoxide (300 mg, 2.7 mmol) was dissolved in benzylamine (1.17 mL, 10.7 mmol) 
under inert atmosphere. The reaction was stirred at 150 °C for 8 hours. Et2O (3 mL), was 
added and the reaction was cooled to -20 °C, filter off and rinse with cold Et2O to yield the 
compound (730 mg, 80%) as a slightly yellow solid. 1H NMR (CDCl3, 400 MHz, ppm): δ 7.32 (br s, 10H), 
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3.94 (d, J = 12.9 Hz, 2H), 3.80 (d, J = 12.9 Hz, 2H), 3.31 (ddd, J = 11.3, 9.2, 4.3 Hz, 2H), 2.50 (dt, J = 12.4, 
3.8 Hz, 1H), 2.41-2.21 (m, 3H), 1.38 (dt, J = 11.7, 11.6 Hz, 1H), 0.83 (dt, J = 11.8, 11.7 Hz, 1H); in 
agreement with literature.27 A suspension of Pd/C (10%, 243 mg, 0.23 mmol) and Pd(OH)2(C) (20%, 322 
mg, 0.46 mmol) in MeOH (5 mL) was added to a solution of the benzylaminodideoxystreptamine analogue 
(155 mg, 0.46 mmol) in MeOH/AcOH (3/1, 8 mL). Stir for 48 hours under H2 atmosphere, filter off over 
Celite® and evaporate the solvent to yield compound as a white solid. 
 
(1R,3S,4S,6R)-1,3-Diazido-cyclohexane-4,6-diol (17)  
Dideoxystreptamine (146 mg, 0.46 mmol) and ZnCl2 (cat.) were dissolved in water (3 mL). 
Et3N (0.418 mL), MeOH (10 mL, slowly) and 0.6 M triflylazide solution (3 mL) in CH2Cl2 
were added. The reaction was stirred vigorously for three hours. The solvents were 
evaporated carefully and flash chromatography (EtOAc/n-heptane, 3/1) to yield compound 17 as a white 
solid (40 mg, 53% over two steps). Rf 0.6 (EtOAc). mp 70.7 °C. IR υmax film: (cm
-1) 3369, 2921, 2358, 2100, 
1737, 1597, 1452, 1370, 1257, 1234, 1072, 1028, 585, 438. 1H NMR (CDCl3, 400 MHz, ppm): δ 3.46 (ddd, J 
= 11.4, 9.2, 4.4 Hz, 2H), 3.29 (ddd, J = 11.4, 8.4, 3.6 Hz, 2H), 2.37-2.11 (m, 2H), 1.48 (dt, J = 12.9, 11.6 
Hz, 1H), 1.31 (dt, J = 13.2, 12.1 Hz, 1H). 13C NMR (CDCl3, 100 MHz, ppm): δ 71.2, 64.2, 38.4, 31.8. MS 
(CI) m/z (M+H+): 199. HRMS (EI) m/z calcd for C16H29O5SiN6 (M)
+: 198.0865, found: 198.0866. 
 
(S)-2-(Isoindolinylmethyl)-N-methylpyrrolidine (20)  
The chiral diamine was prepared according to literature.16 1H NMR (400 MHz, CDCl3) δ 
7.31-7.25 (m, 4H), 3.96 (s, 4H), 3.07 (td, J = 9.1, 1.9 Hz, 1H), 2.93 (dd, J = 11.9, 4.6 Hz, 
1H), 2.65 (dd, J = 11.8, 8.1 Hz, 1H), 2.44 (s, 3H), 2.38-2.29 (m, 1H), 2.25-2.16 (m, 1H), 
2.12-1.98 (m, 1H), 1.95-1.59 (m, 3H); in agreement with literature.16 
 
(-)or(+)(1R,2R,4S,5S)-2,4-Diazido-5-benzoyloxy-cyclohexan-1-ol (18)  
To molecular sieves 4Å was added dideoxystreptamine analogue 17 (10 mg, 0.05 mmol) in 
EtCN and the reaction mixture was cooled to -78 °C. Benzoyl chloride (9 µL, 0.05 mmol) 
and chiral diamine (11 mg, 0.075 mmol) were now added and the reaction mixture was 
stirred for 24 h. (The molecular ratio of the diol: benzoyl chloride :diamine has to be 1:1.5:1.).The reaction 
mixture was now quenched with a phosphate buffer (pH 7) and the organic materials were extracted with 
Et2O and the combined extracts were dried with Na2SO4. Evaporate the solvent and purify by flash column 
chromatography (EtOAc/n-heptane, 1/5) to yield 18 (7 mg, 47%, 78% BORSM). IR υmax film: (cm
-1) 2102, 
1719, 1269, 1070, 713, 668. 1H NMR (CDCl3, 400 MHz, ppm): δ 8.19-8.01 (m, 2H), 7.66-7.61 (m, 1H), 
7.50-7.34 (m, 2H), 5.07-4.88 (m, 1H), 3.79-3.59 (m, 2H), 3.43-3.33 (m, 1H), 2.58 (dt, J = 12.8, 4.9 Hz, 1H), 
2.38 (dt, J = 12.8, 4.9 Hz, 1H), 1.45 (m, 2H). 
 
(1R,2S,3r,4R,5S)-2,4-(diacetoxy)-1,5-diazido-3-[(tert-butyldimethylsilyl)oxy] 
cyclohexane (19)  
Compound 1 (100 mg, 0.30 mmol) was dissolved in CH2Cl2 (3 mL) and Et3N (84 µL, 0.75 
mmol), Ac2O (72 µL, 0.75 mmol) and DMAP (cat) were added. The reaction mixture was 
stirred for 2 hours, diluted with CH2Cl2, washed with brine and dried with Na2SO4. Evaporation of the 
organic solvent and purification by flash column chromatography (EtOAc/n-heptane, 1/10 to 1/5) to yield 19 
as colorless oil (117 mg, 93%). IR υmax film: (cm
-1) 2951, 2930, 2857, 2098, 1746, 1372, 1250, 1215, 1144, 
1096, 1067, 1032, 979, 896, 878, 836, 779. 1H NMR (CDCl3, 300 MHz, ppm): δ 4.97 (t, J = 9.6 Hz, 2H), 
3.69 (t, J = 9.5 Hz, 1H), 3.40 (dt, J = 11.4, 4.5 Hz, 2H), 2.30 (dt, J = 10.0, 3.3 Hz, 1H), 2.17 (s, 6H), 1.62 
(dt, J = 12.9, 12.8 Hz, 1H), 0.85 (s, 9H), 0.08 (s, 6H). 13C NMR (CDCl3, 100 MHz, ppm): δ 169.6, 77.4, 
77.1, 76.8, 75.7, 72.2, 58.7, 31.8, 25.5, 22.8, 21.3, 17.8, -4.3. HRMS (EI) m/z calcd for C16H29O5SiN6 
(M+H)+: 413.1969, found: 413.1971. 
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General procedure for AAA 
To a degassed mixture of Pd2(dba)3 (4 mol%) and a chiral phosphine ligand or DPPB (8 mol%) in a given 
solvent was added allylethylcarbonate (1.5 equiv) and 2-DOS. After 10 min a yellow solution was obtained. 
The reaction mixture was stirred under an argon atmosphere for 30 min to 4h and the volatiles were removed 
under reduced pressure and the residue was purified by flash column chromatography directly to afford the 
allyl protected compound. 
 
(±)-(1S,2R,3R,4S,5R)-3-(allyloxy)-4,6-diazido-2-[(tert-butyldimethylsilyl)oxy]cyclohexan-1-ol (21) and 
(1R,2S,3r,4R,5S)-(1R,2S,3r,4R,5S)-2,4-(diallyloxy)-1,5-diazido-3-[(tert-butyldimethylsilyl)oxy] 
cyclohexane (23)  
Allylation of 1 (20 mg, 0.06 mmol) via general procedure or AAA: 
With DPPB (8 mol%, 4 mg), purification by flash column chromatography (EtOAc/n-heptane, 1/10) to yield 
21 (23 mg, 51%) and 23 (9 mg, 18%).  
With BINAP (8 mol%, 2 mg), purification by flash column chromatography (EtOAc/n-heptane, 1/10) to 
yield 21 (4 mg, 25%) and starting material 1 (6 mg, 30%). 
With DIOP (8 mol%, 2 mg), purification by flash column chromatography (EtOAc/n-heptane, 1/10) to yield 
24 (9 mg, 41%) and 23 (1 mg, <4%).  
 
21: Rf 0.46 (EtOAc/n-heptane, 1/5). IR υmax film: (cm
-1) 2948, 2100, 1453, 1074, 752, 
699. 1H NMR (CDCl3, 400 MHz, ppm): δ 6.09-5.88 (m, 1H), 5.39-5.18 (m, 2H), 
4.42-4.21 (m, 2H), 3.45-3.18 (m, 4H), 3.17-2.96 (m, 1H), 2.32-2.08 (m, 1H), 1.40-
1.19 (m, 1H), 0.91 (s, 9H), 0.27 (s, 3H), 0.12 (s, 3H). HRMS (CI) m/z calcd for 
C15H29O3SiN6 (M+H)
+: 369.2071, found: 369.2077. 
 
23: Rf 0.66 (EtOAc/n-heptane, 1/5). IR υmax film: (cm
-1) 2930, 2101, 1257, 1130, 
1080, 836, 779, 668. 1H NMR (CDCl3, 400 MHz, ppm): δ 6.09-5.88 (m, 2H, allyl), 
5.32-5.12 (m, 4H, Allyl), 4.40-4.19 (m, 4H, CH), 3.55-2.82 (m, 5H, CH), 2.22-2.05 
(m, 1H, CH2a), 1.30-1.19. (m, 1H, CH2b), 0.93 (s, 9H, t-Bu), 0.87 (s, 3H, MeSi), 
0.12 (s, 3H, MeSi). 13C NMR (CDCl3, 75 MHz, ppm): δ 134.7, 134.2, 117.6, 116.6, 
84.4, 83.7, 64.2, 60.3, 32.8, 26.3, 18.4, -3.5, -4.3. HRMS (CI) m/z calcd for C18H33O3SiN6 (M+H)
+: 
409.2386, found:409.2384. 
 
(1S,2R,3R,4S,6R)-3-(allyloxy)-4,6-diazido-2-(benzyloxy)cyclohexan-1-ol (22) and (1R,2S,3r,4R,5S)-2,4-
(diallyloxy)-1,5-diazido-3-(benzyloxy)cyclohexane (24) 
With DPPB (8 mol%, 4 mg), purification by flash column chromatography (EtOAc/n-heptane, 1/10) to yield 
starting material 5 (2 mg, 10%), 22 (7 mg, 35%) and 24 (5 mg, 22%). 
With DIOP (8 mol%, 2 mg), purification by flash column chromatography (EtOAc/n-heptane, 1/10) to yield 
starting material 5 (6 mg, 30%), 22 (7 mg, 44%) and 24 (<1 mg, <5%). 
 
22: Rf 0.44 (EtOAc/n-heptane, 2/3). IR υmax film: (cm
-1) 2100, 1453, 1362, 1257, 
1070,699. 1H NMR (CDCl3, 400 MHz, ppm): δ 7.49-7.21 (m, 5H), 6.12-5.89 (m, 1H), 
6.00 (dd, J = 5.7, 11.6 Hz, 2H), 4.95 (d, J = 11.3 Hz, 1H), 4.72 (d, J = 11.1 Hz, 1H), 
4.31 (br s, 2H), 3.46-3.19 (m, 5H), 2.22-2.01 (m, 1H), 1.68-1.48 (m, 1H). HPLC optical 
purity of 0.05% (ADH-H, 1.0 mL/min, iPrOH/hexane, 3/97, 20 µL): retention times (min): 24.141 and 
28.120, the enantiomeric excess was 0.8%.  
 
24: Rf 0.65 EtOAc/n-heptane, 2/3) IR υmax film: (cm
-1) 2100, 1457, 1259, 1077, 700. 
1H NMR (CDCl3, 400 MHz, ppm): δ 7.45-7.30 (m, 5H), 6.18-5.89 (m, 2H), 5.30-18 
(m, 4H), 4.36 (br s, 2H), 4.41-4.31 (m, 2H), 4.30-21 (m, 2H), 3.49-3.31 (m, 3H), 
3.20 (t, J = 9.6 Hz, 2H), 2.21-2.01 (m, 1H), 1.67-1.49 (m, 1H).13C NMR (CDCl3, 75 
MHz, ppm): δ 128.3, 127.6, 82.9, 74.9, 67.2, 66.6, 57.7, 54.7, 30.0, 1.5. HRMS (CI) m/z calcd for 
C19H25O3N6 (M+H): 385. 
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(1R,2r,3S,4R,6S)-4,6-[di(benzyloxycarbonyl)amino]-2-[(tert-butyldimethylsilyl) 
oxy]cyclohexane-1,3-diol (28)  
To a solution of 4,6-diazidocyclohexanetriol 1 (20 mg, 0.093 mmol) in MeOH was 
added Pd/C (spatula). After the mixture had been stirred for 14 h under 3 bar of H2, 
Pd/C was filtered off and the filtrate was concentrated to yield the product (14 mg, 
95%). IR υmax film: (cm
-1) 3367, 1471, 1121, 836.7, 780, 611.  
The crude compound (92 mg, 0.095 mmol) was now dissolved in MeOH (3 mL) and cooled to 0 °C. CbzCl 
(97 µL, 0.32 mmol) and Et3N (95 µL, mmol) were added and the reaction mixture was stirred overnight. The 
crude product was dried (Na2SO4), concentrated under reduced pressure, and purified by flash 
chromatography (EtOAc/n-heptane, 1/5) to give (160 mg, 91%) of compound 28 as a white solid. IR υmax 
film: (cm-1) 2925, 1688, 1548, 905, 729. 1H NMR (CD3OD, 400 MHz, ppm): δ 7.42-7.21 (m,10H, arom), 
5.12-4.94 (m, 4H, CH2), 3.62-3.45 (m, 2H, CH), 4.42-3.25 (m, 1H, CH), 3.25-3.14 (m, 2H, CH), 2.09-1.89 
(m, 1H, CH2a), 1.49-1.3 (m, 1H, CH2b), 0.86 (s, 9H, t-Bu), 0.12 (s, 3H, MeSi), 0.06 (s, 3H, MeSi). 
13C NMR 
(CD3OD, 100 MHz, ppm): δ 158.6, 158.2, 138.3, 129.4, 128.8, 78.6, 77.7, 76.5, 67.4, 53.4, 26.2, 19.2, -3.5, -
4.5. HRMS (CI) m/z calcd for C28H41O7SiN2 (M+H)
+: 545.2683, found: 545.2669. 
 
(+ or -)-(1S,2R,3R,4S,6R)-3-(allyloxy)-4,6-[di(benzyloxycarbonyl)amino]-2-[(tert-
butyldimethylsilyl)oxy]-cyclohexanan-1-ol (29)  
Using general procedure AAA. Rf 0.6 (EtOAc/n-heptane, 1/1). IR υmax film: (cm
-1). 
2969, 1378, 1303, 1160, 1128, 950, 816. 1H NMR (CD3OD, 400 MHz, ppm): δ 7.41-
7.21 (m, 10H), 5.91-5.62 (m, 1H), 5.21-4.77 (m, 4H), 4.42-3.25 (m, 3H), 4.12-3.89 (m, 1H), 3.58-3.36 (m, 
2H), 3.12-2.85 (m, 1H), 1.99-1.72 (m, 1H), 1.45-1.38 (m, 1H), 0.81 (s, 9H), 0.07 (s, 6H). 13C NMR (CDCl3, 
75 MHz, ppm): δ.155.8, 136.6, 134.9, 128.7, 128.6, 117.6, 73.3, 67.0, 52.4, 51.1, 26.0, 18.4, 1.2, -3.8, -4.5. 
HRMS (CI) m/z calcd for C31H44O7SiN2 (M+H)
+: 585.2996, found: 585.2990. HPLC optical purity of 21% ee 
(OD-H, 1.0 mL/min, iPrOH/hexane, 10/90, 5 µL): retention times (min): 43.45 and 52.20.  
 
(1R,3S,4S,6R)-1,3-Diazido-4,6-di-O-acetyl-cyclohexane (30)  
Compound 17 (40 mg, 0.20 mmol) was dissolved in CH2Cl2 (5 mL). Et3N (30 µL, 0.42 
mmol), Ac2O (20 µL, 0.42 mmol) and DMAP (cat) were added to the reaction mixture. Stir 
for three hours. Evaporate the solvents and flash chromatography (EtOAc/n-heptane, 2/3) 
to yield 30 (40 mg, 70%) as a colorless oil. Rf 0.8 (EtOAc/n-heptane, 2/1). 
1H NMR (CDCl3, 300 MHz, 
ppm): δ 4.77 (ddd, J = 11.7, 9.9, 4.8 Hz, 2H), 3.51 (ddd, J = 12.3, 9.6, 4.5 Hz, 2H), 2.46 (dt, J = 12.6, 4.6 
Hz, 1H), 2.26 (dt, J = 13.5, 4.5 Hz, 1H), 2.09 (s, 6H), 1.49 (dt, J = 12.3, 11.7 Hz, 1H), 1.41 (dt, J = 13.5, 
12.6 Hz, 1H); in agreement with literature.13 
 
(±)-(1R,3S,4S,6R)-1,3-Diazido-4-O-acetyl-cyclohexan-6-ol (31)  
Compound 30 (10 mg, 0.036 mmol) was dissolved in THF (1 mL) and cooled to 0 °C. LiOH 
(0.85 mg, 0.036 mmol) was dissolved in water (100 µL) and added slowly to the substrate. 
Stir for three hours at 0 °C. Evaporate the solvent and purify by flash column 
chromatography (EtOAc/n-heptane, 1/4) to yield 31 (2.7 mg, 32%, 92% BORSM). Rf 0.25 (EtOAc/n-
heptane, 1/3). 1H NMR (CDCl3, 400 MHz, ppm): δ 4.73 (ddd, J = 4.5, 9.8, 11.7 Hz, 1H), 3.54-3.46 (m, 2H), 
3.33 (ddd, J = 4.4, 11.7 Hz, 1H), 2.40 (dt, J = 12.8, 4.5 Hz, 1H), 2.28 (dt, J = 4.5, 13.3 Hz, 1H), 2.10 (s, 
3H), 1.56-1.33 (m, 2H); in agreement with literature. HPLC (OD-H, 1.0 mL/min, iPrOH/hexane, 1/9, 20 
µL): retention times (min): 10.017 and 11.025.  
 
(-)or(+)(1R,3S,4S,6R)-1,3-Diazido-4-O-acetyl-cyclohexan-6-ol (31)  
Compound 30 (6 mg, 0.02 mmol) was dissolved in toluene (1 mL) and a phosphate buffer 
(pH 6.7, 1 mL) and Candida Cylindracea Lipase (CCL, 6.8 mg) were added. Shake for 72 
hours at 30 °C. Filtrate over Celite (flush with excess EtOAc) and evaporate the solvent to yield 31 (5.1 mg, 
99%).1 HPLC (OD-H, 1.0 mL/min, i-PrOH/hexane, 1/9, 20 µL): retention times (min): 10.904 (ee > 99%). 
 
(-)or(+)(1R,3S,4S,6R)-1,3-Diazido-4-O-acetyl-cyclohexan-6-ol (31)  
Compound 30 (10.2 mg, 0.036 mmol) was dissolved in toluene (1 mL) and add phosphate 
buffer (pH 6.2, 1 mL) and Candida Antarctica Lipase (CCL, 11.7 mg). Shake for 120 hours 
HO OAc
N3N3
HO OAc
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N3N3
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at 30 °C. Filtrate over Celite (flush with excess EtOAc) and evaporate the solvent to yield 31 (8.3 mg, 94%). 
(OD-H, 1.0 mL/min, iPrOH/hexane, 1/9, 20 µL): retention times (min): 11.106 (ee > 99%). [α]
D
20
 -22.9 (c 
0.75; CH2Cl2). 
 
Table 5. Desymmetrization of 1,3-DACH via enzymatic resolution with commercially available lipases 
substrate enzymeb enzyme (mg) methoda t (h) product yield (%) ee (%) 
30 CAL (fluka) 11.7 A 120 31 95 99 
19 CAL (fluka) 10.5 A 148 -   
30 CCL 6.8 A2 72 31 99 99 
30 PPL 6.5 A2 72 -   
15 CAL 6.8 A2 144 -   
15 CCL 6.2 A2 144 -   
15 PPL 5.8 A2 144 -   
15 PCL 6.3 A2 312 -   
15 PFL 5.9 A2 312 -   
15 RAL 7.1 A2 144 -   
19 MML 13.7 A2 240 -   
19 PCL 6.7 A2 240 -   
19 PFL 12.2 A2 240 -   
19 RAL 6.7 A2 240 -   
19 RNL 6.5 A2 240 -   
19 PPL 14.7 A2 240 -   
19 AspL 11.2 A2 240 -   
19 CCL 6.3 A2 240 -   
30 AspL 6.3 A2 168 -   
30 MML 5.8 A2 168 -   
30 PCL 5.7 A2 168 -   
30 PFL 6.3 A2 168 -   
30 RAL 6.4 A2 168 -   
30 RNL 6.2 A2 168 -   
15 Novo 435 5.3 A2 480 -   
19 Novo 435 5.5 A2 480 -   
30 Novo 525 10 A2 480 -   
15 Novo 525 10 A2 480 -   
19 Novo 525 10 A2 480 -   
30 PPL 26.6 A3 264 -   
15 PPL 25.4 A3 264 -   
19 PPL 25.8 A3 264 -   
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16 CAL 4.8 A4 120 -   
16 CCL 5.4 A4 120 -   
17 PPL 6.3 B 72 -   
17 CCL 4.9 B 72 31 8% nd 
17 CAL 5.7 B 72 31 34% nd 
17 Novo 435 5.5 B 72 -   
17 Novo 525 10 B 72 -   
14 PPL 4.8 B 72 -   
14 CCL 6.4 B 72 -   
14 CAL 4.8 B 72 -   
14 Novo 435 4.8 B 72 -   
14 Novo 525 10 B 72 -   
1 PPL 5 B 72 -   
1 CCL 6.9 B 72 -   
1 CAL 4.5 B 72 -   
1 Novo 435 6.8 B 72 -   
1 Novo 525 10 B 72 -   
a A: solv. = phosphate buffer pH 6.2/toluene, 1/1; A2: solv. = phosphate buffer pH 6.7/toluene, 1/1; 
A3: solv. = phosphate buffer pH 7.0/toluene, 1/1; A4: solv. = phosphate buffer pH 6.2/toluene, 1/1; 
B: solv. = toluene, reactant = AllOAc 
b CAL = Candida Antarctica Lipase; PCL = Pseudomonas Cepacia Lipase; PPL = Porcine 
Pancreas Lipase; CCL = Candida Cylindracea Lipase; AspL = Aspergillus Lipase; RAL = 
Rhizopus Arrhizus Lipase; MML = Mucor Miehei Lipase; PFL = Pseudomonas Fluorescens 
Lipase; RNL = Rhizopus Niveus Lipase; Novo 435 = Novozym 435 (immobilized CalB); Novo 
525 = Novozym 525 (CalB solution). 
 
(±)-(1R,2S,3S,4R,6S)-4,6-Diazido-2-allyloxycyclohexane-3-acetyloxy-1-ol (34) 
Compound 16 (32 mg, 0.094 mmol) was dissolved in THF (1 mL) and cooled to 0 °C. LiOH 
(4 mg, 0.19 mmol) was dissolved in water (100 µL) and added slowly to the substrate. Stir 
for 8h hours at 0 °C. Evaporate the solvent and purify by flash column chromatography 
(EtOAc/n-heptane, 1/15 to 1/5) to yield 34 (8 mg, 28%, 91% BORSM). 1 HPLC (AD-H, 1.0 
mL/min, i-PrOH/hexane, 3/97, 5 µL): retention times (min): 45.190 and 48.168  
 
(+ or -)-(1R,2S,3S,4R,6S)-4,6-Diazido-2-allyloxycyclohexane-3-acetyloxy-1-ol (34) 
Compound 16 (30 mg, 0.088 mmol) was dissolved in MeCN (200µL) and add phosphate 
buffer (pH 7.5, 2 mL) and Diversa esterase 5 (20 mg).28 Shake the reaction for 72 hours at 
37 °C. Filtrate over Celite (flush with excess EtOAc) and evaporate the solvent to yield 34 
(15 mg, 88% BORSM, 58%, 10 mg starting material). Rf 0.40 (EtOAc/n-heptane, 1/2). IR 
υmax film: cm
-1 2099, 1743, 1372, 1231, 1070, 1032, 610. 1 H NMR (CDCl3, 300 MHz, 
ppm): δ 5.9-5.78 (m, 1H) 5.29 (br s, 1H), 5.19-5.14 (m, 1H), 4.94 (t, J = 9.9 Hz, 1H), 4.18 (d, J = 5.4 Hz, 
2H), 3.49 (q, J = 9.6, 18.9 Hz, 1H), 3.47-3.3.34 (m, 2H), 3.26 (t, J = 9.3 Hz, 1H), (dt, J = 4.5, 13.5 Hz, 1H), 
2.14 (s, 3H), (q, J= 12.3, 25.5 Hz, 1H). 13C NMR (CDCl3, 75 MHz, ppm): δ 169.8, 134.3, 117.8, 81.3, 76.2, 
75.1, 74.2, 59.9, 58.7, 32.1, 21.0. [α]
D
20
 +5.54 (c 0.65; CH2Cl2).
1 HRMS (CI) m/z calcd for C11H17O4SiN6 
(M+H)+: 297.1311, found:297.1325. HPLC (AD-H, 1.0 mL/min, i-PrOH/hexane, 3/97, 5 µL): retention time 
(min): 47.433 (ee > 99%).  
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A carbohydrate mimic of 2-deoxystreptamine  
for the preparation of conformationally constrained 
aminoglycosides 
 
 
 
 
Abstract 
The synthesis of a carbohydrate mimic of 2-deoxystreptamine (2-DOS) is described here. Starting 
from D-ribose, crucial steps of the synthesis involve a nitro aldol condensation and deoxygenation 
via elimination of an acetate group followed by in situ reduction. Moreover, glycosylation of the 
carbohydrate 2-DOS derivative with phenyl thioglycoside in the presence of TTBP and AgOTf 
followed by ring closing metathesis yielded a conformationally restricted protected aminoglycoside 
analogue. 
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5.1 Introduction 
As a consequence of the fact that it is the central scaffold of nearly all aminoglycoside antibitiocs, 
the diaminocyclohexitol called 2-deoxystreptamine (2-DOS) is a logical starting structure for the 
development of novel aminoglycosides. For such an endeavor, however, substantial amounts of 
2-DOS must be readily available and although many synthetic routes toward 2-DOS have been 
developed, as for example in the preceding chapters, the disadvantage of most of these routes is the 
large number of synthetic steps required to synthesize the diaminocyclohexitol ring. From this 
observation, it was reasoned that a carbohydrate-derived entity like compound A (Figure 1) could 
be an interesting alternative for 2-DOS, taken into consideration that the amino group at C-1 is 
modified in several clinically used aminoglycosides and the C-6 hydroxyl is not essential for 
antibacterial activity (2-DOS numbering). Such a synthesis should be readily achievable from a 
cheap carbohydrate precursor and, consequently, lead to enantiomerically pure product. To date, 
only two syntheses of such carbohydrates analogues are known. A diaminocarbohydrate was 
synthesized starting from benzyl-α-D-glucopyranoside by Meyer zu Reckendorf and coworkers (not 
depicted),
1
 in a ten-step synthesis leading to a diaminocarbohydrate quite similar to 2-DOS, but as a 
mixture of anomers.
2
 The observation that carbohydrates could be a good alternative for 2-DOS was 
also brought about by Boons co-workers (see also §5.3).
3
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Figure 1. Retrosynthesis of carbohydrate derivative (A) as a mimic for 2-deoxystreptamine. 
 
Retrosynthetic analysis of β-configured carbohydrate analogue A suggests a synthesis from 
nitroglucopyranoside B, by means of deoxygenation at C-4, reduction of the 3-nitro, and azide 
introduction C-6 (carbohydrate numbering). The nitroglucopyranoside in turn was projected to 
result from a dialdehyde derived from D-ribose,
4
 a cheap and enantiopure carbohydrate, via double 
Henry reaction with nitromethane. Although it is clear that the final carbohydrate analogue lacks the 
C-6 hydroxyl, the fact that the 6-OH of 4,5-linked aminoglycoside antibiotics is only involved in 
indirect binding events with the RNA backbone (Figure 2)
5,6
 led us to assume it could be omitted 
without severe penalty in binding enthalpy. Furthermore, the amino group on the carbohydrate is 
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one carbon further away from the cyclitol, but it was surmised that extension of the hydroxyl would 
not a priori be unfavorable, given some precedented aminoglycoside analogues. 
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Figure 2. Neomycin complexed to nucleobases and the phosphate backbone of 16S rRNA.5,6 
 
5.2 Preparation of 2-DOS carbohydrate mimic 
The first synthetic step in the preparation of carbohydrate analogue A is triple protection of 
D-ribose. In a one-pot reaction, both C-2 and C-3 hydroxyls were protected with a cyclopentylidene 
group and the 1-hydroxyl with an allyl group yielding the protected β-allyl ribofuranoside 2. The 
choice for the cyclopentylidene lies in the fact that various acidic conditions failed to cleanly 
remove the commonly employed isopropylidene group at this position and give acceptable amounts 
of product,
7,8,9,10
 which led us to a paper by Van Heeswijk and co-workers on the stability of a 
variety of –ylidene groups.
11,12
 Indeed, removal of the cyclopentylidene with CH3COOH/H2O 
(80/20) led to β-O-allyl ribofuranoside (3) in acceptable yield although also in this case it turned out 
mandatory to quench the reaction after 48 hours to avoid hydrolysis of the anomeric protective 
group. Investigations on the synthesis of the β-O-allyl ribofuranoside 3 in a single synthetic step by 
Fisher glycosidation of D-ribose with allyl alcohol activated by CuSO4 and H2SO4, SnCl4 or 
Amberlite IR-120 (H
+
, ion-exchange resin) did not improve matters since the α-ribofuranoside was 
always obtained as the main product. 
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Crucial step in the synthetic sequence was oxidative cleavage of the diol to a dialdehyde, followed 
by nitroaldol condensation with nitromethane. Because three new asymmetric centers are formed in 
this transformation, eight stereoisomeric nitro glycosides could theoretically be formed, apart from 
additional stereoisomers engendered by epimerization of α-carbons. The fact that the desired 
stereoisomer 4 has the all-equatorial configuration was an important stimulus to undertake this 
endeavor and we were delighted to find that a single product 3-nitro-β-D-allylpyranoside (4) was 
isolated after acidification and crystallization from EtOAc (Scheme 1).
13
 Two other isomers, 
formed in smaller proportions, were not isolated. It was found that performing the reaction in an 
aqueous solution of sodium hydroxide led to lower yields and predominant formation of another 
isomer. 
 
Scheme 1.  
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Reagents and conditions: (a) CuSO4, cyclopentanone, allyl alcohol, H2SO4, 40 °C, 48h; (b) CH3COOH 80%, 
40 °C, 48h; (c) NaIO4, H2O, 0 °C to rt, 30 min then NaOMe, NO2Me, MeOH, rt, 45 min.  
 
Having the requisite nitrosugar 4 at hand, regioselective deoxygenation was investigated. Initially, it 
was expected that such a transformation could be induced via conversion of the 4,6-diol into a 
cyclic sulfite (5) followed by base-effected elimination reaction. Indeed, reaction of 4 with thionyl 
chloride smoothly led to the desired cyclic sulfite 5 but only starting material 4 was isolated upon 
subsequent attempted elimination with DBU (Scheme 2). Other bases were also investigated such 
as NaHCO3 and an elimination reduction procedure with NaBH4, however under all these reaction 
conditions only nitroglucopyranoside 4 was isolated. A different strategy was followed next, 
involving a regioselective protection of the 2-hydroxyl by iodoetherification with the O-allyl 
group.
14
 Such a methodology was developed by Cipolla and co-workers for allyl 
2,3,4,6-tetra-O-benzyl-α-D-glucopyranoside to afford a cyclic iodoether upon treatment with I2. 
Unfortunately, upon reaction of the glucopyranoside with I2 no conversion of starting material was 
detected even when Et3N was added or when the reaction temperature was increased. 
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Scheme 2.  
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Reagents and conditions: (a) SOCl2, pyridine, EtOAc, 0 °C, 2h; (b) DBU, CH2Cl2 and NaHCO3; (c) NaBH4, 
EtOH, 0 °C, o.n.; (d) I2, Et3N, THF, rt to heating 50 °C. 
 
Given the unsuccessful attempts described above, our next approach involved prior conversion of 
the 6-OH into an azide followed by regioselective discrimination of the resulting diol. Thus, 
treatment of O-6 with tosylchloride followed by displacement with sodium azide gave the 
6-azidopyranoside 9 in good yield (Scheme 3). Much to our satisfaction, subsequent protection of 
the 2-hydroxyl with a triethylsilyl group proceeded uneventfully to yield monosilylated 
glucopyranoside 10.
15
 Subsequent acetylation of O-4 with acetylchloride
16
 and addition of sodium 
borohydride to the crude reaction product lead to a one-step elimination-reduction reaction.17 Finally, 
removal of the TES group with a 2N HCl solution in EtOAc afforded the carbohydrate mimic of 
2-DOS 12 in a total of 8 synthetic steps and an overall yield of 6.6%.  
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Reagents and conditions: (a) TsCl, CH2Cl2/ pyridine (1/1), 0 °C to rt, o.n.; (b) NaN3, DMF, 55 °C, o.n.; (c) 
TESOTf, Et3N, CH2Cl2, 0 °C, 30 min; (d) Ac2O, Et3N, DMAP, CH2Cl2, 0 °C to rt, 30 min, then NaBH4, 
EtOH, rt, 2h; (e) 2N HCl, EtOAc, rt, 10 min. 
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Before further application of 12 was undertaken, reduction of the nitro or azido group was 
investigated. Indeed, hydrogenation of nitroglucopyranoside 12 was achieved upon reaction with 
Ra-Ni, leading to reduction of azido, nitro and the allyl group. Subsequent removal of the TES 
group under aforementioned conditions yielded the carbohydrate analogue 13 quantitatively.  
 
Scheme 4.  
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Reagents and conditions: (a) Ra-Ni, MeOH, H2, 3 bar, rt, 24h; (b) 2N HCl, EtOAc, rt, 10 min. 
5.3 Conformationally constrained aminoglycoside ligand 
NMR spectroscopy and x-ray crystallography studies have indicated that neamine is the minimal 
motif for selective binding to the A-site of 16S rRNA.
5,6
 It has also been shown that 
2,6-diamino-2,6-dideoxyglucopyranoside makes many of the key interactions with RNA. Studies 
by Wong and co-workers have demonstrated that substitution patterns other than 2,6-diamines lead 
to loss of activity of these antibiotics.
18
 Studies by Boons and co-workers
3
 on a library of 24 
disaccharides mimics of neamine including α(1-3) or β(1-3) and α(1-4) or β(1-4) linked dimers 
containing 2-4 amino groups indicated that the compound with best binding affinity was the one 
with 4 amino groups (C-2, C-2', C-6, C-6'), displaying an affinity similar to that of neamine. These 
results stimulated us to investigate incorporation of nitro analogue 12 in a conformationally 
restricted analogue of neamine via coupling to a thioglycoside followed by macrocycle formation. 
Extensive clinical use of the aminoglycosides is limited, due to the global development of microbial 
resistance as the result of structural modification by bacterial enzymes.
19,20
 Another drawback of the 
aminoglycosides is the associated nephro- and ototoxicities.
21
 It is also known that most 
aminoglycosides can bind to a variety of RNA targets with lack of high selectivity. The NMR 
structure derived from paromomycin complexed to 16S rRNA revealed that several intermolecular 
contacts between the aminoglycosides and RNA recognition sides are important for binding.
5a
 Our 
attention was drawn to a hydrogen bond between N-2' and O-4" (Figure 2) and it was reasoned that 
a neamine analogue covalently linked between C-3' and O-5 would be locked in the appropriate 
conformation for binding to rRNA and may therefore show enhanced binding specificity (Scheme 
5, 2-DOS numbering). Along the same line of reasoning, Jiménez-Barbero and co-workers recently 
prepared a conformationally restricted neomycin B analogue and found it to be less susceptible to 
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resistance.
22
 Another recent report on the synthesis of conformationally restricted analogues of both 
neomycin and paromomycin was also published this year by Blount et al.
23
  
Thus, glycosylation of the carbohydrate acceptor 12 with donor 14
24
 was carried out in the 
presence of 2,4,6-tri-tert-butylpyrimidine (TTBP) and AgOTf (Scheme 5).
25
 The product was 
formed in a yield of 45% and the α/β ratio was around 3:1.
26,1
 Apart from that, (unavoidable) 
formation of a side product was observed, NMR analysis of which revealed that elimination product 
(16) was formed in a yield of 32%. Next, after separation of the two products (15 and 16) ring-
closing metathesis reaction was performed. Unfortunately, exposure of the dicarbohydrate (15) to 
the second generation of Grubbs’ catalyst to induce ring-closing metathesis did not yield the desired 
product, presumably caused by incompatibility of the azides with the ruthenium phosphine ligand.
27
 
The undesired Staudinger reduction could be simply avoided by prior reduction of the azido groups 
followed by protection of the corresponding amine groups. However, a more elegant approach 
avoiding the requisite additional two steps, involved the use of the phosphine-free Hoveyda–Grubbs 
catalyst 19. Much to our satisfaction reaction of compound 15 with the Hoveyda-Grubbs catalyst 
indeed afforded the cyclic product 17 in a high yield of 99%.  
 Although no further chemistry was performed with the resulting product 17 at this stage, it 
is assumed that reduction and deprotection of derivative 17 can be performed under the 
aforementioned conditions (Ra-Ni, H2). 
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Reagents and conditions: (a) AgOTf, 4Å MS, TTBP, CH2Cl2, 0 °C to rt, o.n. (α /β ≈ 1/3); (b) Hoveyda’s 
catalyst, toluene, rt, 4h. 
 
5.4 Concluding remarks 
A carbohydrate analogue of 2-DOS was synthesized successfully in 8 steps and an overall yield of 
6.6%. The analogue is enantiopure and orthogonally protected. Model reduction and deprotection of 
the analogue proceeded easily in only two steps in a high yield. More importantly, the carbohydrate 
precursor is conveniently protected for incorporation in new aminoglycoside entities, suited for the 
synthesis of 4,5-linked aminoglycoside antibiotics. Moreover, the allyl at O-1 makes the 
carbohydrate mimic highly suitable for the synthesis of conformationally restricted RNA binders. In 
addition, the carbohydrate derivative was coupled successfully with thioglycoside 14, to form 
neamine mimic 15. A conformationally restricted analogue was synthesized via a ring-closing 
metathesis with the Hoveyda-Grubbs catalysts. Deprotection has to be performed before biological 
tests can be achieved.  
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5.6 Experimental Section 
Allyl-2,3-O-cyclopentanone-β-D-ribofuranoside (2)  
Powdered D-ribose (1, 5.85 g, 38.9 mmol) and anhydrous cuprous sulfate (12.4 g) were 
suspended in a mixture of cyclopentanone (110 mL) and allyl alcohol (32 mL) 
containing a catalytic amount of H2SO4 (0.2 mL). The resulting mixture was stirred at 
40 °C for 48 h and then neutralized with NaHCO3, filtered and the solvents were 
evaporated. The crude product was extracted with EtOAc and washed with brine, dried (Na2SO4), and the 
solvent was evaporated to give the crude product which was purified by flash chromatography (EtOAc/n-
heptane, 1/10), to obtain 2 (3.32 g, 53%) as a colorless oil. 12 [α]D
20 -70.8 (c 0.35; CH2Cl2). IR υmax film: (cm
-
1) 3475, 2964, 1338, 1102, 1043, 1001, 914, 742. 1H NMR (CDCl3, 400 MHz, ppm): δ 5.90 (m, 1H, Allyl), 
5.30 (m, 2H, Allyl), 5.13 (s, 1H, CH), 4.78 (d, 1H, J = 6.0 Hz, CH), 4.55 (d, 1H, J = 6.0 Hz, CH), 4.41 (br s, 
1H, OH), 4.21 (m, 1H, CH), 4.08 (m, 1H, CH), 3.69 (m, 2H, CH), 3.22 (m, 1H, CH), 1.68 (m, 8H, CH2).
13C 
NMR (CDCl3, 75 MHz, ppm): δ 132.9, 121.6, 118.2, 107.6, 88.1, 85.6, 81.3, 68.8, 63.9, 35.6, 35.5, 23.5, 
23.0. HRMS (EI) m/z calcd for C13H20O5 (M)
+: 256.1311, found: 256.1312. 
 
Allyl-β-D-ribofuranoside (3)  
Compound 2 (2.05 g, 8.00 mmol) was dissolved in 80 % acetic acid and heated to 40 
°C for 48 h. The reaction mixture was neutralized with NaHCO3 and evaporated 
flash column chromatography (EtOAc/n-heptane, 1/5) gave 3 as colorless oil (604 mg, 40%, BORSM 65%). 
Rf 0.38 (EtOAc). [α]D
20 -57.1 (c 0.77; CH2Cl2). IR υmax film: (cm
-1) 3347, 2926, 1640, 1084, 1033, 993, 931, 
633, 559. 1H NMR (CDCl3, 400 MHz, ppm): δ 6.04-5.97 (m, 1H, allyl), 5.28 (dd, J = 1.6, 1.8 Hz, 1H, allyl), 
5.20 (dd, J = 1.8, 1.6 Hz, 1H, allyl), 4.97 (s, 1H, CH), 4.20-3.91 (m, 7H, CH), 3.72-3.59 (m, 2H, OH), 3.67 
(br s, 1H, OH). 13C NMR (CD3OD, 75 MHz, ppm): δ 135.4, 116.8, 107.7, 84.8, 76.2, 72.7, 69.1, 65.0. 
HRMS (CI) m/z calcd for C8H15O5 (M+H)
+: 191.0919, found: 191.0920. 
 
Allyl-3-nitro-3-deoxy-β-D-glucopyranoside (4)  
NaIO4 (7.68 g, 35.9 mmol) was dissolved in H2O (90 mL). After cooling the reaction 
mixture to 0 °C, compound 3 (6.83 g, 35.9 mmol) was added and the reaction 
mixture was carefully heated to rt. Note the NaIO4 is only dissolved at rt. The 
oxidation is finished after stirring for 30 min according to TLC analysis in EtOAc. EtOH was added to the 
reaction mixture and cooled to 0 °C and filtered to get rid of the NaIO4. The filtrate was evaporated and 
dissolved in EtOH and filtered again. The reaction mixture was now evaporated twice with MeOH. The 
obtained dialdehyde was dissolved in MeOH and after cooling nitromethane (2.0 mL, 37.34 mmol) was 
added. Freshly prepared NaOMe (2.48 g, 35.9 mmol) was now added and the reaction was stirred at rt for 45 
min. To the reaction mixture was added to a cold solution of Amberlite IR-120 (H+) in MeOH. The yellow 
reaction mixture becomes colorless after stirring for approximately 10 min. The reaction mixture was passed 
through a column of Amberlite and thoroughly rinsed with MeOH. After evaporation twice with EtOAc the 
reaction mixture was stored in the fridge for one night after which the EtOAc was filtered off to yield a white 
powder of compound 4 (2.54 g, 30%). Rf 0.62 (EtOAc). Mp: 158.6 °C. [α]D
20 -24.9 (c 1.0; CH2Cl2). IR υmax 
film: (cm-1) 3285, 1556, 1124, 1079, 1042, 1012. 1H NMR (CD3OD, 400 MHz, ppm): δ 7.09-5.96 (m, 1H, 
CH), 5.37 (ddt, J = 1.6, 1.8 Hz, 1H, CH), 5.31 (ddt, J = 1.3, 1.5 Hz, 1H, CH), 4.46 (t, J = 10.1 Hz ,1H, CH), 
4.48-4.33 (m, 1H, CH2), 4.36 (d, J = 2.5 Hz, 1H, CH), 4.21-4.13 (m, 1H, CH2), 3.92 (t, J = 9.8 Hz, 1H, CH), 
3.90-3.51 (m, 3H, CH), 3.38-3.16 (m, 1H, CH). 13C NMR (CD3Cl3, 75 MHz, ppm): δ 135.1 (CH), 117.3 
(CH2), 102.7 (CH), 95.8 (CH), 78.1 (CH), 72.3 (CH), 71.1 (CH2), 69.2 (CH), 62.0 (CH2). HRMS (ESI) m/z 
calcd for C9H15O7N (M+Na)
+: 272.0746, found: 272.0745. Elemental analysis: calculated for (C9H15O7) C 
43.37, H 6.07, N 5.62, found C 43.00, H 6.10, N 5.51. 
 
Allyl-3-nitro-3-deoxy-6-O-tosyl-β-D-glucopyranoside  
Compound 4 (1.07 g, 5.13 mmol) was dissolved in a mixture of (CH2Cl2/pyridine, 
1/1, 0.2 mL). After cooling the mixture to 0 °C tosylchloride (1.17 g, 6.16 mmol) 
was added. The reaction was stirred overnight. The reaction mixture was quenched 
with water and extracted with EtOAc, dried with Na2SO4. To yield after flash 
column chromatography (EtOAc/n-heptane, 1/10) the compound as a colorless oil (1.74 g, 91%). Rf 0.78 
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(EtOAc). IR υmax film: (cm
-1) 3482, 1559, 1173, 1039, 981, 814, 730, 533. 1H NMR (CD3OD, 400 MHz, 
ppm): δ 7.79, (d, J = 8.2 Hz, 2H, arom), 7.35 (d, J = 8.1 Hz, 2H, arom), 5.94-5.82 (m, 1H), 5.33-5.19 (m, 
2H), 4.54 (t, J = 10.1 Hz, 1H), 4.41-4.33 (m, 2H), 4.34-4.25 (m, 2H), 4.18-4.03 (m, 3H), 3.94 (dq, J = 9.7, 
4.1, 2.1 Hz, 1H), 3.57-3.51 (m, 1H), 1.54 (s, 3H). 13C NMR (CD3Cl3, 75 MHz, ppm): δ 145.3, 132.9, 130.0, 
128.0, 118.6, 101.2, 92.2, 74.1, 70.9, 67.7, 22.1.  
 
Allyl-6-azido-3-nitro-3,6-dideoxy-β-D-glucopyranoside (9)  
Tosyl glucopyranoside (33 mg, 0.082 mmol) was dissolved in DMF (1 mL). The 
reaction mixture was heated to 55 °C and NaN3 (10 mg, 0.16 mmol) was added. 
After stirring overnight the reaction mixture was quenched with water and extracted 
with EtOAc, to yield after flash column chromatography in (EtOAc/n-heptane, 2/3) compound 9 as a white 
solid (17 mg, 84%). Rf 0.28 (EtOAc/n-heptane, 2/3). [α]D
20 -16 (c 0.45; CH2Cl2). IR υmax film: (cm
-1) 3426, 
2103, 1559, 1372, 1281, 1065. 1H NMR (CDCl3, 400 MHz, ppm): δ 6.04-5.81 (m, 1H), 5.52-5.20 (m, 2H), 
4.54 (t, J = 10.0 Hz, 1H), 4.42 (d, J = 7.8 Hz, 1H), 4.36 (d, J = 7.5 Hz, 1H), 4.21-4.30 (m, 2H), 4.18 (t, J = 
9.5 Hz, 1H), 3.63 (br 1, 1H, OH), 3.59-3.38 (m, 3H), 3.24 (br s, 1H, OH). 13C NMR (CD3Cl3, 75 MHz, ppm): 
δ 132.9, 118.9, 100.9, 92.8, 75.5, 70.9, 70.8, 69.0, 51.2. HRMS (CI) m/z calcd for C9H15O6N4 (M+H)
+: 
275.0992, found: 275.0981.  
 
Allyl-6-azido-3-nitro-3,6-dideoxy-2-O-triethylsilyl-β-D-glucopyranoside (10)  
The glucopyranoside 9 (13 mg, 0.047 mmol) was dissolved in CH2Cl2. After cooling 
the reaction to 0 °C triethylsilyl trifluoromethanesulfonate (16 µL, 0.071 mmol) and 
Et3N (17 µL, 1.2 mmol) were added and the reaction mixture was stirred for half an 
hour and quenched with sat. aq. NH4Cl and extracted with CH2Cl2 and dried with 
Na2SO4. Flash column chromatography (EtOAc/n-heptane, 2/3) gave compound 10 (18 mg, 78%) as a 
colorless oil. Rf 0.52 (EtOAc/n-heptane, 1/10). [α]D
20 -14 (c 0.46; CH2Cl2). IR υmax film: (cm
-1) 3425, 2876, 
2099, 1557, 1067, 815, 745. 1H NMR (CDCl3, 400 MHz, ppm): 6.05-5.90 (m, 1H), 5.42-5.18 (m, 2H), 4.49 
(t, J = 6.4 Hz, 1H), 4.45-4.31 (m, 1H, CH), 4.37 (d, J = 7.6 Hz, 1H), 4.19-3.92 (m, 3H), 3.52-3.49 (m, 3H), 
1.14-0.79 (m, 9H, TES), 072-0.45 (m, 6H, TES).13C NMR (CD3Cl3, 75 MHz, ppm): δ 133.1, 118.5, 101.6, 
95.0, 75.3, 72.3, 70.9, 69.4, 51.4, 6.9, 5.1. HRMS (FAB) m/z calcd for C15H29O6N4Si (M+H)
+: 389.1856, 
found: 389.1863. 
 
Allyl-6-azido-3-nitro-3,4,6-trideoxy-2-O-triethylsilyl-β-D-glucopyranoside (11) 
Compound 10 (100 mg, 0.26 mmol) was dissolved in CH2Cl2 (2 mL) and cooled to 0 
°C. Et3N (64 µL, 0.47 mmol), Ac2O (49 µL, 0.51 mmol) and DMAP (cat.) were added 
and the reaction was stirred for 30 min. The reaction mixture was quenched with a 0.1 
M HCl solution and extracted with CH2Cl2 and dried with Na2SO4. The compound was dissolved in EtOH 
(2mL) and NaBH4 (20 mg, 0.51 mmol) was added to the reaction mixture. The reaction mixture was stirred 
at room temperature for 2h and quenched with acetone and evaporated. Flash column chromatography 
(EtOAc/n-heptane, 1/5) gave the compound 11 (87 mg, 91%) as colorless oil. Rf 0.60 (EtOAc/n-heptane, 
2/3). [α]D
20 -29 (c 0.32; CH2Cl2). IR υmax film: (cm
-1) 2954, 2877, 2099, 1558, 1130, 1006, 743. 1H NMR 
(CDCl3, 400 MHz, ppm): δ 6.10-5.82 (m, 1H, allyl), 5.49-5.18 (m, 2H, allyl), 4.64-4.54 (m, 1H, H3), 4.46-
4.38 (m, 1H, H7a), 4.32 (d, 1H, J = 7.6 Hz, H1), 4.15-4.00 (m, 2H, H7b and H2), 3.70-3.65 (m, 1H, H5), 3.62-
3.39 (m, 1H, H6a), 2.20 (dd, 1H, J = 3.5 Hz, H6b), 2.20 (ddd, 1H, J = 1.9 Hz, H4a), 2.04 (q, 1H, J = 5.9 Hz, 
H4b), 1.01-0.81 (m, 9H, TES), 0.71-0.51 (m, 6H, TES). 
13C NMR (CD3Cl3, 75 MHz, ppm): δ 133.2, 118.4, 
101.8, 88.1, 72.5, 71.7, 70.7, 54.0, 33.6, 6.9, 5.2. HRMS (FAB) m/z calcd for C15H29O5N4Si (M+H)
+: 
373.1907, found: 373.1904. 
 
Allyl-3-nitro-3,4,6-trideoxy-6-azido-β-D-glucopyranoside (12)  
Compound 11 (28 mg, 0.075 mmol) was dissolved in a 2M HCl solution and stirred for 
10 min. at room temperature. The reaction mixture was evaporated and flash column 
chromatography (EtOAc/n-heptane, 1/5) gave 12 (12 mg, 63%) as colorless oil. Rf 0.55 
(EtOAc/n-heptane, 1/1). [α]D
20 – 26 (1.4; CH2Cl2). IR υmax film: (cm
-1) 3431, 2924, 2099, 1556, 1065, 1036. 
1H NMR (CDCl3, 400 MHz, ppm): δ 6.07-5.84 (m, 1H), 5.32 (dd, J = 35.2, 17.1 Hz, 2H), 4.59 (ddd, J = 5.0, 
10.0, 12.5 Hz, 1H), 4.38 (d, J = 6.6 Hz, 1H), 4.51-4.31 (m, 1H), 4.14 (ddd, J = 1.1, 6.5, 12.6 Hz, 1H), 4.01 
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(dd, J = 8.0, 9.7 Hz, 1H), 3.75-3.64 (m, 1H), 3.47 (dd, J = 7.2, 13.0 Hz, 1H), 3.21 (dd, J = 3.4, 13.0 Hz, 1H), 
2.71 (br s, 1H), 2.41-2.19 (m, 1H), 2.02 (q, J = 12.1 Hz, 1H). 13C NMR (CDCl3, 75 MHz, ppm): δ 133.3, 
118.8, 101.3, 85.7, 71.8, 71.2, 70.5, 53.8, 33.1. HRMS (CI) m/z calcd for C9H14O5N4 (M+H)
+: 259.1042, 
found: 259.1049. 
 
Propyl-3,6-diamino-3,4,6-trideoxy-2-O-triethylsilyl-β-D-glucopyranoside 
Compound 11 (30 mg, 0.081 mmol) was dissolved in MeOH, Raney Ni in MeOH (7 
mL) was added and the hydrogenation was performed on a Parr apparatus overnight at 
3 bar, followed by filtration over Hyflo-supercel and evaporation of the solvent to 
yield compound as a white powder. IR υmax film: (cm
-1) 3369, 2955, 1582, 1113, 1078, 
823, 741. 1H NMR (CD3OD, 400 MHz, ppm): δ 4.13 (br d, J = 7.4 Hz, 1H), 3.77 (dd, J = 7.3, 16.4, 1H), 
3.57-3.34 (m, 2H), 3.27 (br s, 1H), 3.12-2.94 (m, 1H), 2.79-2.58 (m, 2H), 1.75 (dd, J = 3.0, 12.8 Hz, 1H), 
1.19 (dq, J = 7.2, 14.3 Hz, 2H), 0.92 (dd, J = 11.9, 24.2 Hz, 1H), 1.04-0.83 (m, 12H), 0.77-0.58 (m, 6H). 13C 
NMR (CD3OD, 75 MHz, ppm): δ 104.6, 79.0, 75.0, 72.0, 54.7, 46.7, 36.5, 24.3, 11.1, 7.4, 6.3. HRMS (ESI) 
m/z calcd for C15H35O3N2Si (M+H)
+: 319.2417, found: 319.2404.  
 
Propyl-3,6-diamino-3,4,6-trideoxy-β-D-glucopyranoside (13)  
The diamino glucopyranoside (26 mg, 0.081 mmol) was dissolved in a 2 M HCl 
solution in EtOAc (5 mL). The reaction mixture was stirred for 1 ½ h and the solvent 
was evaporated and the residue was dissolved in t-BuOH and evaporated this was 
repeated a two times, to yield compound 13 as a white powder (22 mg, quant, 2 
steps). [α]D
20 – 3.5 (1.1; H2O). 
1H NMR (D2O, 300 MHz, ppm): δ 4.53 (d, 1H, J = 7.2 Hz), 4.10-3.87 (m, 
2H), 3.71-60 (m, 1H), 3.51-3.42 (m, 2H), 3.40-2.30 (m, 1H), 3.22-3.05 (m, 1H), 2.32-2.15 (m, 1H), 1.81-
1.58 (m, 3H), 0.95 (t, J = 7.2 Hz, 3H). 13C NMR (D2O, 75 MHz, ppm): δ 103.1, 73.3, 71.5, 69.5, 52.3, 43.2, 
32.2, 23.2, 10.7. HRMS (CI) m/z calcd for C9H20O3N2 (M+H)
+: 205.1539, found: 205.1552. 
 
Allyl(2’-C-allyl-3’,4’-di-O-benzyl-2’,6’,-dideoxy-α/β-D-glucopyranosyl)-
(1’,2)-6-azido-3,4,6-trideoxy-3-nitro-β-D-glucopyranoside (15)  
Flask 1: AgOTf (142 mg, 0.552 mmol) was co-evaporated three times with 
toluene and activated molecular sieves (50 mg) were added. Flask 2: Compound 
12 (45 mg, 0.18 mmol) and 14 (93 mg, 0.19 mmol) were co-evaporated three 
times with toluene after which DCE (3 mL) and TTBP were added (137 mg, 
0.552 mmol) and the mixture was stirred for 30 min. Flask 1 with AgOTf was 
now cooled to 0 °C and flask 2 was added under argon atmosphere. The reaction 
mixture was stirred o.n. at room temperature. The reaction mixture was quenched with 50 equiv pyridine and 
filtered through a layer of Hyflo-supercel. The solvents were evaporated and flash column chromatography 
(EtOAc/n-heptane, 1/20 to 1/2) gave product 15 (54 mg, 45%) as colorless oil and 16 (23 mg, 32%) and the 
starting material (4 mg, 9%) and. Rf 0.45 (EtOAc/n-heptane, 1/1). IR υmax film: (cm
-1) 2915, 2098, 1557, 
1453, 1371, 1283, 1066, 919, 740, 699. 1H NMR (CDCl3, 400 MHz, ppm): δ 7.42-7.21 (m, 10H), 6.09-5.69 
(m, 2H), 5.51-5.35 (m, 1H), 5.27-5.21 (m, 1H), 5.15-4.95 (m, 3H), 4.92-4.81 (m, 3H), 4.72-4.65 (m, 4H), 
4.49-4.31 (m, 2H), 4.32-4.04 (m, 2H), 3.82-3.62 (m, 1H), 3.51-3.35 (m, 6H), 2.52-2.32 (m, 1H), 2.28-2.10 
(m, 2H), 1.91-1.82 (m, 1H). HRMS (FAB) m/z calcd for C32H40O8N7 (M+H)
+: 650.2938, found: 650.2918.  
 
1,5-Anhydro-2-allyl-2,6-dideoxy-D-arabino-hex-l-enitol (16)  
Compound 16 (23 mg, 32%): Rf 0.75 (EtOAc/n-heptane, 1/2). IR υmax film: (cm
-1) 3336, 
2070, 1120, 1090, 973, 823, 697. 1H NMR (CD3OD, 400 MHz, ppm): δ 7.39-7.23 (m, 
10H), 6.23 (s, 1H), 5.81-5.52 (m, 1H), 5.11-4.91 (m, 2H), 4.66 (s, 2H), 4.52 (dd, J = 11.5, 
45.9 Hz, 2H), 4.22-4.07 (m, 1H), 3.94 (d, J = 4.3 Hz, 1H), 3.84 (dd, J = 4.3, 5.5 Hz, 1H), 
3.65 (dd, J = 7.2, 13.2 Hz, 1H), 3.45-3.22 (m, 1H), 2.72 (dq, J = 6.3, 15.4 Hz, 2H). 13C NMR (CD3OD, 75 
MHz, ppm): δ 139.4, 135.8, 114.6, 110.5, 75.0, 73.3, 73.3, 71.8, 70.9, 49.4, 32.4. HRMS (EI) m/z calcd for 
C23H26O3N3 (M+H)
+: 392.1974, found: 392.1979. 
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(2R,3S,4R,4R,9R,11S,13S,13R)-2,11-bis(azidomethyl)-3,4-bis(benzyloxy)-13-
nitro-2,3,4,4,5,8,9,11,12,13,13,14-dodecahydrodipyrano[2,3-2',3'-
][1,4]dioxecine (17)  
Compound 15 (6 mg, 9 10-3 mmol) was co-evaporated three times with toluene 
and dissolved in toluene (0.5 mL) again. Argon was bubbled through the solution 
for ten min. To the reaction mixture was added the Hoveyda catalyst (9.8 mg, 15 
10-3 mmol). The mixture was stirred for 4 h at rt and evaporated. Column 
chromatography (EtOAc/n-heptane, 1/10 to 1/1) gave 17 (6 mg, 99%), as a white 
solid. Rf 0.34 (EtOAc/n-heptane, 1/1). IR υmax film: (cm
-1) 2924, 2100, 1557, 1067, 1028, 916. 1H NMR 
(CDCl3, 400 MHz, ppm): δ 7.39-7.21 (m, 10H), 5.41-4.32 (m, 12H), 4.30-4.04 (m, 2H), 3.81-3.62 (m, 1H), 
3.51-3.32 (m, 6H), 2.52-2.32 (m, 1H), 2.28-2.10 (m, 2H), 1.91-1.82 (m, 1H). HRMS (ESI) m/z calcd for 
C30H35O8N7 (M+Na)
+, 644.2445 found 644.2450. 
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Abstract 
The synthesis of new aminoglycoside and peptidyl 2-deoxystreptamine (2-DOS) structures is 
described based on bidirectional functionalization of 2-DOS scaffolds, synthesized in the previous 
chapters. Aminoglycoside-type structures were synthesized by dual glycosylation of the 
diazidocyclitol moiety. Peptidyl 2-DOS structures were obtained by coupling amino acids or 
peptides to the diazidocyclitol scaffold via ester, alkyl amide or carbamate functionality. 
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6.1 Introduction 
In recent years it has become increasingly apparent that RNA is not a passive bystander but plays an 
active and essential role in a large number of biological processes. Awareness has grown of the 
potential to develop tools to target RNA with small organic molecules to find new leads in drug 
development. Natural products with RNA affinity are the aminoglycosides and therefore are 
suitable lead compounds for RNA drug development. However, aminoglycosides bind with 
relatively low affinity and lack sufficient selectivity for a specific RNA sequence. Therefore, efforts 
to generate various derivatives of aminoglycosides could be a versatile strategy to increase both 
affinity and selectivity for a specific RNA construct. 
 The most conserved element of aminoglycosides, the core structure 2-deoxystreptamine 
(2-DOS), has been reported to bind to two base units within a disrupted RNA helix.
1
 Solution 
studies carried out with 2-DOS have shown that it will be bound toward 5'-3' two-base steps 
(including GU, UG and GG). Experiments conducted by Hergenrother and co-workers indicated 
that binding of 2-DOS to specific RNA hairpin loops is low and comparable to kanamycin B (Table 
1, entry 1 and 2).
2
 Interestingly, they also demonstrated that specific 2-DOS dimers bind more 
tightly than kanamycin in low micromolar range (entry 3). Most recently, it was also shown that 
several members of a small library of 2-DOS dimers, prepared by Cu(I)-catalyzed variant of the 
Huisgen 1,3-dipolar cycloaddition of alkynes and azides, were able to bind discriminatively to 
particular RNA secondary structures with high affinity (entry 4).
3
  
 
Table 1. Binding of 2-DOS dimers to RNA hairpin-loops 
entry heteroconjugate Kd value 
(µM)a 
1 kanamycin A or B, ribostamycin, paromomycin, apramycin  >1000 
2 2-DOS >1000 
3 
OH
O NH2
H2N
HO
O
NH2
H2N
HO OH
 
6−16 
 
4 
NH2H2N
OH
O
N
N
N N
N
N
O
N
H
N
H
O O OH
H2N NH2
OH
HO
10
 
0.07−25 
a Average binding constant of 2-DOS based constructs to different stem-loops. 
 
4,6-Linked 2-deoxystreptamines as potential RNA binders 
 87
The observations above indicate that 2-DOS alone, or at least in oligomeric form, has the capacity 
to bind to RNA secondary structures. We therefore reasoned that the 2-DOS precursors synthesized 
in the previous chapters could serve as interesting starting points for the synthesis of new RNA 
binders. It was expected that conjugation of the aminocyclitol with additional RNA binding 
pharmacophores could provide novel structures with the requisite flexibility and functionality to 
bind to RNA (Figure 1). Particularly, trifunctional structures obtained by bidirectional chain-
extension may result in high affinity RNA ligands, which can be divided into (I) aminoglycosides 
and (II) peptidyl 2-DOS structures.  
 
Figure 1. Aminoglycosides and bispeptidyl 2-DOS as potential RNA binders 
 
The following arguments validate the synthesis of such structures: 
(I) Synthesis of aminoglycoside analogues from the existing antibiotics is cumbersome and 
laborious due to the plethora of alcohols and amines necessitating extensive protection-
deprotection schemes. A straightforward route to non-natural aminoglycoside-like 
structures involves the simultaneous glycosylation of both alcohols of the 2-DOS azido 
precursor. This will be described in §6.2. 
(II) In order to find highly selective binders for a particular RNA construct, a combinatorial 
approach is a powerful strategy for variation and diversification of binding elements. 
The RNA-binding specificity of a molecule is dictated by the same structural elements 
applicable to protein ligands, such as hydrogen bonding capability, van der Waals and 
electrostatic interactions, proper stereochemistry, etc. We realized that peptides feature 
not only hydrogen donor and acceptor capabilities but can also be readily prepared and 
diversified by conventional methods. Moreover, the penalty of loss of electrostatic 
interactions between the negatively charged phosphate ions and positively charged 
ammonium ions of aminoglycosides could be compensated for by introduction of 
specific basic amino acids. Consequently, efforts directed towards 4,6-peptidyl-2-DOS 
ligands are described in §6.3.  
OO
H2N NH2
OR
OHHO
N3 N3
OR
OO
H2N NH2
OR
OO
x,y,zx,y,z
(I) aminoglycoside-type structures (II) peptidyl 2-DOS structuresR = TBDMS or Bn
L1 L1L2 L2 L3L3
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6.2 Aminoglycoside-type structures 
A de novo preparation of 4,6-aminosugar-substituted 2-DOS ligands via glycosylation requires the 
preparation of both donor and acceptor molecules. The acceptor molecule, i.e. a 5-O-protected 
diazidohexitol deoxystreptamine precursor, was available from earlier efforts, whereas synthesis of 
the carbohydrate donors was accomplished according to literature procedures. Thus, D-glucosamine 
was converted into a 2-azidosugar via ZnCl2-catalyzed diazotransfer, as described by Wong and co-
workers (Scheme 1).
4
 Hydroxyls were peracetylated followed by selective deacetylation of the 
anomeric position with hydrazine acetate to give 2, and finally conversion into the 
trichloroacetimidate 3, which was isolated as a mixture of anomers (α:β, 2:3) in 65% yield.
5
  
 
Scheme 1.  
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a, b O
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N3AcO
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O
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O
N3AcO
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c d
(85%) (65%)(69%)
1 2 3
Reagents and conditions: (a) TfN3, Et3N, ZnCl2, H2O/MeOH/CH2Cl2, 3/10/3, rt, 3 h; (b) Ac2O, pyridine, rt, 2 
h; (c) H2NNH2·HOAc, DMF, rt, 2 h; (d) CCl3CN, K2CO3, CH2Cl2, rt, 6 h. 
 
Activation of imidate 3 with TMSOTf in the presence of the O-TBDMS protected 2-DOS precursor 
4 yielded trimeric 5 as a mixture of four diastereoisomers. Unfortunately, separation of the 
components by column chromatography was elusive (Scheme 2), and consequently analysis was 
cumbersome.
5
 Since the poor selectivity in the glycosidation of 2-azidosugars is typical with most 
substrates, attention was focused on another carbohydrate donor. 
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Reagents and conditions: (a) 1, TMSOTf, 4 Å MS, CH2Cl2/Et2O (1:1), -30 °C, 2h.  
 
Earlier work in our group has established that glycosidation of 6-azidomannothioglycosides under 
the action of 1-benzenesulfinyl piperidine (BSP) and trifluoromethanesulfonic anhydride (Tf2O) in 
the presence of 2,4,6-tri-tert-butylpyrimidine (TTBP)6 generally displays good stereoselectivity and 
proceeds with high yield.
7
 Thus, in adaptation of such a glycosylation strategy, 
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6-azidomannothioglycoside 6 was activated under the standard conditions followed by addition, and 
hence attachment, of the TBDMS protected 2-DOS acceptor 4 (Scheme 3). The desired bis-coupled 
derivative 7 was formed in a yield of 40% with the α,α-coupled product predominating (ratio 
α,α:β,β:α,β:β,α = 90:4:3:3).
8
 The O-protective groups were removed in one step by addition of 
TFA to yield the azido precursor 8 in 68% yield.
9
 It was recognized at this stage that the 
glycodiversification of 2-DOS with an array of donors would lead to a library of purely 
carbohydrate-based RNA-ligands. Despite the potency of the approach, however, it was also clear 
that relatively large effort is demanded for the preparation of the required donors and attention was 
focused on peptidyl-deoxystreptamine conjugates next. 
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Reagents and conditions: (a) BSP, Tf2O, TTBP, CH2Cl2, 4Å MS, -60 ºC, 2h; (b) TFA, 1 min, rt. 
 
6.3 Ester-linked peptidyl 2-DOS  
The introduction of peptides onto a 2-DOS scaffold is a versatile means to obtain potential RNA 
binders because the common set of 20 amino acid building blocks provides the right tools for not 
only introduction of functionality with great diversity but also for achieving selectivity by 
combinatorial sequence variation. Our building block 4, having two free hydroxyls, can be 
derivatized to a peptidyl-2-DOS conjugate by mono- or bisfunctionalization (symmetrical or 
asymmetrical), by attachment of the peptide tail(s) to the free alcohols of 4. We decided to focus on 
peptides coupled to 2-DOS via an ester, an alkyl amide or carbamate functionality (Figure 2). 
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Figure 2.  
 
The most straightforward strategy to couple peptides to 2-DOS scaffold 4 involves attachment of 
the C-terminus via an ester. However, before the synthesis of peptidyl-substituted structures was 
undertaken, we realized that the final product, after reduction of azides to amines, may be prone to 
O→N acyl migration. Therefore, in a model study 4 was coupled with N-Boc-protected 
phenylalanine (DCC, DMAP, DCM) under standard esterification conditions to give the bis-amino 
acyl compound 9 in 79% yield (Scheme 4).  
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Reagents and conditions: (a) Boc-Phe-OH, DCC, DMAP, CH2Cl2, 0 °C – rt, 20 h; (b) Pd/C, H2, 3 bar, 
MeOH, o.n; (c) 2 M HCl in MeOH, rt, 4 h. 
 
As expected, rearrangement of the amino acyl analogue obtained via hydrogenation of 9 proceeded 
rapidly and quantitatively, leading to the more stable bis-amide. Subsequent Boc-deprotection under 
acidic conditions led to an interesting chiral structure (10) but the lack of the essential 1,3-diamino 
functionality of 2-DOS, and hence loss of ionic interactions with the RNA phosphate backbone, 
gave feed to the expectation that the obtained peptide derivative is a poor RNA binder. Thus, this 
route was further abandoned and attention was focused on alternative peptidyl linkages. 
 
6.4 Alkylamide-linked peptidyl 2-DOS 
Given the fact that direct attachment of peptides through an O-acyl linkage turned out unsuitable for 
our purpose, O-alkyl linked derivatives were explored next. However, the lack of variance of amino 
acid functionalities for direct etherification necessitates the incorporation of a linker (except for Ser 
en Thr). Azidoalcohol (11, Scheme 5), easily synthesized from cheap 1,2-aminocyclohexanol, 
served as a model system by conversion of the amine, via diazotransfer, into azido derivative 11.4 
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The residual free hydroxyl was allylated followed by oxidation of the alkene
10
 leading to acid 13 or, 
preferably, directly alkylated with bromoacetic acid to yield acid 13 in 78% yield. 
 
Scheme 5.  
O
N3
OH
O
(58%)
(±)
OH
N3
O
N3
(68%)
(78%)
b c
d
OH
NH2
(quant.)
a
11 12 13
⋅HCl
 
Reagents and conditions: (a) TfN3, Et3N, ZnCl2, H2O/MeOH/CH2Cl2, 3/10/3, rt, 3 h; (b) AllBr, NaH, TBAI, 
DMF, 0 °C -rt, 4h; (c) NaIO4, RuCl3, H2O/CHCl3/MeCN, 2/1/1, rt, 4 ½ h; (d) BrCH2CO2H, NaH, TBAI, 
THF, 0 °C - rt, 3 h. 
 
Condensation of acid 13 with the model peptide H-Phe-Val-Ala-OMe, synthesized according to 
standard Boc-peptide chemistry, yielded the ether-linked peptidyl structure 14 in a yield of 41% 
(Scheme 6). Subsequent removal of the methyl ester with LiOH followed by reduction of the azides 
yielded the deprotected model system 16 in high yield (91%). 
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Reagents and conditions: (a) H-Phe-Val-Ala-OMe·HCl (15), DIPEA, PyBOP, CH2Cl2, rt, o.n.; (b) LiOH, 
THF/H2O, 4/1, o.n.; (c) Pd/C, H2, 3 bar, MeOH, rt, o.n.  
 
The methodology described above was now applied to 2-DOS aminocyclitol 4 by condensation 
with bromoacetic acid, to yield diacid 17 in 82% yield (Scheme 7). In contrast to above, direct 
PyBOP-induced coupling of peptide H-Phe-Val-Ala-OMe·HCl (15) with diacid 17 failed to produce 
the desired bis-peptide 19. Alternatively, conversion of acid 17 into the bis-N-hydroxysuccinimide 
ester (18) prior to addition of the tripeptide H-Phe-Val-Ala-OMe·HCl (15) was more successful, 
and led to dual introduction of the tripeptide in a yield of 61%. Deprotection of the peptidyl based 
ligand was achieved in three steps: (a) hydrogenolysis of azides with Pd/C, (b) removal of the 
TBDMS protective group and (c) hydrolysis of the methyl ester. Much to our surprise, the resulting 
end product, isolated in 24% yield for the three steps, was not the expected bis(tripeptide) but mass 
spectrometric analysis indicated the loss of one of the tripeptide chains. Apparently, the applied 
conditions for ester hydrolysis were sufficiently basic to induce intramolecular nucleophilic attack 
of the free 2-DOS alcohol onto the amide bond connecting one of the tripeptides, resulting in 
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monopeptidyl based ligand 20. Although such a cleavage can potentially be circumvented by ester 
hydrolysis prior to TBDMS-removal, the risk of late-stage cleavage of a peptide chain urged us to 
investigate an alternative strategy.  
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Reagents and conditions: (a) Bromoacetic acid, NaH, TBAI, THF, 0 °C-rt, 3-4h; (b) HOSu, EDC, 
Et3N/CH2Cl2/DMF (2/5/70), rt, o.n.; (c) H-Phe-Val-Ala-OMe·HCl (15), CH2Cl2/ DMF/ H2O (10/5/2), Et3N, 
rt, o.n.; (d) Pd(OH)2,
11 H2, 3 bar, i-propanol/H2O/AcOH (3/2/1), o.n.; (e) 2 M HCl MeOH, rt, 6h; (f) LiOH, 
THF/H2O (4/1), rt, o.n. 
 
Earlier reports have indicated that the chance of finding a good peptide-based RNA ligand by 
random combination of amino acids has a small chance of success. For example, Dardel and co-
workers screened a library of hexapeptides against the human tRNAlys3 tRNA by flow-injection 
NMR, allowing the detection of weak binding interactions.
 12
 The hexapeptide Tyr-His-Ser-Arg-
Asn-Asn (YHSRNN) was found to be structure-specific, and could provide leads for the design of 
high affinity ligands. In this context, RNA targeting has strong potential since RNA is involved in 
cellular protein interactions such as transcription, splicing and translation or in viral infection such 
as human immunodeficiency virus (HIV). Several systematic screens have been preformed on the 
HIV-1 genomic RNA fragments but in all cases, the high affinity hits were strongly cationic and 
recognition was dominated by electrostatic effects that were often poorly selective.
13
 Thus, there is 
a need for strategies based on selectivity rather than on affinity. The finding of Dardel et al. 
stimulated us to investigate if the affinity of the strongest binding hexapeptide could be enhanced 
further by coupling to an RNA-binding pharmacophore such as 2-DOS.  
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6.5 Carbamate-linked peptidyl 2-DOS 
A third alternative linkage of 2-DOS to a peptide is via carbamate functionality, which can be easily 
installed by step-wise condensation of an alcohol and an amine using phosgene-type reagents. 
However, also in this case an undesired intramolecular O→N migration leading to a urea, much like 
the rapid 1,2-rearrangement of esters to a more stable amide bond (vide supra), could not be 
excluded at forehand. To investigate the propensity of such urea formation we prepared the model 
systems 1,2-aminocarbamate 26 and 1,2-aminoester 22 (Scheme 8). Compound 21 was obtained by 
reacting (racemic) 2-azidocyclohexan-1-ol (11) with benzoyl chloride, followed by hydrogenation 
in the presence of CHCl3 to give HCl-salt 24.
14
 Carbamate 26 was prepared by consecutive 
treatment of 11 with 4-nitrophenyl chloroformate and benzylamine and reduction of the azide under 
aforementioned conditions to afford the corresponding HCl-salt of 26. To compare the stability of 
the respective compounds 22 and 26, the ammonium salts were deprotonated with base, directly 
followed by NMR analysis. As expected, ester 22 instantaneously rearranged to amide 23, while 
carbamate 26 was left unchanged even after heating the reaction mixture at 80 °C for 48 hours, 
which unequivocally established the usefulness of carbamate functionality for attachment of 
peptides to 2-DOS. 
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Reagents and conditions: (a) BzCl, pyridine, DMAP, CH2Cl2, rt, 24h; (b) 10% Pd/C, H2, EtOH, CHCl3, rt, 3 
bar, 24h; (c) DMSO-D6, aq. 1N NaOH, rt, 4h; (d) 4-nitrophenylchloroformate, pyridine, CH2CH2, rt, 2h; (e) 
BnNH2, DIPEA, CH2Cl2, rt, 24h; (f) 10% Pd/C, H2, EtOH, CHCl3, rt, 2h; (g) CD3OD, aq. 1N NaOH, 24h. 
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Thus, in analogy with the model study, 2-DOS precursor 27 was reacted with 
p-nitrophenylchloroformate, leading to the formation of the corresponding activated biscarbonate 
28 in high yield (99%, Scheme 9). Rather disappointingly, addition of H-Phe-Val-Ala-OMe to 
carbonate 28 did not yield the desired biscarbamate 30, but led to an intractable mixture of 
components. Since it was rationalized that unfavorable steric clash may have hampered the desired 
condensation, coupling β-Ala-OMe to the azidocyclitol carbonate (28→29) prior to peptide addition 
was investigated. Next, the methyl ester was removed and peptide H-Phe-Val-Ala-OMe was added 
to the biscarboxylate 29 under peptide coupling conditions (Scheme 9), but again peptidyl based 
ligand was not formed. Finally, direct coupling of a tetrapeptide 32, with β-alanine already attached 
to the N-terminus, was also unfortunate since again many products were formed.  
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Reagents and conditions: (a) p-nitrophenylchloroformate, pyridine, CH2Cl2, rt, 4h; (b) β-Ala-OMe·HCl, 
DIPEA, DMF, rt, o.n.; (c) LiOH, THF/H2O (4 /1), rt, o.n.; (d) Boc-Phe-Val-Ala-OMe (15), TFA, 2h, then 
BOP, DIPEA,CH2Cl2, rt, o.n.; (e) Boc-β-Ala-Phe-Val-Ala-OMe (32), TFA, 2h, then BOP, DIPEA,CH2Cl2, 
rt, o.n. 
 
Despite the unfruitful attempts described above it was not excluded that coupling of carbonate 28 
may be effected successfully by subjection of a resin-bound peptide to a large excess of 28. Thus, 
H-Tyr(t-Bu)-His(Trt)-Ser(t-Bu)-Arg(Pmc)-Asn(Trt)-Asn(Trt) (33), a known tRNA binder as 
described above, was prepared on Wang resin (loading 0.3 mmol/g) by standard solid phase Fmoc 
peptide synthesis and reacted with activated carbonate 28 (Scheme 10). Much to our satisfaction, 
coupling to the hexapeptide proceeded effectively, as indicated by a negative Kaiser test of the 
resin. Subsequently, excess ethylenediamine was added to quench the second carbonate, followed 
by cleavage from the resin with simultaneous removal of protective groups, to yield crude peptidyl 
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2-DOS conjugate 34. Purification on silica gel gave a homogeneous compound, spectral analysis of 
which (HRMS, NMR) was in complete agreement with the proposed structure. Unfortunately, 
deprotection in the final step, i.e. azide reduction and benzyl deprotection under a variety of 
conditions, failed to proceed, and we were hitherto unable to obtain product 35.  
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Reagents and conditions: (a) pyridine, HOBt, DMF, 6h.; (b) ethylenediamine, DMF, rt, o.n. (c) TFA/ 
H2O/TIS/EDT (180/10/5/5), rt, 2-3h; (d) Pd/C, H2, EtOH/CHCl3 (5/1) o.n.. 
 
At this stage it had become clear that the preparation of 2-DOS peptide conjugates was not as 
straightforward as at forehand anticipated. However, we realized that interesting 2-DOS based 
polyamines could also be prepared from intermediate 28 via condensation with less intricate 
structures. For example, condensation of activated carbonate 28 with mono-Boc protected 
1,2-ethylenediamine (36) or 1,3-propylenediamine (37) proceeded smoothly to give, after 
deprotection of the Boc group a free diamine (Scheme 11). Apart from being a direct precursor of a 
tetraamine derivative of 2-DOS, by virtue of the presence of the free amine functionality, amino 
acids can be directly C-coupled to 38 and 39. For example, coupling of the bisazido derivative of 
ornithine to either ethylene- or propyleneamine extended structures 38 or 39 yielded the respective 
peptidyl ligands 43 and 44 in 71% and 78% yield. Several conditions to reduce the azides and to 
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remove the benzyl were investigated such as Raney-nickel, Pd/C in several solvents, and PMe3 in 
THF, and it was determined that optimal conditions were found to involve simultaneous 
hydrogenolysis of azides and removal of the benzyl group under the action of Pd(OH)2 in an i-propyl 
alcohol/H2O/AcOH mixture to yield compound 45 and 46 in 76% and 69% yield, respectively. 
 
Scheme 11.  
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Reagents and conditions: (a) DIPEA, DMF, rt, o.n.; (b) TFA/CH2Cl2 (1/1), rt, 2h; (c) Pd(OH)2, H2, 3 bar, 
i-propanol/ H2O/AcOH (3/2/1), o.n. (d) BOP, DIPEA, HOBt, rt, o.n. 
 
6.6 Concluding remarks 
Previously synthesized diazidocyclitols were established as useful scaffolds for the preparation of 
2-DOS based carbohydrate and peptide conjugates. For example, functionalized 
6-azidomannothioglycoside (6) was coupled successfully to 2-DOS to form trimeric 
aminoglycoside 7 in 40% yield and with high selectivity. Conjugation of peptides to 2-DOS via 
ester functionality was found unsuitable for the preparation of new RNA binders, due to rapid 
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O→N migration. On the other hand, alkylamide and carbamate functionalized 2-DOS ligands were 
found sufficiently stable for preparation of new peptidyl 2-DOS derivatives, although care has to be 
taken in application of basic conditions to avoid peptide cleavage by intramolecular amide 
hydrolysis. The protected hexapeptide H-Tyr(t-Bu)-His(Trt)-Ser(t-Bu)-Arg(Pmc)-Asn(Trt)-
Asn(Trt) was successfully coupled to 2-DOS but deprotection was not successful sofar. The 
structures 20 and 40, 41, 45, 46 resulting from the synthetic efforts described above are currently 
under evaluation as potential RNA affinity ligands by flow-through NMR detection of binding to a 
tRNA construct. 
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6.8 Experimental Section 
2-Azido-2-deoxy-1,3,4,6-tetra-O-acetyl-α,β-glucopyranoside (1)  
Glucosamine·HCl (4.00 gr, 4.63 mmol) and ZnCl2 (6 mg, 1 mol%) were dissolved in water 
(15.5 mL). Et3N (1.93 mL, 13.9 mmol) and, slowly, MeOH (50 mL) were added. TfN3 in 
CH2Cl2 (0.6 M, 15.5 mL) was added at once to the vigorously stirring solution. The 
reaction mixture was stirred for 3 hours at room temperature and quenched with NaHCO3 
(sat. aq.) the solvents were evaporated. The crude product was now dissolve in pyridine (25 mL, 185 mmol) 
and Ac2O (15 mL, 62 mmol) and DMAP (cat.) were added. After stirring the reaction mixture for 2 hours at 
rt, H2O was added and the product was extracted with EtOAc, dried with MgSO4 and the solvent were 
evaporated. Flash column chromatography (EtOAc/n-heptane, 3/2) to yield 1 (1.21 g, 69%) as a white solid. 
Rf 0.44 (EtOAc/n-heptane, 1/1). IR υmax film: (cm
-1) 2941, 2111, 1748, 1363, 1208, 1035, 611. 1H NMR 
(CDCl3, 300 MHz, ppm): 5.53 (d, J = 8.4 Hz, 1H), 5.08-4.98 (m, 2H), 4.28 (dd, J = 4.5, 12.0 Hz, 1H), 4.11-
3.99 (m, 2H), 3.78-3.68 (m, 1H), 2.18 (s, 3H), 2.10 (s, 3H), 2.08 (s, 3H), 2.02 (s, 3H). 13C NMR (CDCl3, 75 
MHz, ppm): δ 170.3, 169.4, 168.3, 92.6, 90.1, 72.9, 72.8, 70.9, 69.9, 67.9, 62.8, 61.6, 60.5, 21.1. In 
agreement with literature.15  
 
2-Azido-2-deoxy-3,4,6-tri-O-acetyl-α,β-glucopyranoside (2)  
Compound 1 (100 mg, 0.268 mmol) was dissolved in dry DMF (0.5 mL) and 
H2NNH2·HOAc (25 mg, 0.27 mmol) were added. The reaction mixture was stirred for 2 
hours. Quench with iPrOH/EtOAc (1/9) and wash with water. The product was purified with 
flash column chromatography (EtOAc/n-heptane, 1/1) and compound 2 was obtained as 
colorless oil (75.4 mg, 85%). Rf 0.35 (EtOAc/n-heptane, 1/1). IR υmax film: (cm
-1) 3442, 2950, 2360, 2110, 
1745, 1432, 1367, 1225, 1140, 1044, 962, 911, 734. 1H NMR (CDCl3, 400 MHz, ppm): 5.53 (t, J=9.2 Hz, 
1H), 5.07-4.94 (m, 2H), 4.31-4.19 (m, 2H), 4.18-4.08 (m, 1H), 3.52-3.39 (m, 1H), 2.08 (s, 9H). HRMS (ESI) 
m/z calcd for C12H18O8N3 (M+H)
+: 332.1094, found 332.1097.15 
 
2-Azido-2-deoxy-3,4,6-tri-O-acetyl-1-trichloroimidate-α,β-glucopyranoside (3)  
Compound 2 (118 mg, 0.36 mmol) and CCl3CN (80 µL, 0.80 mmol) were dissolved in 
dry CH2Cl2 (2 mL). Freshly powdered K2CO3 (44 mg, 0.32 mmol) was added and the 
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reaction was stirred for 6 hours. Filter over Celite and the product was purified with flash column 
chromatography (EtOAc/n-heptane, 1/2) and compound 3 (110 mg, 65%) was obtained as a white solid. Rf 
0.20 (β), 0.27 (α) (EtOAc/n-heptane, 1/2). 1H NMR (CDCl3, 400 MHz, ppm): δ 8.84 (s, 1H), 6.50 (s, 1H), 
5.52 (t, J = 9.6 Hz, 1H), 5.16 (t, J = 9.6 Hz, 1H), 4.40-4.28 (m, 2H), 4.13-4.07 (m, 1H), 3.78 (dd, J = 3.5, 
10.4 Hz, 1H), 2.10 (s, 9H). In agreement with literature.15  
 
4,6-Diazido-2-[(tert-butyldimethylsilyl)oxy]cyclohexanediol-(1’,2)- 
(1’’-6)-di(2-azido-2-deoxy-3,4,6-tri-O-acetylglucopyranoside) (5)  
Compound 4 (30 mg, 0.091 mmol) and 3 (65 mg, 0.14 mmol) were 
coevaporated three times with toluene. 4 Å MS and a mixture of 
CH2Cl2/Et2O (1/1, 6 mL) were added to compound 4. The reaction 
mixture was cooled to -30 °C and TMSOTf (40 µL, 0.22 mmol) was 
added slowly. The reaction was stirred for 2 hours and quenched with DIPEA (40 µL, 0.22 mmol). After the 
reaction was diluted with CH2Cl2 (12 mL) the mixture was allowed to warm up to room temperature. The 
reaction mixture was washed with 0.1 M HCl, dried with MgSO4 and the solvent was evaporated to yield an 
inseparable mixture of diastereoisomers (5). 
 
4,6-Diazido-2-[(tert-butyldimethylsilyl)oxy]cyclohexanediol-
(1’-2)-(1’’-6)-di(6-desoxy-azido-2-trimethylsilyl-3,4-
dimethoxybutane-manopyranoside) (7)  
Compound 4 and the thioglycoside 6 were coevaporated three 
times with toluene. To the stirred solution containing activated 4 Å 
MS (80 mg) the thioglycoside 6 (122 mg, 0.252 mmol), 1-
benzenesulphinyl (BSP, 63 mg, 0.30 mmol) and TTBP (156 mg, 
0.63 mmol) in CH2Cl2 (5 mL) at -60 °C was added Tf2O (51 µL, 0.30 mmol). After stirring the reaction 
mixture was for 10 min. 2-DOS acceptor 4 (41 mg, 0.126 mmol) was added in CH2Cl2 (5 mL). After stirring 
the reaction for 20 minutes the reaction mixture was quenched with P(OEt)3 (52 µL, 0.30 mmol) and warmed 
up to -30 °C. Saturated aq. NaHCO3 was added and the reaction was warmed up to rt after which the reaction 
mixture was extracted with CH2Cl2, dried with Na2SO4 and evaporated. The product was purified by flash 
column chromatography (EtOAc/n-heptane, 1/8) to obtain 7 (54 mg, 40%) as a white solid. Rf 0.4 (EtOAc/n-
heptane, 2/3). [α]D
20 + 114 (c 0.25; CH2Cl2). IR υmax film: cm
-1 2950, 2098, 1128, 1038, 842, 779. 1H NMR 
(CDCl3, 400 MHz, ppm): δ 7.70 (d, 1H, J = 3.2 Hz, Th), 7.32-7.69 (m, 3H, arom), 6.79 (d, 2H, J = 8.5 Hz, 
arom), 5.50 (m, 1H, allyl), 5.14-4.89 (m, 3H, allyl and CH), 4.35 (d, 1H, J = 14.9 Hz, CH2), 3.79 (s, 4H, 
OMe and CH), 3.51 (d, 1H, J = 14.9 Hz, CH2), 2.78 (m, 1H, CH2a), 2.36(m, 1H, CH2b), 1.44 (s, 9H, t-Bu).
 
13C NMR (CDCl3, 100 MHz, ppm): δ 159.3, 158.3, 142.9, 134.7, 130.0, 119.0, 118.4, 114.2, 82.0, 74.7, 65.4, 
55.9, 55.0, 36.1, 32.6, 29.7, 23.44, 14.89. HRMS (ESI) m/z calcd for C42H78O15N12Si3Na (M+Na)
+ 
1097.4915, found: 1097.4925. 
 
4,6-Diazido-2-[(tert-butyldimethylsilyl)oxy]cyclohexanediol-(1’-2)-(1’’-
6)-di(6-desoxy-azido-2-manopyranoside) (8)  
Compound 7 (35 mg, 0.032 mmol) was dissolved in 1 mL TFA. The 
mixture was stirred for 1 min and evaporated. The product was purified 
with flash column chromatography (EtOAc to H2O/MeCN, 1/4) to obtain 8 
(19 mg, 68%) as a white solid. IR υmax film: cm
-1 3367, 2103, 1672, 1259, 
1132, 1051, 839. 1H NMR (CDCl3, 400 MHz, ppm): δ 5.41 (br s, 1H), 5.15 (br s, 1H), 4.23-4.08 (m, 2H), 
3.99 (br s, 1H), 3.79-3.51 (m, 7H), 3.50-3.90 (m, 7H), 2.42-2.22 (m, 1H), 1.61-1.53 (m, 1H). 13C 
NMR(CDCl3, 100 MHz, ppm): δ 102.8, 102.6, 83.8, 81.5, 76.5, 74.1, 73.7, 72.2, 72.1, 71.9, 71.9, 69.2, 68.8, 
62.2, 60.7, 53.0, 52.7. HRMS (FAB) m/z calcd for C18H28O11N12 (M+H)
+: 589.2079, found: 589.2088; 
(M+Na)+ 611.1899 found: 611.1877. 
 
1,3-diazido-5-O-(tert-butyldimethylsilyl)- 4,6-bis-O-[(2S)-2-(tert-
butyloxycarbonyl)amino-3-phenylpropanoyl]-1,3-dideamino-2-
deoxystreptamine (9)  
N-Boc-L-PheOH (145 mg, 0.546 mmol) was dissolved in CH2Cl2 and 
cooled to 0 °C. DCC (122 mg, 0.546 mmol) and DMAP (67 mg, 0.456 
O
OHHO
OH
O
N3
N3 N3
OH
O O
N3
HO OH
OH
O
OO
O
O
N3
MeO
OMe
N3 N3
OTBDMS
O O
N3
O
TMS TMS
O
O
OMe
OMe
O
N3AcO
OAc
O
OAc
N3 N3
OTBDMS
O O
OAc
N3 OAc
OAc
O O
N3N3
O O
NHBocBocHN
Ph Ph
OTBDMS
4,6-Linked 2-deoxystreptamines as potential RNA binders 
 99
mmol) were added and the reaction was stirred at 0 °C for 20 minutes. Compound 4 (60 mg, 0.182 mmol) 
was added and the reaction was stirred at 0 °C for 4 hours. The reaction mixture was filtered after stirring for 
20 hours at room temperature. CH2Cl2 was evaporated, and the residue was dissolved in EtOAc, washed 
once with NaHCO3 (sat), H2O and NaCl (sat). The solvents were evaporated and the product was purified 
with flash column chromatography (EtOAc/n-heptane, 1/10) to yield 9 (118 mg, 79%) as colorless oil. IR 
υmax film: (cm
-1) 2929, 2099, 1704, 1365, 1162, 536. 1H NMR (CDCl3, 300 MHz, ppm): δ 7.31-7.04 (m, 
10H), 5.12-4.84 (m, 2H), 5.03-4.72 (m, 2H), 4.68-4.49 (m, 2H), 3.70 (s, 4H), 3.54-3.29 (m, 2H), 3.12-2.98 
(m, 1H), 1.99-1.78 (m, 1H), 1.56 (s, 18H), 1.38 (s, 9H), 0.92-0.61 (m, 1H), 0.13 (s, 3H), 0.08 (s, 3H). HRMS 
(FAB) m/z calcd for C40H59O9SiN8 (M+H)
+: 823.4174, found: 823.4181. 
 
N,N’-[(2S)-2-amino-3-phenylpropanoyl]-2-deoxystreptamine (10)  
Compound 9 (92 mg, 0.11 mmol) was dissolved in MeOH (8.0 mL) and Pd/C 
(10%, 8.0 mg) was added. After stirring at room temperature for 19 h under an 
atmosphere of H2, the mixture was filtered off and the filtrate was 
concentrated in vacuo affording the crude product (55 mg, 64%). To a 
solution of the obtained material (29 mg, 38 µmol) in MeOH (2.0 mL) at 0 °C 
was slowly added AcCl (0.14 ml, 2.0 mmol). The mixture was allowed to rise to room temperature and 
stirred for 16 h. Upon completion, the reaction mixture was concentrated in vacuo and the crude product was 
purified using an Isolute SPE column (Flash SCX-2 resin) affording the product 10 (17 mg, quant) as an off-
white solid. IR υmax film: (cm
-1) 3283, 2922, 1643, 1553, 1097, 1030. 1H NMR (DMSO-D6, 400 MHz, ppm): 
δ 7.72-7.69 (m, 2H, NH), 7.28-7.16 (m, 10H, arom), 3.47-2.83 (m, 9H, CH and CH2), 2.60-2.50 (m, 2H, 
CH2), 1.84-1.72 (m, 1H, CH2a), 1.09-0.96 (m, 1H, CH2b). 
13C NMR (CD3OD, 75 MHz, ppm): δ 175.9, 
138.5, 130.1, 129.3, 127.5, 77.7, 76.2, 52.3, 51.4, 42.5, 35.3. 
 
(±)-(1R,2R)-2-azidocyclohexanol (11)  
To a solution of (±)-(1R, 2R)-2-aminocyclohexanol (3.4 g, 22 mmol), ZnCl2 (31 mg, 1 mol%), 
and Et3N (9.4 mL, 67 mmol) in H2O (56 mL) was slowly added MeOH (185 mL). TfN3 in 
CH2Cl2 (0.6 M, 56 mL) was added at once to the vigorously stirring solution and the reaction mixture was 
stirred for 3 hours at room temperature. Upon completion, the mixture was quenched with saturated aqueous 
NaHCO3 and the solvent evaporated in vacuo. The crude product was purified using colmn chromatography 
(EtOAc/n-heptane, 1/5) to obtain the desired product 11 (3.2 g, quant) as a colourless oil. Rf 0.35 (EtOAc/n-
heptane, 1/5). IR νmax film: (cm
-1) 3350, 2937, 2862, 2095. 1H NMR (CDCl3, 300 MHz, ppm): δ 3.42-3.34 
(m, 1H, CH), 3.21-3.13 (m, 1H, CH), 2.09-2.00 (m, 2H, CH2), 1.79-1.74 (m, 2H, CH2), 1.41-1.23 (m, 4H, 
CH2). 
 
(±)-(1R,2R)-1-(allyloxy)-2-azidocyclohexane (12)  
A solution of azidocyclohexanol 11 (50 mg, 0.35 mmol) in DMF (4.0 mL) was cooled to 0 
°C and TBAI (2 mg, 1 mol%), NaH (36 mg, 0.91 mmol) and allylbromide (45 µL, 0.53 
mmol) were added. After stirring for 3 h at room temperature, the mixture was quenched using saturated 
aqueous NH4Cl and i-PrOH/EtOAc (1/9) was added. The mixture was extracted three times with H2O, dried 
with Na2SO4 and concentrated in vacuo to yield the crude product. Purification by column chromatography 
(EtOAc/n-heptane, 1/10) resulted in isolation of 12 as a colourless (for UK) oil (43 mg, 68%). Rf 0.67 
(EtOAc/n-heptane, 1/5). 1H NMR (CDCl3, 400 MHz, ppm): δ 5.92 (tdd, 1H, J = 5.6, 10.4, 17.2 Hz), 5.31 
(ddd, 1H, J = 1.6, 3.4 Hz, 17.2 Hz), 5.14 (ddt, 1H, J = 1.3, 1.8, 10.4 Hz), 4.11 (ddt, 1H, J = 1.5, 5.7, 12.7 
Hz), 4.02 (ddt, 1H, J = 1.6, 5.5, 12.6 Hz), 3.30-3.23 (m, 1H), 3.17-3.12 (m, 1H), 2.09-2.03 (m, 1H), 1.95-
1.89 (m,1H), 1.70-1.63 (m, 2H), 1.24-1.16 (m, 4H). 
 
(±)-2-[(1R,2R)-2-azidocyclohexyloxy]acetic acid (13)  
NaH (63 mg, 1.6 mmol) was washed three times with n-heptane and dissolved in THF 
(1.0 mL). The mixture was cooled to 0 °C and a solution of bromoacetic acid (80 mg, 0.58 
mmol) and TBAI (6.0 mg, 1 mol%) in THF (1.0 mL) was added dropwise. After stirring 
for 1 h, azidocyclohexanol 11 (50 mg, 0.35 mmol) was added and the mixture was allowed to warm to room 
temperature and stirred for 3 h. The reaction mixture was diluted with EtOAc and quenched with 10% 
aqueous HCl solution. The aqueous solution was extracted three times with EtOAc. The combined organic 
organic layers were dried with Na2SO4 and concentrated in vacuo. The crude product was purified by column 
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chromatography (EtOAc and 2% AcOH) to obtain the product 13 (55 mg, 78%, based on 1H NMR) and 
bromoacetic acid as an inseparable mixture. Rf 0.54 (EtOAc and 2% AcOH). IR νmax film: (cm
-1) 2937, 2863, 
2095, 1446, 1258, 1116. 1H NMR (CDCl3, 400 MHz, ppm): δ 4.22 (s, 2H), 3.39-3.33 (m, 1H), 3.28-3.22 (m, 
1H), 2.16-2.2.10 (m, 1H), 2.01-1.94 (m, 1H), 1.74-1.67 (m, 2H), 1.36-1.22 (m, 4H). 13C NMR (CD3OD, 75 
MHz, ppm): δ 173.9, 83.4, 67.5, 65.9, 31.3, 31.2, 24.8, 24.5. HRMS (CI) m/z calcd for C8H14N3O3 (M+H)
+: 
200.1038, found: 200.1035. 
Methyl N-{[(1R,2R)-2-azidocyclohexyloxy]acetyl} 
phenylalaninylvalinylalaninate (14) 
A solution of HCl·H-Phe-Val-Ala-OMe (35 mg, 91 µmol) and 
DIPEA (35 µL, 0.20 mmol) in CH2Cl2 (3.0 mL) were stirred for 5 
min at room temperature. Azidocyclohexanol 13 (27 mg, 0.10 mmol) and PyBOP (52 mg, 0.10 mmol) were 
added and the reaction mixture was stirred for 24 h at room temperature. After removal of the solvent the 
crude product was purified by column chromatography (EtOAc) which afforded 14 (20 mg, 41%) as an off-
white solid. Rf 0.41 (EtOAc and 2% AcOH). IR νmax film: (cm
-1) 2937, 2863, 2097, 1736, 1647, 1451, 1358, 
1260, 1235, 845. 1H NMR (CD3OD, 400 MHz, ppm): δ 7.28-7.18 (m, 5H, arom), 4.42-4.36 (m, 1H), 4.24-
4.20 (m, 3H, CH and CH2), 4.03-4.00 (m, 1H), 3.70 (s, 3H, OMe), 3.27-3.11 (m, 2H), 3.04-2.94 (m, 2H), 
2.13-1.69 (m, 3H, CH and CH2), 1.71-1.65 (m, 2H), 1.40 (d, 3H, J = 7.9 Hz), 1.31-1.23 (m, 4H), 0.96 (dd, 
6H, J = 6.8, 13.0 Hz). 13C NMR (CD3OD, 75 MHz, ppm): δ 173.9, 172.6, 172.4, 172.2, 130.1, 129.2, 128.0, 
127.0, 83.4, 69.1, 65.8, 59.8, 55.3, 52.7, 49.5, 39.2, 32.4, 31.3, 25.0, 24.7, 19.7, 18.9, 17.4. HRMS (CI) m/z 
calcd for C26H39N6O6 (M+H)
+: 531.2931, found: 531.2931. 
 
HCl·NH2-Phe-Val-Ala-OMe (15)  
According to the general peptide coupling procedure, to a solution of 
HCl·H-Val-Ala-OMe (2.56 g, 10.7 mmol) and DIPEA (4.10 mL, 23.6 
mmol) in CH2Cl2 (360 mL), were added Boc-Phe-OH (3.13 g, 11.8 mmol) 
and PyBOP (12.3 g, 23.6 mmol) and the reaction mixture was stirred for 24 
h. Purification by column chromatography (MeOH/CH2Cl2, 1/9) afforded 
the product (4.81 g, quant) as a white solid. Rf 0.42 (MeOH/CH2Cl2, 1/9).
 1H NMR (CD3OD, 400 MHz, 
ppm): δ 7.28-7.17 (m, 5H, arom), 4.40-4.30 (m, 2H, CH), 4.22 (dd, 1H, J = 7.4, 8.6 Hz, CH), 3.70 (s, 3H, 
OMe), 3.10 (dd, 1H, J = 5.3, 13.9 Hz, CH2), 2.81 (dd, 1H, J = 9.3, 13.8 Hz, CH2), 2.05 (dq, 1H, J = 6.9, 13.8, 
20.6 Hz, CH), 1.40-1.35 (m, 12H, t-Bu and CH3), 0.97 (dd, 6H, J = 6.8, 12.2 Hz, CH3). HRMS (FAB) m/z 
calcd for C23H36N3O6 (M+H)
+: 450.2604, found: 450.2605. According to the general Boc-deprotection 
procedure, a solution of Boc-Val-Ala-OMe (3.25 g, 10.7 mmol) in 2 M HCl/EtOAc (110 mL) was stirred for 
3 h. Work-up afforded the HCl-salt 15 (2.56 g, quant) as a white solid. 1H NMR (CD3OD, 400 MHz, ppm): δ 
8.35 (d, 1H, J = 6.7 Hz, NH), 6.51 (d, 1H, J = 8.6 Hz, NH), 4.46-4.38 (m, 1H, CH), 3.92-3.88 (m, 1H, CH), 
3.70 (s, 3H, OMe), 2.02 (dq, 1H, J = 6.7, 13.5, 20.2 Hz, CH), 1.39 (d, 3H, J = 7.3 Hz, Me), 0.95 (dd, 1H, J = 
6.8, 20.8 Hz, Me). 
 
N-{[(1R,2R)-2-aminocyclohexyloxy]acetyl} 
phenylalaninylvalinylalanine and N-{[(1S,2S)-2-
aminocyclohexyloxy]acetyl}phenylalaninylvalinylalanine (16)  
Compound 14 (28 mg, 52 µmol) was dissolved in H2O/THF (mL, 
1/4). LiOH (4 mg, 0.16 mmol) was added, and the mixture was stirred 
overnight at room temperature. THF was evaporated in vacuo, and the aqueous phase was acidified with 
10% aqueous HCl solution and extracted three times with EtOAc. The combined organic layers were dried 
with Na2SO4 and concentrated in vacuo. The crude product (27 mg, 52 µmol) which was used without 
further purification was redissolved in MeOH (5.0 mL) and Pd/C (10%, 5 mg) was added. After stirring at 
room temperature for 19 h, the mixture was filtered off and the filtrate was concentrated in vacuo. The crude 
product was purified using an Isolute SPE column (Flash SCX-2 resin) affording the product 16 (32 mg, 
91%) as an off-white solid. Rf 0.14 (H2O/MeCN, 1/4). IR νmax film: (cm
-1) 3374, 2929, 2856, 1740, 1649, 
1535, 1449, 1221, 1123. 1H NMR (CD3OD, 400 MHz, ppm): δ 7.29-7.18 (m, 5H, arom), 4.24-4.00 (m, 5H), 
3.30-3.10 (m, 2H), 3.03-2.84 (m, 2H), 2.22-2.01 (m, 3H), 1.82-1.72 (m, 2H), 1.45-1.33 (m, 7H), 0.99-0.94 
(m, 6H). 13C NMR (CD3OD, 75 MHz, ppm): δ 175.2, 173.6, 172.2, 171.9, 130.2, 129.1, 127.6, 127.2, 83.4, 
69.0, 68.7, 67.5, 65.7, 55.2, 54.8, 38.9, 33.1,32.4, 31.2, 25.0, 24.6, 18.8. HRMS (ESI) m/z calcd for 
C25H39N4O6 (M+H)
+: 491.2870, found: 491.2831. 
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2,2’-[1,3-diazido-5-O-(tert-butyldimethylsilyl)-1,3-dideamino-2-
deoxystreptamine-4,6-O-diyl]diacetic acid (17) 
NaH (83 mg, 2.1 mmol) was washed three times with n-heptane and dissolved 
in THF (1.0 mL). The mixture was cooled to 0 °C and a solution of 
bromoacetic acid (0.11 mg, 0.76 mmol) and (1 mg, 1 mol%) TBAI in THF (1.0 
mL) was added dropwise. After stirring for 1 h, azidocyclohexanol 4 (75 mg, 0.23 mmol) was added and the 
mixture was allowed to warm to room temperature and stirred for 3 h. The reaction mixture was diluted with 
EtOAc and quenched with 10% aqueous HCl solution. The aqueous solution was extracted three times with 
EtOAc. The combined organic organic layers were dried with Na2SO4 and concentrated in vacuo. The crude 
product was purified by column chromatography (EtOAc and 2% AcOH to MeOH/CHCl3, 1/9) to obtain the 
product 17 (84 mg, 82%). Rf 0.17 (MeOH/CHCl3, 1/9). IR νmax film: (cm
-1) 3365, 2954, 2872, 2358, 2101, 
1635, 1254, 1087 836. 1H NMR (CD3OD, 400 MHz, ppm): δ 4.48-4.30 (m, 4H, CH2), 3.62-3.53 (m, 1H, 
CH), 3.43-3.23 (m, 4H, CH), 2.19 (dt, 1H, J = 4.1, 12.7 Hz CH2a), 1.36 (dd, 1H, J = 12.4, 24.9 Hz, CH2b), 
0.93 (s, 9H, t-Bu), 0.18 (s, 3H, Me), 0.10 (s, 3H, Me). 13C NMR (CD3OD, 75 MHz, ppm): δ 174.4, 85.9, 
77.2, 61.3, 33.0, 26.5, 18.8, -4.0, -4.5. HRMS (ESI) m/z calcd for C16H28N6O7Si (M+Na)
+: 467.1686, found: 
467.1729. 
 
N-{2,2’-[1,3-azido-5-O-(tert-butyldimethylsilyl)-1,3-dideamino-2-
deoxystreptamine-4,6-O-diyl]bisacetoxy}disuccinimide (18)  
To a solution of 17 (245 mg, 0.550 mmol), N-hydroxysuccinimide 
(130 mg, 1.13 mmol), Et3N ( 32 µL), and DMF (100 µL) in CH2Cl2 
(1.2 mL) was added EDC (217 mg, 1.13 mmol) at 0 °C. The mixture 
was stirred at room temperature for 19 h and evaporated in vacuo. The residue was dissolved in EtOAc and 
washed with H2O. The organic layer was dried with MgSO4 and evaporated in vacuo to obtain 17 (277 mg, 
79%) as a white solid. IR νmax film: (cm
-1) 2927, 2848, 2104, 1737, 1258, 1203, 1084. 1H NMR (CDCl3, 400 
MHz, ppm): δ 4.82-4.64 (m, 4H), 3.55-3.48 (m, 1H), 3.40-3.22 (m, 4H), 2.82 (s, 8H), 2.25 (dt, 1H, J = 4.4, 
13.1 Hz), 1.40 (dd, 1H, J = 12.8, 25.6 Hz), 0.92 (s, 9H, t-Bu), 0.17 (s, 3H, Me), 0.11 (s, 3H, Me). 13C NMR 
(CDCl3, 75 MHz, ppm): δ 165.1, 164.8, 85.6, 76.0, 68.2, 62.0, 32.3, 30.0, 18.4, -3.9, -4.3. HRMS (CI) m/z 
calcd for C24H34N8O11SiNa (M+Na)
+: 661.2014, found: 661.2054. 
 
Dimethyl N,N’-{2,2’-[1,3-azido-5-
O-(tert-butyldimethylsilyl)-1,3-
dideamino-2-deoxystreptamine-
4,6-O-diyl]bisacetoxy}di(phenyl 
alaninylvalinylalaninate) (19)  
To a suspension of 
HCl·H-Phe-Val-Ala-OMe (63 mg, 0.16 mmol) in DMF (1.5 mL), H2O (0.6 mL), Et3N (30 µL), and CH2Cl2 
(3.0 mL) at 0 °C was added 18 (50 g, 78 µmol). The mixture was stirred for 1 h at 0 °C, and the temperature 
was allowed to rise to room temperature within 19 h. The solvent was removed in vacuo, and the residue was 
dissolved in EtOAc/n-heptane and washed with H2O three times. The organic layers were combined, dried 
with MgSO4 and evaporated in vacuo. The residue was purified by column chromatography (EtOAc/n-
heptane, 1/1 to H2O/MeCN, 1/4) to obtain 19 (53 mg, 61%). Rf 0.65 (H2O/MeCN, 1/4). IR νmax film: (cm
-1) 
3300, 2933, 2868, 2366, 2327, 2102, 1740, 1648, 1539, 1256, 1090. 1H NMR (CD3OD, 400 MHz, ppm): δ 
7.28-7.14 (m, 10H, arom), 4.45-4.35 (m, 2H), 4.23-4.07 (m, 8H), 3.71 (s, 6H, OMe), 3.37-3.32 (m, 1H), 
3.20-3.09 (m, 6H), 3.01-2.91 (m, 2H), 2.26-2.17 (m, 1H), 2.08-1.97 (m, 2H), 1.47-1.38 (m, 7H), 1.00-0.91 
(m, 17H), 0.18 (s, 3H), 0.03 (s, 3H). 13C NMR (CD3OD, 75 MHz, ppm): δ 173.1, 173.0, 172.6, 172.4, 171.0, 
138.3, 138.0, 137.9, 130.6, 130.5, 130.4, 129.5, 127.9, 127.8, 84.8, 84.6, 77.5, 77.4, 73.4, 72.3, 63.3, 61.2, 
59.9, 55.3, 55.0, 54.9, 54.7, 52.7, 52.6, 39.4, 39.3, 39.0, 32.8, 32.2, 26.5, 19.1, 18.9, 17.4, -3.5, -4.3. [α] 20
D
= -
28.4 (c = 0.61, H2O). HRMS (ESI) m/z calcd for C52H78N12O13SiNa (M+Na)
+: 1129.5478 found: 1129.53996. 
 
Dimethyl N,N’-[2,2’-(1,3-azido-
1,3-dideamino-2-deoxystrep-
tamine -4,6-O-diyl)bisacetoxy] 
di(phenylalaninylvalinylalaninate)  
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A solution of 19 (30 mg, 27 µmol) in 2 M HCl/EtOAc (2.0 mL) was stirred for the 2-3 h at room 
temperature. The reaction mixture was diluted with EtOAc and quenched with H2O solution. The aqueous 
layer was extracted three times with EtOAc. The combined organic organic layers were dried with MgSO4 
and concentrated in vacuo. To afford the crude product (27 mg, quant) as a white solid which was used 
without further purification. 1H NMR (CD3OD, 400 MHz, ppm): δ 7.32-7.17 (m, 10 H, arom), 4.43-4.17 (m, 
10H), 3.70 (s, 6H, OMe), 3.62-3.51 (m, 1H), 3.41-3.25 (m, 3H), 3.22-3.08 (m, 3H), 3.04-2.89 (m, 2H), 2.18-
2.09 (m, 3H), 1.41-1.25 (m, 7H), 0.99-0.94 (m, 6H). HRMS (ESI) m/z found for C46H65N12O13 (M+H)
+: 993. 
 
2-[4-O-(N-acetoxyphenylalaninylvalinylalaninyl)-2-
deoxystreptamin-6-O-yl]acetic acid (20)  
A solution of the compound described above (27 mg, 27 
µmol) and LiOH (4.0 mg, 0.16 mmol) in H2O/THF (2.0 
mL, 1/4) was stirred for 16 h. After stirring for 18 h at 
room temperature THF was removed in vacuo. EtOAc was added and the H2O solution was acidified using 
10 % aqueous hydrochloric acid. The aqueous layer was extracted with EtOAc four times, dried with Na2SO4 
and concentrated in vacuo. To a solution of the above-obtained material in iPrOH/H2O/AcOH (3/1/1, 10 mL) 
was added charcoal (25 mg). After brief stirring, the charcoal was filtered off and washed with iPrOH. The 
filtrate was concentrated in vacuo and redissolved in iPrOH/H2O/AcOH (3/1/1, 10 mL). Pd/C (25 mg about, 
1time the weight of the compound) was added and the mixture was placed under an atmosphere of H2 and 
stirred overnight. The Pd/C was filtered off and the filtrate was concentrated in vacuo. The Pd/C was filtered 
off and the filtrate was concentrated in vacuo. The crude product was purified by prep-TLC to yield product 
20 (3.9 mg, 24%). Rf 0.56 (25% NH3 in H2O/CHCl3/n-BuOH/EtOH, 6/2/4/5). 
1H NMR (H2O, 400 MHz, 
ppm): δ 7.29-7.13 (m, 5H, arom), 4.35-3.80 (m, 7H), 3.68-3.11 (m, 5H), 3.04-2.91 (m, 2H), 2.31-2.26 (m, 
1H, CH2a), 2.11-2.04 (m, 1H), 1.67-1.63 (m, 1H, CH2b), 1.22-1.18 (m, 3H, Me), 0.81-0.77 (m, 6H, Me). 
(ESI) m/z found for C27H42N5O10 (M+H)
+: 596. 
 
(±)-(1R, 2R)-2-azido-1-benzoicacidcyclohexanol (21)  
To a solution of compound 11 (100 mg, 0.718 mmol) in CH2Cl2 (7mL) was added pyridine 
(87 µL, 1.07 mmol) and benzoylchloride (125 µL, 1.07 mmol). After 2 h DMAP (cat.) was 
added the reaction mixture was stirred overnight and washed with a 2N solution of citric 
acid, brine and dried with Na2SO4. The solvent was evaporated and the product was purified with flash 
column chromatography (EtOAc/n-heptane, 1/10) to yield 21 (176 mg, quant.) as a white powder. Rf 0.43 
(EtOAc/n-heptane, 1/5), IR υmax film: (cm
-1) 2094, 1728, 1268, 1108, 710. 1H NMR (CDCl3, 400 MHz, 
ppm): δ 7.98-8.11 7.49-7.58 (m, 2H, arom), 7.35-7.46 (m, 2H, arom), 5.01-4.82 (m, 1H, CH), 3.68-3.48 (m, 
1H, CH), 2.28-2.15 (m, 1H, CH2), 2.13-1.96 (m, 1H, CH2), 1.86-1.18 (m, 2H, CH2), 1.28-1.1.49 (m, 4H, 
CH2). 
13C NMR (CDCl3, 100 MHz, ppm): δ 165.9, 133.2, 129.8, 128.5, 76.1, 63.6, 30.6, 30.5, 23.9, 23.6. 
HRMS (CI) m/z calcd MS C13H16O2N3 (M+H)
+: 246.1245, found: 246.1247.  
 
(±)-(1R, 2R)-2-amino hydrochloride-1-benzoicacidcyclohexanol (22)  
Compound 21 (80 mg, 0.33 mmol) was dissolved in EtOH (25 mL) and CHCl3 (0.5 mL). 
10 % Pd/C (50 mg) was added to the solution and the reaction was shaken overnight under 
3 Barr hydrogen atmosphere in a Parr apparatus. The reaction mixture was filtered trough 
Hyflo-Supercel and evaporated to yield 22 (82 mg, 99%.) as a cream colored powder. IR 
υmax film: (cm
-1) 2929, 1714, 1262, 710. 1H NMR (DMSO-D6, 400 MHz, ppm): δ 8.44 (br s, 3H, NH), 8.06 
(dd, 2H, J = 1.3, 8.4 Hz, arom), 7.55 (t, J = 7.4 Hz, 1H, arom), 7.53 (t, J= 7.7 Hz, 2H, arom), 4.88 (dt, J = 
4.5, 10.3 Hz, 1H, CH), 3.09-2.92 (m, 1H, CH), 2.22-2.03 (m, 2H, CH2), 1.82-1.61 (m, 2H, CH2), 1.52-1.31 
(m, 4H, CH2). 
13C NMR (D2O, 100 MHz, ppm): δ 167.4, 133.6, 129.1, 128.2, 74.5, 52.7, 44.1, 29.4, 28.5, 
22.6, 22.5, 21.7, 21.0. HRMS (CI) m/z calcd for C13H18NO2 (M+H)
+: 220.1338, found: 220.1344. 
 
(±)-(1R, 2R)-2-aminobenzoicacidcyclohexanol (23)  
Compound 22 was dissolved in DMSO –D6 and a 1 N solution of NaOH was added. The 
reaction was followed by NMR. NMR of the rearranged product 23: 1H NMR (DMSO-D6, 
400 MHz, ppm): δ 7.98-7.78 (m, 2H, arom), 7.39-7.28 (m, 3H, arom), 2.9-2.85 (m, 1H, 
CH), 2.28-2.07 (m, 1H, CH), 1.70-1.69 (m, 2H, CH2), 1.61-1.49 (m, 2H, CH2), 1.1.44-1.38 
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(m, 1H, CH2), 1.18-0.93 (m, 3H, CH2). 
13C NMR (D2O, 75 MHz, ppm): δ170.1, 139.9, 128.9, 127.0, 75.1, 
56.3, 46.5, 33.6, 32.9, 27.2, 26.4, 24.4, -0.7. 
 
(±)-(1R, 2R)-Benzylcarbamicacid-2-azidocyclohexylester (25)  
To a solution of compound 11 (100 mg, 0.718 mmol) in CH2Cl2 (7mL) was added 
pyridine (87 µL, 1.07 mmol) and 4-nitrophenylchloroformate (217 mg, 1.07 mmol). 
After stirring for 2h the reaction mixture was washed with a 2N solution of citric acid, 
brine and dried with Na2SO4. Evaporate the organic solvent and dissolve the reaction mixture in CH2Cl2 and 
add heptane, the white solid was filtered of and the organic solvents were evaporated the procedure was 
repeated three times. Rf 0.61 (EtOAc/n-heptane, 3/2). The obtained compound was again dissolved in CH2Cl2 
(7 mL) and benzylamine (80 µL, 0.93 mmol) and DIPEA (162 µL, 0.93 mmol) were added. After the 
reaction mixture had been stirred overnight the reaction mixture was diluted with CH2Cl2 and washed with 
NaHCO3 (sat.) and dried with Na2SO4. The solvent was evaporated and the product was purified with flash 
column chromatography (EtOAc/n-heptane, 1/10, to 2/1) to yield 25 (144 mg, 73%) as a white powder. Rf 
0.18 (EtOAc/n-heptane, 1/5), IR υmax film: (cm
-1) 3315, 2938, 2095, 1701, 1258, 611. 1H NMR (CDCl3, 400 
MHz, ppm): δ 7.40-7.21 (m, 5H, arom), 5.12 (br s, 1H, NH), 4.52-4.78 (m, 1H, CH), 4.38 (d, 2H, J = 5.9 Hz, 
CH2), 3.42-3.21 (m, 1H, CH), 2.18-2.11 (m, 1H, CH2), 2.07-1.94 (m, 1H, CH2), 1.69-1.60 (m, 2H, CH2) 
1.40-1.20 (m, 4H, CH2). 
13C NMR (CDCl3, 75 MHz, ppm): δ 155.8, 138.5, 128.8, 127.6, 76.4, 63.7, 45.2, 
31.2, 30.4, 23.9, 23.6. HRMS (CI) m/z calcd for C14H19N4O2(M+H)
+: 275.1508, found: 275.1510. 
 
(±)-(1R,2R)-Benzylcarbamicacid-2-aminohydrochloridecyclohexylester (26)  
See procedure of compound (22). The hydrogenation was carried out at atmospheric 
pressure; according to TLC the reaction was finished after 2h. IR υmax film: (cm
-1) 
2937, 1701, 1526, 1453, 1252, 700. 1H NMR (CD3D, 400 MHz, ppm): δ 7.52-7.12 
(m, 5H, arom), 4.56 (br s, 1H, NH), 4.29-4.19 (m, 2H, CH2), 3.72-3.49 (m, 1H, CH), 
3.29-3.09 (m, 1H, CH), 2.29-2.03 (m, 2H, CH2), 1.79-1.56 (m, 2H, CH2), 1.58-1.09 (m, 4H, CH2). 
13C NMR 
(CD3OD, 75 MHz, ppm): δ157.8, 140.2, 129.5, 128.2, 75.6, 58.3, 54.7, 45.6, 31.9, 30.4, 24.7, 18.4. HRMS 
(CI) m/z calcd for C14H20O2N2 (M+H)
+: 249.1603, found: 249.1609. 
 
1,3-diazido-5-O-benzyl-1,3-dideamino-2-deoxy-4,6-O-bis[(4-
nitrofenoxy)carbonyl]streptamine (28)  
To a solution of compound 27 (40 mg, 0.13 mmol) in CH2Cl2 
(1.5 mL) were added 4-nitrophenylchloroformate (80 mg, 0.40 
mmol) and pyridine (32 µL,0.39 mmol). After stirring for 3 h at room temperature, the reaction mixture was 
diluted with CH2Cl2 and 10% aqueous citric acid solution was added. The aqueous layer was extracted with 
EtOAc three times and the combined layers were washed with H2O and brine, dried with Na2SO4 and 
concentrated in vacuo. The crude product was purified by column chromatography (EtOAc/n-heptane, 1/5 to 
1/3 to 100% EtOAc) to afford 28 (82 mg, 99%). Rf 0.28 (EtOAc/n-heptane, 1/3). IR υmax film: cm
-1 3123, 
2859, 2102, 1775, 1525, 1348, 1251, 1210, 860. 1H NMR (Aceton-D6, 400 MHz, ppm): δ 8.32 (d, 4H, J = 
9.3 Hz, arom), 7.42 (d, 4H, J = 9.3 Hz, arom), 7.37-7.35 (m, 5H, arom), 5.22 (t, 2H, J = 9.8 Hz, CH), 4.88 (s, 
2H, CH2 OBn), 4.13 (t, 1H, J = 9.6 Hz, CH), 4.09-4.02 (m, 2H, CH), 2.59 (dt, 1H, J = 4.7, 12.8 Hz, CH2a), 
2.04 (dd, 1H, J = 12.4, 25.1 Hz, CH2b). 
13C NMR (Aceton-D6, 75 MHz, ppm): δ 156.6, 139.3, 129.8, 129.1, 
128.8, 126.7, 123.5, 82.0, 80.9, 76.7, 59.4, 32.2. HRMS (ESI) m/z calcd for C27H22N8O11Na (M+Na)
+: 
657.1306 found: 657.1353. 
 
N,N’-[(1,3-diazido-5-O-benzyl-1,3-dideamino-2-
deoxystreptamin-4,6-O-diyl)dicarbonyl]bis(β-alanine) (29)  
To a solution of 28 (40 mg, 63 µmol) in DMF (2.0 mL) were 
added β-H-Ala-OMe (26 mg, 0.19 mmol) and DIPEA (44 µl, 
0.25 mmol). After stirring for 21 h at room temperature, the mixture was concentrated in vacuo and 
covaporated with toluene. After addition of i-PrOH/EtOAc (1/9), the mixture was extracted with H2O four 
times, dried with Na2SO4 and concentrated in vacuo. Column chromatography (EtOAc/n-heptane, 1/1 to 
MeOH/CHCl3, 1/9) afforded the compound (32 mg, 91%) as a white solid. Rf 0.79 (MeOH/CHCl3, 1/9). IR 
υmax film: cm
-1 3287, 3049, 2950, 2928, 2101, 1737, 1697, 1531, 1251, 1013. 1H NMR (CDCl3 , 400 MHz, 
ppm): δ 7.33-7.22 (m, 5H, arom), 5.26 (bs, 2H, NH), 4.91 (t, 2H, J = 9.9 Hz, CH), 4.59 (s, 2H, CH2 OBn), 
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3.65 (s, 6H, OMe), 3.53-3.37 (m, 7H, CH and CH2), 2.52 (ddq, 4H, J = 4.7, 6.9, 17.2 Hz, CH2), 2.22 (dt, 1H, 
J = 4.5, 13.2 Hz, CH2a ), 1.51 (dd, 1H, J = 13.3, 26.4 Hz, CH2b).
 13C NMR (CDCl3, 75 MHz, ppm): δ 173.1, 
155.0, 137.9, 127.9, 127.8, 126.3, 79.5, 76.2, 74.3, 58.8, 51.9, 36.8, 34.1, 31.9. HRMS (CI) m/z calcd for 
C23H31N8O9 (M+H)
+: 563.2214, found: 563.2203.To a solution of the compound (31 mg, 55 µmol) in 
H2O/THF (1.0 mL, 1/4) was now added LiOH (8.0 mg, 0.33 mmol). After stirring for 16 h at room 
temperature the reaction mixture was concentrated in vacuo. After removal of the solvent, the product was 
redissolved in H2O and acidified using aqueous hydrochloric acid (1M). The aqueous solution was extracted 
with EtOAc four times, dried with Na2SO4 and concentrated in vacuo to afford 29 (30 mg, quant) as a white 
solid. Rf 0.47 (H2O/MeCN, 1/4).
 1H NMR (CD3OD, 400 MHz, ppm): δ 7.23-7.13 (m, 5H, arom), 4.74 (t, 2H, 
J = 9.9, CH), 4.52 (s, 2H, CH2 OBn), 3.52 (ddd, 2H, J = 7.1, 14.1, 20.3 Hz, CH), 3.27 (t, 4H, J = 6.6 Hz, 
CH2), 2.40 (t, 4H, J = 6.6 Hz, CH2), 2.10 (dt, 1H, J = 3.9, 8.4 Hz, CH2a), 1.35 (dd, 1H, J = 12.6, 25.2 Hz, 
CH2b). 
 
N,N’-[(2-deoxystreptamin-4,6-O-diyl)dicarbonyl]bis(β-
alanine) dihydrochloride  
According to general procedure for the deprotection, to a solution 
of 29 (7.0 mg, 13 µmol) in i-PrOH/H2O/AcOH (8.0 mL) was 
added Pd(OH)2 (14 mg). Work-up and purification afforded the 
product (5.9 mg, 98%) as an off-white solid. Rf 0.35 (25% NH3 in H2O/CHCl3/n-BuOH/EtOH, 6/2/4/5). IR 
υmax film: cm
-1 3131, 3038, 2353, 1718, 1527, 1400, 1242, 1077. 1H NMR (D2O, 400 MHz, ppm): δ 4.89 (t, 
2H, J = 10.0 Hz, CH), 3.79 (t, 1H, J = 9.6 Hz, CH), 3.66-3.59 (m, 2H, CH), 3.47-3.35 (m, 4H, CH2), 2.58 
(dt, 1H, J = 4.0, 8.5 Hz, CH2a), 2.52-2.48 (m, 4H, CH2), 2.10-1.98 (m, 7H, Me AcOH and CH2b). 
13C NMR 
(D2O, 75 MHz, ppm): δ 178.8, 156.4, 73.4, 71.0, 48.4, 47.7, 37.0, 35.5, 21.2. HRMS (ESI) m/z calcd for 
C14H24N4O9 (M+H)
+: 393. 
 
 
Boc-β-Ala-Phe-Val-Ala-OMe (32)  
According to the general peptide coupling procedure, to a solution 
of TFA·H-Phe-Val-Ala-OMe (424 mg, 1.10 mmol) and DIPEA (422 
µL, 2.42 mmol) in CH2Cl2 (20.0 mL), were added Boc-β-Ala-OH 
(229 mg, 1.21 mmol) and PyBOP (630 mg, 1.21 mmol) and the 
reaction mixture was stirred for 48 h. Purification by column chromatography (EtOAc/n-heptane, 2/1) 
afforded 32 (228 mg, 40%). Rf 0.24 (EtOAc/n-heptane, 2/1).
 1H NMR (CD3OD, 400 MHz, ppm): δ 7.24-7.14 
(m, 5H, arom), 7.09 (bm, 1H, NH), 7.01 (bm, 1H, NH), 6.89 (bm, 1H, NH), 5.28 (bs, 1H, NH t-Bu), 4.73 (q, 
1H, J = 7.2, 14.1 Hz, CH), 4.55-4.48 (m, 1H, CH), 4.27 (t, 1H, J = 7.8 Hz, CH), 3.70 (s, 3H, OMe), 3.35 (t, 
2H, J = 6.8 Hz, CH2), 3.08 (dd, 1H, J = 6.1, 13.9 Hz, CH2), 2.96 (dd, 1H, J = 7.8, 14.0 Hz, CH2), 2.42 (t, 2H, 
J = 5.7 Hz, CH2), 2.03 (dq, 1H, J = 6.9, 13.8, 20.6 Hz, CH), 1.39-1.36 (m, 12H, t-Bu and CH3), 0.88 (dd, 6H, 
J = 6.8, 14.2 Hz, CH3). 
 
Fmoc-Asn(Trt)-Asn(Trt)-Arg(Pmc)-Ser(t-Bu)-His(Trt)-Tyr(t-Bu)-
OH (33)  
A suspension of Wang-resin (5.94 g, 1.136 mmol/g OH) in DMF (60.0 
mL) was cooled to 0 °C after which Fmoc-Asn(Trt)-OH (8.00 g, 13.5 mmol), HOBt (3.65 g, 27.0 mmol) and 
DIPCDI (1.70 g, 13.5 mmol) was added. This mixture was shaken for 6 h. The functionalised resin was 
filtered and washed repeatedly with CH2Cl2, DMF and i-PrOH. Unfunctionalised groups on the resin were 
capped by adding benzoylchloride (2.04 mL, 17.6 mmol) and pyridine (1.68 mL, 20.6 mmol) to a suspension 
of the resin in CH2Cl2 (60.0 mL) at 0 °C. This mixture was shaken for 30 minutes, filtered and washed 
repeatedly with CH2Cl2, DMF and i-PrOH. Then the Fmoc-Asn(Trt)-OH functionalised resin (loading 0.3 
mmol/g) was swollen and filtered three times in DMF (50.0 mL). Next DMF (50.0 mL) containing 20 v/v % 
piperidine (3 * 6 min) was added to remove the Fmoc group. A positive Kaiser test indicated completeness 
of this reaction. The next amino acid was coupled by adding a mixture of Fmoc-Asn(Trt)-OH (24.1 g, 40.5 
mmol 3eq), in DMF (180 mL), with DIPCDI (5.63 g, 22.3 mmol 3.3 eq.) and HOBt (6.57 g, 48.6 mmol 3.6 
eq). A negative Kaiser test indicated completeness of the reaction after which the mixture was washed with 
DMF and twice with CH2Cl2 and i-PrOH and again with DMF. This procedure was repeated with the 
following four amino acids: Fmoc-Arg(Pmc)-OH, Fmoc-Ser(t-Bu)-OH, Fmoc-His(Trt)-OH, Fmoc-Tyr(t-
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Bu)-OH. HRMS (FAB) m/z calcd for C47H58N13O13 (M+H)
+: 1012.4277, found: 1012.4282 (cleavage from 
resin with TFA/H2O/TIS/EDT, 180/10/5/5, 3 h). 
 
General procedure for peptide couplings reactions in solution A solution of amino ester and DIPEA (2.2 
equiv) in CH2Cl2 was stirred for 5 min at room temperature under Ar-atmosphere. Boc-protected amino acid 
(1.1 equiv) and PyBOP (1.1 equiv) were added and the reaction mixture was stirred at room temperature for 
the indicated time. After removal of the solvent the crude product was purified with column 
chromatography. 
 
N-({6-O-[(2-aminoethyl) 
carbamoyl]-1,3-diazido-5-O-
benzyl-1,3-dideamino-2-
deoxystreptamin-4-O-
yl}carbonyl)tyrosinylhistidinylser
inylarganinylarganinylaspargine 
trifluoroacetic acid salt (34)  
Functionalised Wang resin 33 (0.10 
g, 0.20 mmol) was swollen in DMF for 30 minutes. After which pyridine (40 µL, 0.49 mmol), HOBt (0.14 g, 
1.0 mmol) and 28 (50 mg, 79 µmol) were added. After shaking for 6 h, ethylenediamine (21 µL, 0.32 mmol) 
was added and the resulting mixture was shaken for 13 h. Then the resin was filtered and washed with DMF, 
CH2Cl2, i-PrOH, CH2Cl2 and Et2O. After the resin was dried, TFA/H2O/TIS/EDT (4.0 mL, 180/10/5/5) was 
added and the resin was shaken for 2 h. The mixture was concentrated in vacuo and the desired product 34 
(30 mg, 31%) was precipitated in Et2O and freeze dried from H2O to yield a fluffy white solid. IR υmax film: 
cm-1 3326, 2359, 2339, 2104, 1669, 1516, 1254, 1203, 1136. 1H NMR (D2O, 400 MHz, ppm): δ 8.64-8.59 
(m, 1H), 8.27-8.26 (m, 1H), 7.39-6.64 (m, 11H), 4.76-4.18 (m, 15H), 3.95-3.67 (m, 4H), 3.55-2.69 (m, 10H), 
2.41-2.29 (m, 1H), 1.93-1.49 (m, 5H). 13C NMR (D2O, 75 MHz, ppm): δ 175.4, 174.8, 173.5, 172.2, 172.1, 
163.7, 163.2, 157.3, 155.0, 140.9, 137.7, 134.1, 131.0, 130.9, 129.2, 119.0, 117.8, 116.1, 115.2, 80.3, 78.0, 
77.2, 76.2, 62.0, 58.8, 58.6, 57.6, 56.4, 54.4, 54.3, 51.4, 41.5, 40.1, 39.0, 37.6, 37.5, 37.3, 31.6, 29.2, 27.5, 
25.4. HRMS (ESI) m/z calcd for C49H68N21O16 (M+H)
+ 1206.5153 found: 1206.5121. 
 
N-tert-Butoxycarbonyl-1,2-ethanediamine (36)  
A solution of (Boc)2O (5.00 g, 23.9 mmol) in dioxane (60 mL) was added over a period of 
2.5 h to a solution of 1,2-diaminoethane (10.8 g, 181 mmol) in dioxane (60 mL). The mixture was allowed to 
stir for 24 h and the solvent was evaporated in vacuo. H2O (100 mL) was added to the residue and the 
insoluble bis-substituted product was removed by filtration. The filtrate was extracted with CH2Cl2 (100 mL) 
three times and concentrated in vacuo affording the desired product 36 (3.20 g, 87%) as a clear oil. 1H NMR 
(CDCl3, 400 MHz, ppm): δ 5.01 (s, 1H, NH Boc), 3.12 (dd, 2H, J = 5.8, 11.6 Hz, CH2), 2.75 (t, 2H, J = 6.1 
Hz, CH2), 1.40 (s, 9H, t-Bu).
16 Compound 37 was prepared by an analogous procedure.  
 
1,3-diazido-5-O-benzyl-1,3-dideamino-2-deoxy-4,6-bis-O-({2-
[(tert-butyloxycarbonyl)amino]ethyl}carbamoyl)streptamine 
To a solution of 28 (50 mg, 79 µmol) in DMF (1.0 mL) were 
added Boc-protected amine 36 (38 mg, 0.24 mmol) and DIPEA 
(28 µL, 0.16 mmol). After stirring for 24 h at room temperature, 
the mixture was concentrated in vacuo. The crude product was redissolved in toluene and concentrated in 
vacuo. After addition of i-PrOH/EtOAc (1/9), the mixture was extracted with H2O four times, dried with 
Na2SO4 and concentrated in vacuo. Column chromatography (EtOAc/n-heptane, 1/4 to EtOAc) afforded the 
compound (37.4 mg, 70%) as a white solid. Rf 0.36 (EtOAc). IR υmax film: cm
-1 2965 2892, 2359, 2101, 
1700, 1684, 1165, 612. 1H NMR (Aceton-D6, 400 MHz, ppm): δ 7.34-7.26 (m, 5H, arom) 6.55 (bs, 2H, 
NH), 6.00 (bs, 2H, NH), 4.99 (t, 2H, J = 9.8 Hz, CH), 4.65 (s, 2H, CH2 OBn), 3.75-3.68 (m, 2H, CH), 3.62 
(t, 1H, J = 9.7 Hz, CH), 3.28-3.18 (m, 8H, CH2), 2.27 (dt, 1H, J = 4.4, 9.7 Hz, CH2a), 1.66 (dd, 1H, J = 12.8, 
25.3, CH2b), 1.39 (s, 18H, t-Bu). 
13C NMR (Aceton-D6, 75 MHz, ppm): δ 156.4, 139.5, 129.0, 128.7, 128.3, 
81.0, 78.9, 76.6, 75.1, 59.6, 42.1, 41.3, 32.2, 28.6. HRMS (FAB) m/z calcd for C29H45N10O9 (M+H)
+: 
677.3371, found: 677.3370. 
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1,3-diazido-5-O-benzyl-1,3-dideamino-2-deoxy-4,6-bis-
O-({3-[(tert-butyloxycarbonyl)amino] 
propyl}carbamoyl)streptamine  
Following the same procedure as for 37, to a solution of 28 
(42 mg, 66 µmol) in DMF (1.0 mL), were added Boc-protected amine (35 mg , 0.20 mmol) and DIPEA (23 
µl, 0.13 mmol). Work-up and purification by column chromatography (EtOAc/n-heptane, 1/4 to EtOAc) 
afforded the compound (32 mg, 70%) as a white solid. Rf 0.42 (EtOAc). IR υmax film: cm
-1 3330, 2980, 2933, 
2095, 1714, 1691, 1526, 1261, 732. 1H NMR (CDCl3 , 400 MHz, ppm): δ 7.31-7.24 (m, 5H, arom), 5.43 (bs, 
2H, NH), 4.93 (t, 2H, J = 9.9 Hz, CH), 4.76 (bs, 2H, NH), 4.65 (s, 2H, CH2 OBn), 3.52-3.43 (m, 3H, CH), 
3.28-3.14 (m, 4H, CH2), 3.08 (dd, 4H, J = 6.1, 12.2 Hz, CH2), 2.22 (dt, 1H, J = 4.3, 12.9 Hz, CH2a), 1.59-
1.50 (m, 4H, CH2b and CH2), 1.44 (s, 18H, t-Bu). 
13C NMR (CDCl3 , 75 MHz, ppm): δ 156.8, 155.4, 138.1, 
128.3, 127.8, 127.7, 79.7, 76.1, 74.4, 58.9, 37.7, 36.8, 32.0, 29.8, 28.5, 25.5. HRMS (ESI) m/z calcd for 
C31H48N10O9Na (M+Na)
+: 727.3503, found: 727.3521. 
 
4,6-bis-O-[(2-aminoethyl)carbamoyl]-1,3-diazido-5-O-benzyl-1,3-
dideamino-2-deoxystreptamine di(trifluoroacetic acid salt) (38) 
The Boc protected compound (19 mg, 28 µmol) was dissolved thi 
stime in TFA/ CH2Cl2 (1.0 mL, 1/1 v/v) and stirred for 2 h at room 
temperature. After removal of the solvent, the product was 
redissolved in tolueen and again concentrated in vacuo. The crude product 38 (13 mg, quant) was obtained as 
an off-white solid and used without further purification. 1H NMR (CD3OD , 400 MHz, ppm): δ 7.34-7.25 (m, 
5H, arom), 4.95-4.84 (m, 2H, CH), 4.67 (s, 2H, CH2 OBn), 3.72-3.63 (m, 1H, CH), 3.44-3.38 (m, 2H, CH), 
3.35-3.27 (m, 4H, CH2), 2.97 (t, 4H, J = 6.5 Hz, CH2), 2.27 (dt, 1H, J = 4.4, 10.4 Hz, CH2a), 1.52 (dd, 1H, J 
= 12.4, 25.5 Hz, CH2b). 
 
4,6-bis-O-[(3-aminopropyl)carbamoyl]-1,3-diazido-5-O-
benzyl-1,3-dideamino-2-deoxystreptamine di(trifluoroacetic 
acid salt) (39)  
Following the same procedure as for 38, a solution of the BOC 
protected compound (15 mg, 21 µmol) in TFA/CH2Cl2 (1.0 mL) 
was stirred for 2 h. Additional work-up afforded the crude product 39 (12 mg, quant) as an off-white solid. 
1H NMR (CD3OD , 400 MHz, ppm): δ 7.33-7.25 (m, 5H, arom), 4.88 (t, 2H, J = 9.9 Hz, CH), 4.65 (s, 2H, 
CH), 3.72-3.62 (m, 3H, CH), 3.32-3.24 (m, 2H, CH2), 3.16 (dt, 2H, J = 7.0, 20.9 Hz, CH2), 2.87 (t, 4H, J = 
7.1 Hz, CH2), 2.24 (dt, 1H, J = 4.6, 12.9 Hz, CH2a), 1.82 (ddt, 4H, J = 2.8, 6.8, 13.9 Hz, CH2), 1.46 (dd, 1H, 
J = 12.6, 25.1 Hz, CH2b). 
 
General procedure for the deprotection of final molecules  
To a solution of protected compound in i-PrOH/H2O/AcOH (3/1/1) was added Pd(OH)2 (Degussa type, 2 
times the weight of the protected compound). The mixture was placed under an atmosphere of H2 and stirred 
overnight. The Pd(OH)2 was filtered off and the filtrate was concentrated in vacuo. The crude product was 
purified by column chromatography (25% NH3 in H2O/CHCl3/n-BuOH/EtOH, 6/2/2/5 to 25% NH3 in 
H2O/CHCl3/n-BuOH/EtOH, 6/2/4/5) to afford the corresponding amine. The compound was further purified 
(from silica and NH4Ac) by chromatography on Amberlite CG-50 (NH4
+, 0.5-cm-diameter × 6.0-cm 
column). Fractions containing the product were pooled and concentrated under reduced pressure. The residue 
was dissolved in H2O, acidified with acetic acid and concentrated in vacuo. The corresponding acetate salt 
was then applied to chromatography on Dowex 1×8 200-400 (Cl-, 0.5-cm-diameter × 6.0-cm column) 
affording the product as the HCl-salt.  
 
4,6-bis-O-[(2-aminoethyl)carbamoyl]-2-deoxystreptamine 
tetrahydrochloride (40)  
Compound 38 (21 mg, 38 µmol) was dissolved in 2 M HCl/EtOAc 
(5.0 mL) and stirred for 2.5 h at room temperature. The EtOAc 
solution was concentrated in vacuo and t-BuOH was added. After 
removal of the t-BuOH, toluene was added and the mixture was concentrated in vacuo affording the crude 
product. According to general procedure for the deprotection, to a solution of the HCl-salt (21 mg, 38 µmol) 
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in PrOH/H2O/AcOH (8.0 mL) was added Pd(OH)2 (42 mg). Work-up and purification afforded 40 (15 mg, 
82% ) as an off-white solid. Rf 0.19 (25% NH3 in H2O/CHCl3/n-BuOH/EtOH, 6/2/4/5). IR υmax film: cm
-1 
2941, 1710, 1531, 1402, 1257, 1014. 1H NMR (D2O, 400 MHz, ppm): δ 4.89 (t, 2H, J=10.0Hz), 3.81 (t, 1H, 
J = 9.7 Hz, CH), 3.62-3.52 (m, 2H, CH), 3.48 (t, 4H, J = 5.6 Hz, CH2), 3.16 (t, 4H, J = 5.8 Hz, CH2), 2.52 
(dt, 1H, J = 4.4, 7.8 Hz, CH2a), 1.96 (dd, 1H, J = 12.8, 25.7 Hz, CH2b), 1.93 (s, 12H, Me AcOH).
 13C NMR 
(D2O, 75 MHz, ppm): δ 180.4, 156.9, 74.1, 71.1, 47.7, 38.7, 37.6, 28.4. HRMS (ESI) m/z calcd for 
C12H26N6O5 (M+Na)
+: 357.1862, found: 357.1889. 
 
4,6-bis-O-[(3-aminopropyl)carbamoyl]-2-deoxystreptamine 
tetrahydrochloride (41)  
Compound 39 (25 mg, 36 µmol) was dissolved in 2 M 
HCl/EtOAc (5.0 mL) and stirred for 2 h at room temperature. 
The EtOAc solution was concentrated in vacuo and t-BuOH was 
added. After removal of the t-BuOH, toluene was added and the mixture was concentrated in vacuo affording 
the crude product. According to general procedure for the deprotection, to a solution of the obtained 
intermediate (21 mg, 36 µmol) in i-PrOH/H2O/AcOH (10 mL) was added Pd(OH)2 (42 mg). Work-up and 
purification afforded 41 (17 mg, 94%) as an off-white solid. Rf 0.15 (25% NH3 in 
H2O/CHCl3/n-BuOH/EtOH, 6/2/4/5). IR υmax film: cm
-1 2935, 2395, 2332, 1707, 1535, 1401, 1257, 1051. 1H 
NMR (D2O, 400 MHz, ppm): δ 4.86 (t, 2H, J = 10.0 Hz, CH), 3.75 (t, 1H, J = 9.6 Hz, CH), 3.53 (ddd, 2H, J 
= 4.2, 11.1, 12.5 Hz, CH), 3.33-3.19 (m, 4H, CH2), 3.04 (t, 4H, J = 7.7 Hz, CH2), 2.52 (dt, 1H, J = 4.3, 13.0 
Hz, CH2a), 1.97-1.93 (m, 13H, Me AcOH and CH2b), 1.91-1.86 (m, 4H, CH2).
 13C NMR (D2O, 75 MHz, 
ppm): δ 180.6, 156.9, 73.9, 71.3, 47.6, 37.0, 36.5, 28.4, 26.5, 22.6. HRMS (ESI) m/z calcd for C14H30N6O5 
(M+Na)+: 385.2175, found: 385.2157. 
 
(S)-2,5-diazidopentanoic acid (42)  
To a solution of ornithine (1.0 g, 5.9 mmol), ZnCl2 (16 mg, 2 mol%), and Et3N (5.0 mL, 36 
mmol) in H2O (100 mL) was slowly added MeOH (333 mL). TfN3 in CH2Cl2 (0.6 M, 100 mL) 
was added at once to the vigorously stirring solution and the reaction mixture was stirred for 15 
hours at room temperature. Upon completion, the mixture was quenched with saturated aqueous 
NaHCO3 and the solvent evaporated in vacuo. The crude product was purified using column chromatography 
(EtOAc/n-heptane, 1/2 and 2% AcOH) to obtain the desired product 42 (0.87 g, 80%) as clear oil. Rf 0.23 
(EtOAc/n-heptane, 1/2 and 2% AcOH). IR νmax film: (cm
-1) 2940, 2101, 1719, 1352, 1234, 1188, 1154. 1H 
NMR (CDCl3, 400 MHz, ppm): δ 3.98 (dd, 1H, J = 5.0, 8.3 Hz, CH), 3.35 (t, 2H, J = 6.5 Hz, CH2), 2.01-1.93 
(m, 1H, CH2), 1.90-1.79 (m, 1H, CH2), 1.78-1.69 (m, 2H, CH2).
 13C NMR (CD3OD, 300 MHz, ppm): δ 
173.2, 62.8, 51.8, 29.8, 26.3. HRMS (CI) m/z calcd for C5H9N6O2 (M+H)
+: 185.0787, found: 185.0791. 
 
1,3-diazido-5-O-benzyl-1,3-dideamino-2-deoxy-
4,6-bis-O-[(2-{[(2S)-2,5-diazidopentanoyl] 
amino}ethyl)carbamoyl]streptamine (43)  
Compound 38 (13 mg, 28 µmol), HOBt (8.0 mg, 56 
µmol), BOP (25 mg, 56 µmol), ornithine compound 
42 (12 mg, 67 µmol), and DIPEA (30 µL, 0.17 mmol) were placed in a flame-dried Schlenk tube for 21 h at 
room temperature in DMF/CH2Cl2 (3.0 mL, 1/2). Upon completion, the reaction mixture was concentrated in 
vacuo and redissolved in i-PrOH/EtOAc (1/9). The mixture was washed using 10 % aqueous KHSO4 
solution and saturated aqueous NaHCO3. The combined organic layers were dried with MgSO4, evaporated 
to dryness and purified by column chromatography (EtOAc/n-heptane, 1/1 to EtOAc) affording 43 (16 mg, 
71%) as an oil (containing some enclosed DMF). Rf 0.39 (MeOH/CHCl3, 1/9). IR υmax film: cm
-1 2937, 2102, 
1715, 1657, 1438, 843. 1H NMR (CD3OD , 400 MHz, ppm): δ 7.33-7.23 (m, 5H, arom), 4.85 (t, 2H, J = 10.1 
Hz, CH), 4.65 (s, 2H, CH2 OBn), 3.83 (ddd, 2H, J = 1.9, 5.3, 7.4 Hz, CH), 3.72-3.60 (m, 3H), 3.33-3.21 (m, 
12H), 2.24 (dt, 1H, J = 4.4, 13.2 Hz, CH2a), 1.90-1.73 (m, 4H), 1.66-1.58 (m, 4H), 1.45 (dd, 1H, J = 12.5, 
25.1 Hz, CH2b). 
13C NMR (CD3OD , 75 MHz, ppm): δ 171.8, 157.4, 138.9, 129.3, 128.7, 125.7, 80.8, 77.2, 
75.8, 63.5, 59.2, 51.4, 40.6, 40.1, 32.2, 29.6, 25.5. HRMS (ESI) m/z calcd for C29H41N22O7 (M+H)
+: 
809.3529, found: 809.3504. 
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1,3-diazido-5-O-benzyl-1,3-dideamino-2-
deoxy-4,6-bis-O-[(3-{[(2S)-2,5-
diazidopentanoyl]amino}propyl)carbamoyl]st
reptamine (44)  
Following the same procedure as for 43, to a 
solution of 39 (32 mg, 62 µmol) in DMF/CH2Cl2 
(1.5 mL) were added HOBt (17 mg, 0.13 mmol), 
BOP (55 mg, 0.13 mmol), ornithine compound 42 (28 mg, 0.15 mmol), and DIPEA (0.13 mL, 0.75 mmol). 
Work-up and purification by column chromatography (EtOAc/n-heptane, 1/1 to EtOAc) affording 44 (41 
mg, 78%) as an oil (containing some enclosed DMF). Rf 0.80 (MeOH/CHCl3, 1/9). IR υmax film: cm
-1 2963, 
2924, 2359, 2099, 1731, 1716, 1260, 1079. 1H NMR (CDCl3, 400 MHz, ppm): δ 7.32-7.24 (m, 5H, arom), 
6.82 (t, 2H, J = 6.3 Hz, NH), 5.42 (q, 2H, J = 6.1, 12.2 Hz, NH), 4.94 (t, 2H, J = 9.9 Hz, CH), 4.64 (s, 2H, 
CH), 3.96 (ddd, 2H, J = 1.4, 4.9, 6.5 Hz, CH), 3.52-3.43 (m, 3H), 3.33 (dt, 4H, J = 2.2, 6.6 Hz CH2), 3.26-
3.12 (m, 8H, CH2), 2.23 (dt, 1H, J = 4.3, 12.9 Hz, CH2a), 2.01-1.84 (m, 4H, CH2), 1.73-1.57 (m, 8H, CH2), 
1.52 (dd, 1H, J = 12.7, 25.8 Hz, CH2b).
 13C NMR (CDCl3 , 75 MHz, ppm): δ 171.6, 157.6, 139.8, 130.8, 
129.6, 127.2, 81.6, 78.0, 76.5, 65.7, 60.6, 52.9, 39.5, 37.7, 33.7, 31.7, 31.4, 26.8. HRMS (ESI) m/z calcd for 
C31H44N22O7Na (M+Na)
+: 859.3661, found: 859.3672. 
 
4,6-bis-O-[(2-{[(2S)-2,5-
diazidopentanoyl]amino}ethyl)carbamoyl]-2-
deoxystreptamine hexahydrochloride (45)  
According to general procedure for the 
deprotection, to a solution of 43 (19 mg, 24 µmol) 
in PrOH/H2O/AcOH (8.0 mL) was added Pd(OH)2 
(40 mg). Work-up and purification afforded 45 (14 mg, 76%) as an off-white solid. Rf 0.15 (25% NH3 in 
H2O/CHCl3/n-BuOH/EtOH, 6/2/4/5). IR υmax film: cm
-1 2959, 1540, 1402, 1049. 1H NMR (D2O, 400 MHz, 
ppm): δ 3.96 (t, 2H, J = 5.6 Hz, CH), 3.74 (t, 1H, J = 9.5, CH), 3.34 (dt, 2H, J = 3.3, 11.4, CH), 3.26-2.92 
(m, 12H, CH2), 2.91 (t, 4H, J = 7.5 Hz, CH2), 2.41 (dt, 1H, J = 4.3, 12.9 Hz, CH2a), 1.87-1.76 (m, 19H, Me 
AcOH and CH2b), 1.65-1.58 (m, 4H, CH2).
 13C NMR (D2O, 75 MHz, ppm): δ 180.3, 169.1, 156.7, 73.7, 
71.0, 52.3, 47.7, 39.3, 38.5, 38.2, 28.1, 27.4, 22.7, 22.4. [α] 20
D
= +9.8 (c = 0.56, H2O). HRMS (ESI) m/z calcd 
for C22H46N10O7 (M+Na)
+: 585.3449, found: 585.3438. 
 
4,6-bis-O-[(3-{[(2S)-2,5-diazidopentanoyl] 
amino}propyl)carbamoyl]-2-
deoxystreptamine hexahydrochloride (46)  
According to general procedure for the 
deprotection, to a solution of 44 (17 mg, 20 
µmol) in PrOH/H2O/AcOH (8.0 mL) was 
added Pd(OH)2 (35 mg). Work-up and purification afforded 46 (11 mg, 69%) as an off-white solid. Rf 0.14 
(25% NH3 in H2O/CHCl3/n-BuOH/EtOH, 6/2/4/5). IR υmax film: cm
-1 3226, 3062, 2937, 2359, 1540, 1401, 
1258, 1048. 1H NMR (D2O, 400 MHz, ppm): δ 3.95 (t, 1H, J = 6.3 Hz, CH), 3.74 (t, 1H, J = 9.7Hz), 3.55-
3.48 (m, 2H, CH), 3.32-3.27 (m, 6H, CH2), 3.21-3.16 (m, 6H, CH2), 3.04 (t, 1H, J = 7.4 Hz), 2.50 (dt, 1H, J 
= 4.3, 12.9 Hz, CH2a), 1.97-1.89 (m, 19H, CH2 and CH2b), 1.77-1.72 (m, 8H, CH2).
 13C NMR (D2O, 75 
MHz, ppm): δ 180.6, 169.0, 156.8, 74.0, 71.3, 52.3, 47.7, 38.2, 37.5, 36.3, 28.5, 27.7, 27.5, 22.6, 22.0. [α] 20
D
= 
+8.0 (c = 0.55, H2O). HRMS (ESI) m/z calcd for C24H50N10O7 (M+Na)
+: 613.3762, found: 613.3761. 
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Summary 
The research described in this thesis deals with aminoglycosides. Aminoglycosides form a large 
class of clinically important antibiotics with a broad antibacterial spectrum and proven efficacy, 
particularly against aerobic Gram-negative bacteria. Despite the apparent advantages, extensive 
clinical use of the aminoglycoside antibiotics is limited due to the associated toxicities and the 
global development of microbial resistance. The field of research on aminoglycoside analogs is 
rapidly expanding. The search is on for new antibiotics, new anti-HIV entities or any new RNA-
affinity drugs that may be derived from a natural aminoglycoside (or bear a close similarity). A 
quick combined search in Chemical Abstracts on the terms ‘aminoglycoside’ and ‘synthesis’ clearly 
reveals the increase in interest in the field (Figure 1). 
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Figure 1. Number of publications on the synthesis of aminoglycosides in the period 1974-2005. 
 
Despite the apparent advantages of the aminoglycosides antibiotic, practical application in the clinic 
is limited due to high associated toxicities as well as the microbial resistance. A possible strategy to 
develop new aminoglycoside antibiotics that do not display the undesirable features but maintain a 
strong bacterial effect is based on a combinatiorial assembly of new aminoglycoside-like structures 
by combination of individually prepared components. Key scaffold of nearly all aminoglycosides is 
a diaminocyclohexitol termed 2-deoxystreptamine (2-DOS). Therefore, an overview of synthetic 
routes leading toward this aminocyclitol moiety is described in chapter 1. 
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A diastereoselective synthetic route from D-allylglycine to an enantiopure (protected) 2-DOS 
derivative is presented in chapter 2 (Figure 2). Key steps involve two consecutive chain extensions 
with crucial stereodirective roles for the amino protective groups, followed by ring closure by olefin 
metathesis and a face selective dihydroxylation. The resulting 1,2-diol was reacted with 
thionylchloride and subsequently oxidized to obtain the cyclic sulfate. The last step involves 
opening of the cyclic sulfate with lithium azide, to afford a 2-DOS derivative with a protective 
group pattern ideal for the preparation of both 4,5- and 4,6-linked aminoglycoside antibiotics. 
 
D-allylglycine
OBn
OH
NHBoc
OBn
NHBoc
OTBDMS
N3
HO
 
Figure 2.  
 
In chapter 3 another synthesis route toward 2-DOS is described. The synthetic route described in 
this chapter starts from p-benzoquinone and cyclopentadiene and comprises a Pd(0)-catalyzed 
rearrangement and a retro-Diels–Alder reaction by flash vacuum thermolysis (Figure 3). Final 
stereoselective introduction of the desired trans-azidoalcohol was explored with a variety of 
methods e.g. via an Yb(III)-directed regioselective epoxide opening, via diepoxide opening, or via 
dihydroxylation, cyclic sulfate forming and opening with lithium azide. The obtained orthogonally 
protected diazidocyclohexitol (DACH) derivatives are suitable 2-DOS precursors, conveniently 
protected for incorporation in new aminoglycoside entities. 
 
O
O
+ O
OTBDMS
OR
N3
OTBDMS
HO
N3
R= Ac
R= H  
Figure 3.  
 
In chapter 4 several methodologies are explored to obtain enantiopure and orthogonally protected 
1,3-diazidocyclohexitols (1,3-DACHs), via resolution of chiral intermediate of the synthetic route 
or via resolution of a meso 5-O-protected precursor, for example by asymmetric alkylation, 
asymmetric allylic alkylation or enzymatic resolution (Figure 4). Moreover, a straightforward 
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synthesis of 5-O-benzylprotected 1,3-diazido-4,5,6-cyclohexanetriol is developed, starting from 
commercially available kanamycin.  
N3N3
OTBDMS
HO OR
enantiopure
N3N3
R
PO OPP
N3N3
R
HO OH
 
Figure 4.  
 
The synthesis of a carbohydrate mimic of 2-DOS is described in chapter 5. Starting from D-ribose, 
crucial steps of the synthesis involve a nitro-aldol condensation and deoxygenation via elimination 
of an acetate group followed by in situ reduction. Moreover, glycosylation of the carbohydrate 
2-DOS derivative with a phenyl thioglycoside in the presence of TTBP and AgOTf followed by 
ring closing metathesis yielded a conformationally restricted aminoglycoside analogue (Figure 5). 
 
O
NO2
O
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N3
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O
N3
OBn
OBnD-ribose
 
Figure 5.  
 
The synthesis of new aminoglycoside and peptidyl 2-deoxystreptamine (2-DOS) structures is 
described in chapter 6. These new structures are based on bidirectional functionalization of 2-DOS 
scaffolds, synthesized in the previous chapters. Aminoglycoside-type structures were synthesized 
by dual glycosylation of the diazidocyclitol moiety. Peptidyl 2-DOS structures were obtained by 
coupling amino acids or peptides to the diazidocyclitol scaffold via ester, alkyl amide or carbamate 
functionality (Figure 6). 
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Figure 6.  
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Samenvatting 
Het werk beschreven in dit proefschrift gaat over aminoglycoside analoga. Aminoglycosiden zijn 
antibiotica met vooral klinische activiteit tegen Gram-negatieve bacteriën. Desondanks is het 
gebruik van deze antibiotica beperkt omdat deze verbindingen erg giftig en gevoelig zijn voor 
microbiële resistentie. De laatste jaren staat onderzoek over aminoglycoside analoga erg in de 
belangstelling. Een zoekopdracht op de termen “aminoglycosiden” en “synthese” in chemische 
samenvattingen laat al snel zien dat er de laatste jaren veel meer wordt gepubliceerd op dit vlak 
(Figuur 1). 
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Figuur 1. Aantal publicaties over de synthese van aminoglycoside antibiotica in de periode 1974-2005. 
 
In hoofdstuk 1 wordt uitgelegd wat het belang van 2-deoxystreptamine (2-DOS) is. Dit 
aminocyclitol is de basisstructuur van bijna alle aminoglycoside antibiotica. Vanuit 2-DOS kunnen 
mogelijkerwijs nieuwe antibiotica worden ontwikkeld, die een hoge mate van bacteriële activiteit 
vertonen én geen bijwerkingen hebben. Daarom is een overzicht van alle synthetische routes naar 
dit aminocyclitol weergegeven in hoofdstuk 1. 
 
Hoofdstuk 2 beschrijft op welke wijze een enantiomeer zuiver (en orthogonaal beschermd) 2-DOS 
derivaat vanuit D-allylglycine kan worden gesynthetiseerd (Figuur 2). De belangrijkste synthese 
stappen zijn twee ketenverlengingen met een cruciale rol voor de beschermgroepen op het stikstof 
atoom gevolgd door ringsluitingsmetathese. De verkregen dubbele binding wordt vervolgens 
gedihydroxyleerd en omgezet naar cyclisch sulfaat, waarna het verkregen cyclisch sulfaat nucleofiel 
wordt geopend met lithium azide om zo het orthogonaal beschermde 2-DOS te verkrijgen. 
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D-allylglycine
OBn
OH
NHBoc
OBn
NHBoc
OTBDMS
N3
HO
 
Figuur 2.  
 
In hoofdstuk 3 wordt een alternatieve synthese naar 2-DOS beschreven uitgaande van 
p-benzoquinon en cyclopentadieen. De belangrijkste synthesestappen zijn een Pd(0)-gekatalyseerde 
omlegging en een retro-Diels–Alder reactie door middel van flits-vacuüm thermolyse (Figuur 3). 
De laatste trans azide-groep wordt ingevoerd door middel van hetzij een Yb(III)-gekatalyseerde 
epoxide opening of via dihydroxylering gevolgd door cyclisch sulfaat vorming en nucleofiele 
opening met azide. De verkregen 2-DOS precursors uit hoofdstuk 1 en 2 zijn direct te gebruiken 
voor de synthese van nieuwe aminoglycoside verbindingen. 
O
O
+ O
OTBDMS
OR
N3
OTBDMS
HO
N3
R= Ac
R= H  
Figuur 3.  
 
Ook in hoofdstuk 4 worden verscheidene methoden uiteengezet om enantiomeer zuivere en 
orthogonaal beschermde 1,3-diazidocyclohexitolen te synthetiseren. Technieken die onder de loep 
worden genomen zijn resolutie met enzymen, asymmetrische alkylering en asymmetrische 
allylering van een meso 5-O-beschermde precursor (Figuur 4). In hoofdstuk 4 wordt ook een 
synthese van 5-O-benzyl- of allyl-beschermde cyclohexaantriolen beschreven. Deze verbindingen 
worden verkregen door middel van hydrolyse van het commercieel verkrijgbare kanamycine. 
 
N3N3
OTBDMS
HO OR
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N3N3
R
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N3N3
R
HO OH
 
Figuur 4.  
 
Hoofdstuk 5 beschrijft de synthese van een suikeranalogon van 2-DOS, uitgaande van D-ribose. 
Cruciale stappen van de synthese zijn een nitroaldol condensatie gevolgd door deoxygenering via 
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eliminatie van een acetaat-groep en een in situ reductie. Vervolgens wordt het verkregen 2-DOS 
suiker gekoppeld met een thioglycoside in aanwezigheid van TTBP en AgOTf. Het conformationeel 
vastgelegde aminoglycoside derivaat wordt uiteindelijk door metathese verkregen (Figuur 5). 
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Figuur 5.  
 
De synthese zowel van aminoglycosides als niet-aminoglycoside structuren wordt tenslotte 
gedetailleerd beschreven in hoofdstuk 6. Beide aminocyclitolen worden gesynthetiseerd uit de 
2-DOS precursors om vervolgens verder gederivatiseerd te worden door invoering van 
verschillende elementen die voor extra affiniteit met RNA kunnen zorgen. Door gelijktijdige 
glycosylering van beide alcoholen van het intermediaire diazidocyclitol ontstaan aminoglycoside-
type structuren. Peptidyl 2-DOS conjugaten worden verkregen door middel van gelijktijdig 
koppelen van peptiden aan  2-DOS via zowel een ester, een alkyl amide als een carbamaat 
functionaliteit (Figuur 6).  
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Dankwoord 
Eén van mijn oud lab-genootjes in de Scheeren groep schreef al, “en nu het leukste”, dat klopt wel 
een beetje. Na vier jaar hard ploeteren ligt hier dan het resultaat. Ik wil een aantal mensen die al dan 
niet op wetenschappelijk vlak een bijdrage hebben geleverd aan dit boekje in het bijzonder 
bedanken. 
Op de eerste plaats Floris van Delft. Altijd enthousiast en boordevol nieuwe ideeën, jammer dat ik 
je nu al ga verlaten. Jouw uitspraken worden inmiddels overgenomen door de hele groep; “My TLC 
looked like a stairway to hell”, “There might be more snakes under the grass”,“Er is niks 
opwindender dan een volledig verklaard NMR spectrum”. Lege vlakken op zijn poster zijn 
“rustvlakken” en nadat een route niet na te werken blijkt, zegt Floris “He didn’t suck it out of his 
thumb”. Zo zijn er nog veel meer. Tijdens congressen en andere uitjes hebben we veel gesprekken 
gevoerd over van alles en nog wat, dat heb ik altijd heel erg gewaardeerd. De beklimming van de 
bergen in Grenoble staat me nog scherp bij en ik denk dat er niet veel mensen met hun baas in de 
botsauto’s zijn geweest. Floris bedankt voor jou niet te stuiten enthousiasme en de leuke tijd. Ik zal 
met heel veel plezier terugkijken op onze samenwerking.  
Ook wil ik mijn promotor Floris Rutjes bedanken. In één van mijn eerste werkbesprekingen waren 
wij (Floris van Delft en ik) heel enthousiast dat we eindelijk 2-deoxystreptamine hadden gemaakt. 
We waren helemaal door het dolle heen, maar jij wist ons weer bij positieven te brengen door op te 
merken “Hij is nog wel meso”, dat heb ik vervolgens nog vaak moeten horen op de afdeling. Maar 
gelukkig in mijn laatste week is het dan toch nog gelukt 2-DOS te desymmetriseren. Mede omdat jij 
een samenwerking aanging met Diversa. Uiteraard wil ik de leden van de manuscript commissie 
graag bedanken voor het zorgvuldig doorlezen en corrigeren van het manuscript. Ton Dirks wil ik 
bedanken voor het ontwerp van de voorkant van dit boekje. Toen ik ging publiceren heb jij mij 
enorm geholpen om ‘de voorkant te halen’. Voor dit manuscript blijkt dit weer een uitkomst.  
Natuurlijk wil ik Stan Groothuys bedanken voor een groot deel van de syntheses beschreven 
in hoofdstuk 3. Hij eet het liefst penny wafels, “clicked” graag en loopt in “nuchtere” (drie bier) 
toestand tegen een muur op. En de altijd vrolijke Bart Verheijen, jij hebt aan een heleboel 
verschillende projecten gewerkt, heel erg bedankt daarvoor. Enkele voorbeelden typisch Bart: 
“Goedendag, heeft u nog appartementen onder de 585 euro”, “Je mag wel 160 km per uur rijden 
alleen als er dan een foto wordt gemaakt moet je betalen”. Hij is altijd zijn labbril kwijt en als hij 
boodschappen doet gaat hij altijd naar de rij met de knapste caissière. Zo voorkom je frustratie als 
het wat langer duurt.  
 120
Bas Ritzen (Alias Sjlieps) heel erg bedankt voor al jouw doorzettingsvermogen om de RNA 
liganden te synthetiseren, ondanks dat het zo nu en dan wel heel erg tegenzat! “High flow...”, 
“Afganistaan”.  Hans Adams en Dennis Löwik wil ik graag bedanken voor de hulp bij de synthese 
van de RNA liganden beschreven in hoofdstuk 6.  
En dan mijn projectgenootje Daniel Gironés “Main lovers”, “I am never strict”. Dat laatste 
klopt ook in alle opzichten, we zijn je ooit verloren midden in Parijs, omdat jij nog even in een 
kwartier Parijs ging bekijken en toen de trein miste. Vliegtuig naar Glasgow gemist nadat je een 
verlopen toeristenkaart meenam en jij miste de bus op een haar na tijdens het “social event” Spring 
school Maastricht. Reactie van Floris van Delft “I never want to be in public transport with you 
again”.  
Papa Bas (Bas van den Broek) heel erg bedankt voor de hulp bij de synthese van de 
carbohydrate derivaten vermeld in hoofdstuk 5 en natuurlijk voor de leuke tijd op het lab. “Mensen 
die slapen zijn toch altijd leuk!”, “Aromaten zijn niet te vertrouwen”.  
Ook René de Gelder wil ik graag bedanken voor het ophelderen van alle kristalstructuren, 
beschreven in hoofdstuk 3. Onze samenwerking heeft geresulteerd in een hele mooie publicatie in 
JOC. Ad Swolfs, Peter van Galen, Han Peeters en Helene Amatdjais-Groenen wil ik bedanken voor 
hun bijdrage bij de karakterisering van talloze verbindingen. Chris Kroon en Wim van Luyn, ben ik 
dankbaar voor de onmisbare logistieke ondersteuning. Maria Versteeg en Désirée van der Wey wil 
ik bedanken voor alle secretariële hulp. Maar natuurlijk ook de altijd vrolijke Peter van Dijk. Ik 
hoop dat ik nog eens jou kantoortje binnen mag lopen om weer even bij te kletsen. 
En natuurlijk alle andere labgenootjes die voor de goede sfeer op het lab zorgden! Roel 
“Tijd heb ik wel de vraag is alleen wanneer”.“Tinus wat moet ik doen als mijn computer niet meer 
vooruit gaat?”, Martijn “Het nadeel van opruimen is dat je dan dingen kwijt bent”. En hij staat er tot 
nog toe nog steeds achter. Heel erg bedankt voor de leuke tijd op het lab en voor het altijd 
enthousiast zijn om weer een nieuwe practical joke uit te halen (koffie aan de film verdamper is nog 
steeds mijn favoriet!). Maarten, omdat jij mijn computer altijd weer wist te repareren. En natuurlijk 
Bas GR, ik hoop dat we in de toekomst nog vaak een biertje of een wijntje samen zullen drinken! 
Bedankt voor jou nuchtere kijk op eigenlijk wel alles. Patrick Beusker, jammer dat we nooit meer 
samen hardlopen. Dat je nu plaats hebt genomen in mijn manuscript commissie maakt veel goed.  
En natuurlijk alle andere (ex)-collega’s van de afdeling Organische Chemie: Dani IUPAC 
“Just change the rules!”, Wim “Oh nee he... dit gaat Roel niet leuk vinden?”, Koen, Jorge, Kaspar, 
Pieter, Jan D., Claudia, Leon, Sander, Valeria, Brian, Christien, Hans Adams, René Aben, Irene, Dr. 
Otten, Femke, Piotr, Henri, Susanne, Bertus, Nethanja, Hester, Christien. Ik mis jullie en de 
speciale ‘lab-sfeer’ nu al een beetje.  
 121
En natuurlijk ook, de mensen die buiten de chemie een belangrijke rol gespeeld hebben. Vrienden, 
kennissen opa’s en oma’s. Rosalie voor de culinaire verwenning en ontspannen vrouwen avondjes 
en natuurlijk omdat je een van mijn paranimfen wil zijn! En natuurlijk Jantine (de andere paranimf) 
die ervoor zorgde dat Romie steeds weer beter werd, zo knapte ze na een flinke koliek aanval weer 
op door een antibiotica kuur. Natuurlijk met een aminoglycoside (neomycine) in combinatie met 
Penicilline G. Jelle voor de vele ontspannen ritjes op Romie en Raketje. Mijn schoonfamilie (Hans 
en Zus) voor de interesse die jullie altijd voor mijn onderzoek hebben getoond. Janneke voor de 
vele leerzame momenten. Anthony en Julia, ik hoop dat de ruimte die jullie in de boekenkast 
hebben vrijgemaakt niet te groot is. En natuurlijk paps en mams voor hun steun en interesse in mijn 
onderzoek, zonder jullie steun was dit nooit gelukt. Tenslotte, wil ik nog opa Prak bedanken omdat 
hij de enige van de familie zou zijn die dit boekje met grote precisie zou lezen, tot mijn spijt kan jij 
er niet meer bij zijn. 
Guido, mijn laatste woord is voor jou omdat jij de afgelopen jaren nogal wat moest slikken, 
omdat ik of aan mijn promotie aan het werken was of aan het trainen. Jouw steun telkens weer was 
van onschatbare waarde en heeft in grote mate bijgedragen tot de daadwerkelijke voltooiing van dit 
boekje. Ik hoop dat we nog vele jaren samen gelukkig zullen zijn. 
 
 
En iedereen die ik vergeten ben! 
Dank je wel!!! 
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